<SEC-DOCUMENT>0001144204-17-029188.txt : 20170524
<SEC-HEADER>0001144204-17-029188.hdr.sgml : 20170524
<ACCEPTANCE-DATETIME>20170524084959
ACCESSION NUMBER:		0001144204-17-029188
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170627
FILED AS OF DATE:		20170524
DATE AS OF CHANGE:		20170524
EFFECTIVENESS DATE:		20170524

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FENNEC PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001211583
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32295
		FILM NUMBER:		17865539

	BUSINESS ADDRESS:	
		STREET 1:		PO BOX 13628
		STREET 2:		68 TW ALEXANDER DRIVE
		CITY:			RESEARCH TRIANGLE PARK
		STATE:			NC
		ZIP:			27709
		BUSINESS PHONE:		(919) 636-4530

	MAIL ADDRESS:	
		STREET 1:		PO BOX 13628
		STREET 2:		68 TW ALEXANDER DRIVE
		CITY:			RESEARCH TRIANGLE PARK
		STATE:			NC
		ZIP:			27709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FENNEC PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20140903

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADHEREX TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20021223
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>v467708_def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities and Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">Filed by the
Registrant&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">Filed by a
Party other than the Registrant&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">Check the appropriate
box</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
Proxy Statement</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Definitive Additional Materials</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting Material Pursuant
to &sect;240.14a-12</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Payment of Filing Fee (Check the appropriate
box)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fee required.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fee computed on table below
per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">&uml;</font></td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Title of each class of securities to which the transaction applies:</font></td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">&uml;</font></td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Aggregate number of securities to which the transaction applies:</font></td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">&uml;</font></td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Per unit price or other underlying value of the transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</font></td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">&uml;</font></td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Proposed Maximum aggregate value of the transaction:</font></td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">&uml;</font></td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Total fee paid:</font></td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fee paid previously with
preliminary materials.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Check box if any part of
the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.
Identify the previous filing by registration statement number, or the Form or Schedule and the date of the filing.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">&uml;</font></td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Amount Previously Paid:</font></td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">&uml;</font></td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Form, Schedule or Registrant Statement No.:</font></td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">&uml;</font></td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Filing Party:</font></td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">&uml;</font></td>
    <TD STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Date Filed:</font></td></tr>
<tr>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>EXPLANATORY NOTE</U>: This notice, management
proxy circular and the schedules attached thereto with respect to the upcoming annual meeting of security holders (the &ldquo;Proxy
Solicitation Materials&rdquo;) are being furnished to the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) pursuant
to the requirements of Form 10-K under &ldquo;Supplemental Information Furnished with Reports Filed Pursuant to Section 15(d) of
the Act by Registrants Which Have Not Registered Securities Pursuant to Section 12 of the Act&rdquo; and shall not be deemed to
be &ldquo;filed&rdquo; with the Commission or otherwise subject to the liabilities of Section 18 of the Act, nor be deemed incorporated
by reference to any filing of the registrant with the Commission unless otherwise expressly provided herein. These Proxy Solicitation
Materials are being submitted to the SEC in electronic (rather than paper) format on Form DEF 14A pursuant to Release Nos. 33-7427;
34-38798 (dated July 1, 1997) and Rule 101(a)(iii) of Regulation S-T.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TO BE HELD ON JUNE 27, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTICE IS HEREBY GIVEN</B>
that the annual and special meeting (the &ldquo;<B>Meeting</B>&rdquo;) of the holders of common shares (&ldquo;<B>Common Shares</B>&rdquo;)
in the capital of Fennec Pharmaceuticals Inc., 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, 27709 (&ldquo;<B>Fennec</B>&rdquo;
or the &ldquo;<B>Corporation</B>&rdquo;) will be held at Lotte New York Palace in the Chairman&rsquo;s Office, 455 Madison Avenue,
New York, New York, USA at 10:00 am EST on June 27, 2017 for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">to receive the consolidated financial statements of the Corporation for the year ended December
31, 2016, together with the report of the auditors thereon;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">to elect the five directors named in the Management Proxy Circular;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">to appoint auditors and to authorize the directors of the Corporation to fix the auditors&rsquo;
remuneration;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">to consider, and, if thought advisable, pass an ordinary resolution approving the proposed Shareholder
Rights Plan Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">to vote on an advisory (non-binding) vote on executive compensation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">to transact such further or other business as may properly come before the Meeting or any adjournment
thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A copy of the Management Proxy Circular and
a form of proxy accompanies this notice, as well as a copy of the Corporation&rsquo;s annual report which contains the consolidated
financial statements of the Corporation for the year ended December 31, 2016, together with the report of the auditors thereon
and management&rsquo;s discussion and analysis of financial condition and results of operations relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board of directors of Fennec has fixed
5:00 p.m. ET on May 19, 2017 (the &ldquo;<B>Record Date</B>&rdquo;), as the record date for determining the holders of record of
Common Shares who are entitled to receive notice of the Meeting and to attend and vote at the Meeting and any adjournment or postponement
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Shareholders who are unable to attend the
Meeting in person are requested to date and sign the enclosed form of proxy and return it to Computershare Trust Company of Canada,
100 University Ave., 8th Floor, Toronto, Ontario M5J 2Y1 attention Proxy Department in the enclosed envelope, no later than 10:00
am EST on June 22, 2017, or if the Meeting is adjourned or postponed, no later than 48 hours, excluding any day which is not a
business day in Toronto preceding the reconvened Meeting.</B> Proxies may also be deposited with the scrutineers of the Meeting,
to the attention of the Chair of the Meeting at and immediately prior to the commencement of the Meeting or any adjournments or
postponement thereof. In order to be represented by proxy, you must complete and submit the enclosed form of proxy or other appropriate
form of proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Important Notice Regarding the Availability
of Proxy Materials for the Shareholder Meeting to be held on June 27, 2017:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>This Notice,
Management Proxy Circular and the Corporation&rsquo;s Annual Report on Form 10-K are available to you on the Internet at <U>www.sec.gov
</U>and <U>www.sedar.com.</U> We encourage you to access and review all of the important information contained in these materials
before voting.</B></FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DATED at Research Triangle Park, North Carolina
this 19<SUP>th</SUP> day of May, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; text-align: justify">&nbsp;</td>
    <td style="width: 50%; text-align: justify"><font style="font-size: 10pt">By Order of the Board of Directors of Fennec Pharmaceuticals Inc.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><i>/s/ <b>Khalid Islam</b></i></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Dr. Khalid Islam</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Chairman of the Board</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MANAGEMENT PROXY CIRCULAR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Unless otherwise stated, information contained
in this management proxy circular (the &ldquo;<B>Circular</B>&rdquo;) is given as of May 19, 2017</I>. <I>Except as otherwise indicated,
all amounts are expressed in United States dollars. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Solicitation and Appointment of Proxies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Circular is furnished in connection with
the solicitation of proxies by management of Fennec Pharmaceuticals Inc.,<B> </B>68 TW Alexander Drive, PO Box 13628, Research
Triangle Park, NC, 27709 (&ldquo;<B>Fennec</B>&rdquo; or the &ldquo;<B>Corporation</B>&rdquo;) for use at the annual and special
meeting (the &ldquo;<B>Meeting</B>&rdquo;) of the shareholders of Fennec to be held at 10:00 am EST on June 27, 2017 at Lotte New
York Palace in the Chairman&rsquo;s Office, 455 Madison Avenue, New York, New York, USA and at any adjournment thereof, for the
purposes set forth in the accompanying notice of annual general and special meeting (the &ldquo;<B>Notice of Meeting</B>&rdquo;).
This Circular was first mailed to shareholders on or about May 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The persons named in the form of proxy accompanying
this Circular are officers and/or directors of Fennec. A holder of Common Shares (a &ldquo;<B>Shareholder</B>&rdquo;) has the right
to appoint a person, other than the persons named in the form of proxy accompanying this Circular, as nominee to attend and act
for and on behalf of such Shareholder at the Meeting, and may exercise such right by inserting the name of such person in the blank
space provided on the form of proxy, or by executing a proxy in a form similar to the form of proxy accompanying this Circular.
If a Shareholder appoints one of the persons named in the form of proxy accompanying this Circular as the nominee of the Shareholder
and does not direct such nominee to vote either for or against or withhold from voting on a matter or matters with respect to which
an opportunity to specify how the Common Shares registered in the name of such Shareholder are to be voted, the proxy shall be
voted FOR the matter or matters set forth on such proxy and in the discretion of the person appointed on all other matters (if
any) upon which the Shareholder is entitled to cast a vote. A proxy nominee need not be a Shareholder. If the Shareholder is a
corporation, the proxy must be executed by an officer or properly appointed attorney.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order for a proxy to be effective at the
Meeting, it must be addressed to the Secretary of Fennec and returned to Computershare Trust Company of Canada, 100 University
Ave., 8th Floor, Toronto, Ontario M5J 2Y1 attention Proxy Department in the enclosed envelope, not later than 10:00 am EST on June
22, 2017 or, if the Meeting is adjourned or postponed, not later than 48 hours (excluding any day which is not a business day in
Toronto) before the time of the reconvened Meeting. Proxies may also be deposited with the scrutineers of the Meeting, to the attention
of the Chair of the Meeting, at or immediately prior to the commencement of the Meeting, or any adjournment or postponement thereof.
An undated but executed proxy will be deemed to be dated the date of this Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The solicitation of proxies for the Meeting
will be primarily by mail, but proxies may also be solicited personally or by telephone by employees or agents of Fennec. Employees
of Fennec will not receive any extra compensation for such activities. Fennec will pay brokers or other persons holding Common
Shares in their own names, or in the names of nominees, for their reasonable expenses for sending proxies and proxy material to
beneficial owners of Common Shares and requesting authority to execute proxies in respect of such Common Shares. The solicitation
of proxies by this Circular is being made by or on behalf of the management of Fennec and its board of directors (the &ldquo;<B>Board</B>&rdquo;)
and the total cost of this solicitation will be borne by Fennec.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Voting of Proxies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Only registered shareholders or duly appointed
proxy holders are permitted to vote at the Meeting. The Common Shares represented by a proxy at the Meeting will be voted for or
withheld from voting in each of the election of directors, appointment of auditors and authorizing the Board to fix the auditors
remuneration and advisory vote on executive compensation (together, the &ldquo;<B>Ordinary Matters</B>&rdquo;), and the approval
of the Rights Plan (the &ldquo;<B>Special Matters</B>&rdquo;) in accordance with the instructions of the Shareholder. If no choice
is specified in the proxy or the instructions are not certain, the persons named in the form of proxy accompanying this Circular
will vote FOR all of the matters proposed by management at the Meeting and described in the Notice of Meeting and in the discretion
of the person appointed on all other matters (if any) upon which the Shareholder appointing the proxy is entitled to cast a vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The form of proxy accompanying this Circular,
when properly completed and executed, confers discretionary authority upon the persons named therein with respect to any amendment
or variation to the matters identified in the Notice of Meeting and with respect to other matters which may properly come before
the Meeting. Management of Fennec and the Board knows of no matters to come before the Meeting other than those referred to in
the Notice of Meeting. However, if any other matters (other than the election of directors not currently named in this Circular)
that are not now known to management of Fennec or the Board should properly come before the Meeting, the Common Shares represented
by proxies given in favour of the persons named in the form of proxy accompanying this Circular will be voted on such matters in
accordance with the discretion of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Revocation of Proxies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Shareholder may revoke a previously given
proxy by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">completing and signing a proxy bearing a later date and depositing it with Computershare Trust
Company of Canada as described above;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">depositing an instrument in writing signed by the Shareholder or an attorney authorized by a document
signed in writing or by electronic signature (if the Shareholder is a corporation, under its corporate seal by an officer or attorney
thereof properly authorized, indicating the capacity under which such officer or attorney is signing), or by transmitting, by telephonic
or electronic means, a revocation signed by electronic signature, or by any other manner permitted by law, which must be received
either (A) with Computershare Trust Company of Canada, 100 University Ave., 8th Floor, Toronto, Ontario M5J 2Y1 attention Proxy
Department in the enclosed envelope, not later than 10:00 am EST on June 22, 2017, or (B) with the scrutineers of the Meeting to
the attention of the Chair of the Meeting on the day of the Meeting, or any adjournment thereof, prior to the taking of the vote
to which such proxy relates; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">in any other manner permitted by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Advice to Beneficial Holders of Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>This section applies to beneficial holders
of Common Shares who are not registered holders. The information set forth in this section is of significant importance to many
holders of Common Shares, as a substantial number of Shareholders do not hold Common Shares in their own name.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Notice of Meeting, the proxy and this Circular
are being sent to both registered and non-registered owners of Common Shares. Only registered holders of Common Shares, or the
persons that they appoint as proxies, are permitted to attend and vote at the Meeting. In many cases, Common Shares are beneficially
owned by a shareholder and are registered in the name of an intermediary such as a bank, broker or other nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation has distributed copies of the
Notice of Meeting, the proxy and this Circular (collectively, the &ldquo;<B>Meeting Materials</B>&rdquo;) to all of the intermediaries
for delivery to beneficial holders. Intermediaries are required to forward the Meeting Materials to beneficial holders unless a
beneficial holder has waived the right to receive them. This permits beneficial holders to direct the voting of the Common Shares
that they beneficially own. If a beneficial holder wishes to attend and vote at the Meeting in person (or have another person attend
and vote on behalf of the beneficial holder), the beneficial holder should strike out the names of the persons named in the proxy
and insert the beneficial holder&rsquo;s (or such other person&rsquo;s) name in the blank space provided. In any case, beneficial
holders should carefully follow the instructions of the intermediaries, including those regarding when and where the proxy or proxy
authorization form is to be delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Record Date and Entitlement to Vote</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Record Date for the purpose of determining
Shareholders entitled to receive the Circular and to vote at the Meeting has been fixed as 5:00 p.m. ET on May 19, 2017 (the &ldquo;<B>Record
Date</B>&rdquo;). Each Shareholder at the close of business (5:00 p.m. ET) on the Record Date is entitled to attend the Meeting
in person or by proxy and to cast one (1) vote for each Common Share held by such Shareholder on the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Quorum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to the Corporation&rsquo;s articles,
the quorum for the transaction of business at any meeting of Shareholders shall be two or more persons present in person or represented
by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Voting Securities and Principal Holders
of Voting Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As at May 19, 2017, there were 13,707,306 Common
Shares issued and outstanding. Each Common Share carries the right to one vote at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beneficial ownership of the Common Shares in
the following table is determined in accordance with the rules and regulations of the U.S. Securities Exchange Commission (the
&ldquo;<B>SEC</B>&rdquo;). Under these rules, a person is deemed to beneficially own a Common Share if that person has or shares
voting power or investment power with respect to that share, or has the right to acquire beneficial ownership of that share within
60 days, including through the exercise of any option, warrant or other right or the conversion or any other security. Shares issuable
under stock options and warrants are deemed outstanding for computing the percentage of the person holding options or warrants
but are not outstanding for computing the percentage of any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As at May 19, 2017, the directors and Named
Executive Officers (defined below under &ldquo;Executive Compensation&ndash;Summary Compensation Table&rdquo;) of Fennec and, to
the knowledge of the directors and Named Executive Officers of Fennec, after reasonable enquiry, their respective associates, as
a group, beneficially owned, directly or indirectly, or exercised control or direction over 40,740 Common Shares (approximately
0.30% of all outstanding Common Shares on such date) and options and warrants to purchase 1,596,820 Common Shares (approximately
11.65% of the aggregate of all outstanding Common Shares on such date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the number of
Common Shares beneficially owned as of May 19, 2017 by: (1) each director and Named Executive Officer; (2) all directors and Named
Executive Officers as a group; and (3) each person known by us to own 5 percent or more of the outstanding Common Shares. The percentage
of beneficial ownership for the following table is based upon 13,707,306 Common Shares outstanding as of May 19, 2017. Except as
indicated below, the security holders listed possess sole voting and investment power with respect to the shares beneficially owned
by that person. The address for each listed shareholder who is a director or a Named Executive Officer is c/o Fennec Pharmaceuticals
Inc., PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, North Carolina 27709.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common Shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common Share<BR> Options Exercisable<BR> Within 60 Days</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common Share<BR> Purchase Warrants<BR> Exercisable Within<BR> 60 Days</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>Total Stock and</b></font><br> <font style="font-size: 10pt"><b>Stock Based</b></font><br> <font style="font-size: 10pt"><b>Holdings<sup>(1)</sup></b></font></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>%</b></font><br> <font style="font-size: 10pt"><b>Ownership<sup>(1)</sup></b></font></TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: justify">Adrian J. Haigh</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">153,579</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">153,579</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.11</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Dr. Khalid Islam</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,825</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,825</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.54</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Robert Andrade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">406,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">406,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.95</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Marco Brughera</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.26</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Chris A. Rallis</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.81</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Rostislav Raykov</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">666,010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">666,010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.92</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">All Officers and Directors as a Group</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,596,820</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,637,560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.70</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Southpoint Capital Advisors, LP.<sup>(2)</sup></font></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,997,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,997,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29.16</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Essetifin SpA<sup>(3)</sup></font></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,631,579</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,631,579</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19.20</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">683 Capital Management, LLC.<sup>(4)</sup></font></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">778,729</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,834</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">899,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.51</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Robert Butts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">768,592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">768,592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.61</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Manchester Management Company, LLC.<sup>(5)</sup></font></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">999,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">999,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,999,998</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.60</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0; padding-left: 0; text-align: left"><font style="font-size: 10pt">(1)</font></td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><font style="font-size: 10pt">For purposes of this table &ldquo;beneficial ownership&rdquo; is determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, pursuant to which a person or group of persons is deemed to have &ldquo;beneficial ownership&rdquo; of any Common Shares that such person or group has the right to acquire within 60 days after May 19, 2017. For purposes of computing the percentage of outstanding Common Shares held by each person or group of persons named above, any shares that such person or group has the right to acquire within 60 days after May 19, 2017 are deemed outstanding but are not deemed to be outstanding for purposes of computing the percentage ownership of any other person or group. As of May 19, 2017 there were 13,707,306 Common Shares issued and outstanding.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left">&nbsp;</td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><font style="font-size: 10pt">(2)</font></td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><font style="font-size: 10pt">Southpoint Capital Advisors, LP, 623 Fifth Avenue, Suite 2503, New York, New York 10022. John S. Clark, II holds dispositive power over the shares owned by Southpoint Capital Advisors, LP.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left">&nbsp;</td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><font style="font-size: 10pt">(3)</font></td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><font style="font-size: 10pt">Essetifin SpA, Via Sudafrica 20, Rome, Italy 00144. Mario Artali holds dispositive power over the shares by Essetifin SpA.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left">&nbsp;</td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><font style="font-size: 10pt">(4)</font></td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><font style="font-size: 10pt">683 Capital Management, LLC, 595 Madison Avenue, 17th Floor, New York, New York 10025. Ari Zweiman holds dispositive power over the shares owned by 683 Capital Management LLC.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left">&nbsp;</td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><font style="font-size: 10pt">(5)</font></td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><font style="font-size: 10pt">Manchester Management Company, LLC, 131 Charles Street, 1<sup>st</sup> Floor, Boston Massachusetts 02114. Includes 1,250,000 shares owned by Manchester Explorer, L.P. and 416,666 shares owned by JEB Partners, L.P. Manchester Management holds dispositive power over the shares held by Manchester Explorer, L.P. and JEB Partners, L.P. Jeb Besser and Morgan Frank hold shared dispositive power over the shares held by Manchester Management Company, LLC. Additionally, Jeb Besser owns 166,666 shares for which he has sole dispositive power and Morgan Frank owns 166,666 shares for which he has sole dispositive power.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Approval Requirements and Eligible Voting
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of the Ordinary Matters and Special Matters
must be approved by a simple majority of the votes cast by Shareholders, present in person or by proxy at the Meeting. For these
purposes, any spoiled votes, illegible votes, defective votes, abstentions, and broker non-votes will not be considered votes cast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than the Ordinary Matters and Special
Matters discussed elsewhere in this Circular, management of Fennec does not intend to present and does not have any reason to believe
that others will present, at the Meeting, any item of business other than those set forth in this Circular. If, however, any other
business is properly presented at the Meeting and may properly be considered and acted upon, proxies will be voted by those named
in the applicable form of proxy in their sole discretion, including with respect to any amendments or variations to the matters
identified herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ORDINARY MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Presentation of Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The audited financial statements of the Corporation
for the fiscal year ended December 31, 2016, together with the report of the auditors thereon, will be placed before the Meeting.
Shareholders who wish to be added to the mailing list for the annual financial statements and Management&rsquo;s Discussion and
Analysis should complete the appropriate sections of the proxy or contact the undersigned at PO Box 13628, 68 TW Alexander Drive,
Research Triangle Park, North Carolina 27709 Attention: Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The number of directors of Fennec to be elected
at the Meeting is five (5). The following are the names of the persons for whom it is intended that votes will be cast for their
election as directors of the Corporation pursuant to the proxy which is hereby solicited, unless the Shareholder directs therein
otherwise:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Dr. Khalid Islam</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Mr. Adrian Haigh</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Mr. Chris A. Rallis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Mr. Marco Brughera</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Mr. Rostislav Raykov</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The term of office for each such person will
be until Fennec&rsquo;s next annual meeting of Shareholders or until such person&rsquo;s successor is elected or duly appointed.
<B>In the event that prior to the Meeting any vacancies occur in the slate of nominees submitted above, it is intended that discretionary
authority shall be exercised to vote the proxy hereby solicited (unless otherwise directed as aforesaid) for the election of any
other person or persons as directors. Fennec management is not now aware that any of such nominees would be unwilling to serve
as a director if elected.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The Board unanimously recommends that Shareholders
vote FOR the election of the above-named director nominees. The persons named in the enclosed form of proxy will vote FOR the election
of each of the director nominees to hold office until the close of the next annual meeting of Shareholders, unless a Shareholder
has specified in the proxy that his or her Common Shares are to be withheld from voting in respect thereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fennec has adopted a majority voting policy
in director elections that will apply at any meeting of Shareholders where an uncontested election of directors is held. Pursuant
to this policy, if the number of proxy votes withheld for a particular director nominee is greater than the votes for such director,
the director nominee will be required to submit his or her resignation as a director to the Chair of the Board promptly following
the applicable Shareholders&rsquo; meeting. Following receipt of resignation, the Governance Committee will consider whether or
not to accept the offer of resignation and make a recommendation to the Board. Within 90 days following the applicable Shareholders&rsquo;
meeting, the Board shall publicly disclose in a news release their decision whether to accept the applicable director&rsquo;s
resignation or not, including the reasons for rejecting the resignation, if applicable. The Board shall accept the resignation
absent exceptional circumstances. A director who tenders his or her resignation pursuant to this policy will not be permitted
to participate in any meeting of the Board or the Governance Committee at which the resignation is considered. A copy of the majority
voting policy may be found on the Fennec website at <FONT STYLE="color: windowtext"><U>www.fennecpharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the name of
each of our executive officers and directors, such person&rsquo;s principal occupation or employment, all other positions with
Fennec and any significant affiliate thereof now held by such person, if any, the year in which such person became a director of
Fennec and such person&rsquo;s age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation has an Audit Committee, a Compensation
Committee, and a Governance Committee. The current members of such committees are noted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 30%; text-align: center; vertical-align: bottom"><b>Name and Province/State and</b><br>
<b>Country of Residence, Position</b></td>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 35%; text-align: center; vertical-align: bottom"><b>Current Principal Occupation and</b><br>
<b>Principal Occupation for Previous</b><br>
<b>Five Years</b></td>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 9%; text-align: center; vertical-align: bottom"><b>Director</b><br>
<b>Since</b></td>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 8%; text-align: center; vertical-align: bottom"><b>Common</b><br>
<b>Shares</b><br>
<b>Held</b></td>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 10%; text-align: center; vertical-align: bottom"><b>Options to</b><br>
<b>Acquire</b><br>
<b>Common</b><br>
<b>Shares </b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Robert Andrade, Texas USA</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chief Financial Officer</P></td>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">CFO of Fennec Pharmaceuticals; previously senior analyst Magnetar Capital; previously Portfolio Manager Millennium Partners</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center; vertical-align: bottom">N/A</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">-</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">416,011</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chris A. Rallis, North Carolina, USA</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Director<sup>(1)(2)</sup></P></td>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">Executive in-residence at Pappas Ventures; previously, CEO of ImmunoBiosciences</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center; vertical-align: bottom">August 2011</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">-</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">111,850</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rostislav Raykov, New Jersey, USA</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chief Executive Officer, Director</P></td>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">CEO of Fennec Pharmaceuticals Inc.; Co-Founder and Manager, DCML LLC; previously Portfolio Manager Alchem Partners; previously Portfolio Manager John Levin &amp; Company</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center; vertical-align: bottom">July 2009</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">40,740</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">666,010</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Marco Brughera, Milano, Italy</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Director<sup>(2)(3)</sup></P></td>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">CEO Leadiant Biosciences SpA, previously Global Head Rare Disease and R&amp;D at Sigma-tau, VP Preclinical Development Nerviano Medical Sciences.</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center; vertical-align: bottom">August, 2016</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">-</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">35,545</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Adrian J. Haigh, Dublin, Ireland</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Director<sup>(1)(3)</sup></P></td>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">Senior Vice President and General Manager of EMEA Region at PTC Therapeutics; previously Chief Operating Officer, Gentium GmbH; previously Regional VP Commercial Operations, Biogen Idec</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center; vertical-align: bottom">April 2014</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">-</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">153,579</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Khalid Islam, Zug, Switzerland</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chairman of Board, Director<sup>(1)(2)(3)</sup></P></td>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">Founder/co-founder Sirius Healthcare Partners GMbH; previously Chairman and CEO of Gentium S.p.A.; previously CEO of Arpida AG</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center; vertical-align: bottom">April 2014</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">-</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom">213,825</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Member of the Audit Committee</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Member of the Compensation Committee</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Member of the Governance Committee</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Robert Andrade</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Andrade has served as Chief Financial Officer
since November 2015. Mr. Andrade was previously Chief Financial Officer and Director of Fennec from September 2009 until August
2013. In addition to his role with Fennec, Mr. Andrade was a senior analyst at Magnetar Capital, a portfolio manager for Millennium
Partners and a senior analyst at Caxton Associates. Mr. Andrade graduated from University of Southern California, where he earned
a Masters of Arts degree and Bachelor of Arts degree in economics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Chris A. Rallis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Chris A. Rallis has&nbsp;served as&nbsp;a
director of Fennec since August 2011. Mr. Rallis has been an executive-in-residence at Pappas Ventures, a life&nbsp;science venture
capital firm since January 2008.&nbsp;Previously, Mr. Rallis was the&nbsp;President and Chief Executive Officer of ImmunoBiosciences,
Inc. (&ldquo;IBI&rdquo;), a vaccine&nbsp;technology company formerly located in Raleigh, North Carolina from April 2006 through
June 2007.&nbsp;Prior to joining IBI, Mr. Rallis served as an executive in residence (part time) for Pappas Ventures,&nbsp;and
as a consultant for Duke University and Panacos Pharmaceuticals, Inc.&nbsp;Mr. Rallis is the former President&nbsp;and Chief Operating
Officer and director of Triangle Pharmaceuticals, Inc.,&nbsp;which was acquired by Gilead Sciences in January 2003 for approximately
$465&nbsp;million.&nbsp;Prior to assuming the role of President and COO in March 2000, he was&nbsp;Executive Vice President, Business
Development and General Counsel. While at&nbsp;Triangle, Mr. Rallis&nbsp;participated in 11 equity financings generating gross
proceeds&nbsp;of approximately $500 million.&nbsp;He was also primarily responsible for all business&nbsp;development activities
which included a worldwide alliance with Abbott&nbsp;Laboratories and the in-licensing of ten compounds. Before joining Triangle
in&nbsp;1995, Mr. Rallis served in&nbsp;various business development and legal management roles with Burroughs Wellcome Co. over
a 13-year period, including Vice President of Strategic Planning&nbsp;and Business Development. Mr. Rallis also&nbsp;serves on
the boards of Aeolus Pharmaceuticals, a biopharmaceutical company&nbsp;located in Mission Viejo, California and Tenax Therapeutics,
Inc., a biopharmaceutical company located in Morrisville, North Carolina.&nbsp;Mr. Rallis received his A.B. degree in&nbsp;economics
from Harvard College and a J.D. from Duke University. As a result of these and other professional experiences, Mr. Rallis possesses
particular healthcare industry knowledge and experience which strengthens the Board&rsquo;s collective qualifications, skills,
and experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Rostislav Raykov</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Raykov has served as a director of Fennec
since July 2009 and as Chief Executive Officer since July 2009.&nbsp;Since May 2007, Mr. Raykov has also been a General Partner
at DCML, a private investment partnership.&nbsp;Prior to DCML, from January 2006 to December 2007, Mr. Raykov was a portfolio manager
for Alchem Investment Partners and John Levin &amp; Co. prior to founding Alchem, Mr. Raykov was a portfolio manager and securities
analyst for John A. Levin &amp; Co. Event Driven Fund (2002-2005). Prior to joining John A. Levin &amp; Co., Mr. Raykov was a securities
analyst for the Merger Fund at Tiedemann Investment Group (1999-2002) and an investment banking analyst at Bear Stearns (1998-1999).&nbsp;&nbsp;Mr.
Raykov earned a B.S. in Business Administration from the University of North Carolina at Chapel Hill. As a result of these and
other professional experiences, Mr. Raykov has financial expertise and experience with the Company as it has developed within the
drug development industry and, as such, is able to provide the Company with unique insight and guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Marco Brughera</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since January 2011, Dr. Brughera <FONT STYLE="font-family: Times New Roman, Times, Serif">is
</FONT>currently CEO of Leadiant Biosciences SpA and has held several positions for the Sigma-Tau Group, including CEO and Global
Head of Sigma Tau Rare Disease, President of Sigma-Tau Research and President of Sigma-Tau Pharmaceuticals.&nbsp;He drove the commercial
revival of a lead oncology product line resulting in its successful sale for a total of around $900M.&nbsp;He also successfully
out-licensed the Defibrotide US rights to Jazz Pharmaceuticals. From 2004 to 2010, Dr. Brughera served as the Vice President of
Preclinical Development at Nerviano Medical Sciences (NMS), a pharmaceutical oncology-focused integrated discovery and development
company.&nbsp;He also served as the Managing Director at Accelera, an independent contract research organization with the NMS Group.&nbsp;From
1999 to 2004, Dr. Brughera held several senior level positions in the areas of research and development with Pharmacia and Pfizer.
Prior to 1999, he held various positions at Pharmacia &amp; Upjohn and Farmitalia Carlo Erba SpA, an Italian pharmaceutical company.
He currently serves on the Board of Solgenix and Lee&rsquo;s Pharmaceutical and until early 2014 was a member of the Board of Gentium
SpA.&nbsp;Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist<FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4C4C4C; background-color: white">.</FONT>
Mr. Brughera has wide-spread experience and knowledge of pharmaceutical drug development in international companies. His knowledge
in particular, of clinical drug development in Europe, deepens the Board&rsquo;s collective qualifications, skills and experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Adrian J. Haigh </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Mr. Adrian Haigh
has been Senior Vice President and General Manager of EMEA Region at PTC Therapeutics, Inc. since September 2014. Previously Mr.
Haigh served as Senior Vice President, Commercial Operations and Chief Operating Officer of Gentium GmbH since March 2011. Prior
to joining Gentium, Mr. Haigh served as Regional Vice President, Commercial Operations at Biogen Idec where he managed several
affiliates</FONT>&nbsp;<FONT STYLE="font-size: 10pt">and also the global distributor business and prior to that was the General
Manager Amgen Nordis and Portugal. He served as the Executive Vice President of Global Marketing and Corporate Planning at EUSA
Pharma and joined EUSA from Amgen where he led the international oncology franchise. Mr. Haigh previously&nbsp;has held senior
commercial and marketing positions at SmithKline Beecham, Schering Plough, Organon and Novo Nordisk. He has been a Director of
Fennec Pharmaceuticals Inc. since April 28, 2014 and a Director at Arch Biopartners Inc. since August 21, 2014. He received a Bachelor
of Arts with Honors in Economic History from Huddersfield Polytechnic, West Yorkshire, England and a Diploma in Marketing from
the Institute of Marketing. As a result of these and other professional experiences, Mr. Haigh has extensive international oncology
development expertise which strengthens the Board&rsquo;s collective qualifications, skills and experience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Dr. Khalid Islam</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Khalid Islam was the Chairman and CEO of
Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led the transition from a loss-making to a cash-flow positive and
profitable company. Under his leadership, the company value increased from US$25 million leading to a successful all cash US$1
billion merger with Jazz Pharmaceuticals, plc. From 1999-2008, Dr. Islam was President and CEO of Arpida AG where he transitioned
the early-stage start-up to a SWX-listed company and raised US$300 million in the IPO and follow-ons. From 1987-1999, he held various
positions in HMR &amp; MMD (now Sanofi-Aventis). From 1977-1987, Dr. Islam worked in academia at Imperial College (Univ. of London)
and in Milan University, where he was a contract professor. Dr. Islam is a graduate of Chelsea College and received his Ph.D. from
Imperial College, University of London. He holds several patents and has published over 80 articles in leading journals. He is
an advisor to the venture group Kurma Biofund (Paris). He is a founder/co-founder of Sirius Healthcare Partners GmbH (Zurich),
PrevAbr LLC (D.C.), BioAim LLC (L.A.) &amp; Life Sciences Management GmbH (Zug). Dr. Islam is Board Chair at Minoryx Therapeutics
(Spain). He serves on the board of Karolinska Development (Sweden), MolMed S.p.A. (Italy) and Immunomedics Inc. (IMMU) all of which
are traded publicly, and the private company OxThera (Sweden). In the past, he has served as Chairman of the Board of Directors
of Pcovery Aps (Copenhagen), Adenium Aps (Copenhagen) and C10 Pharma AS (Oslo). Dr. Islam&rsquo;s extensive international pharmaceutical
expertise in transitioning companies from development to production strengthens the Board&rsquo;s collective qualifications, skills
and experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Appointment of Auditors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 12, 2017, the Corporation&rsquo;s auditors,
Deloitte LLP, resigned at their own initiative and on May 12, 2017, the Corporation appointed Haskell &amp; White LLP as the Corporations
successor auditors. A copy of the reporting package in connection with the change in auditors, consisting of the Corporation&rsquo;s
Notices of Change of Auditor and response letters from the former and successor auditors, is attached as Schedule &ldquo;C&rdquo;
hereto. There were no &ldquo;reportable events&rdquo; within the meaning of NI 51-102 nor any disagreements with Deloitte LLP reportable
pursuant to Item 3.04(a)(1)(iv) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholders will be asked to vote for the
appointment of Haskell &amp; White LLP as auditors of the Corporation, to hold office until the next annual meeting of Shareholders
of the Corporation or until a successor is duly elected or appointed, at a remuneration to be fixed by the Board of Directors.
Approval of the ordinary resolution requires the affirmative vote of a majority of the votes cast in respect thereof by holders
of Common Shares represented at the Meeting. The person designated in the enclosed form of proxy intends to vote FOR the appointment
of Haskell &amp; White LLP<B> </B>as auditors of the Corporation, unless instructed otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The Board unanimously recommends that Shareholders
vote FOR the appointment of Haskell &amp; White LLP as auditors of the Corporation at the Meeting. The persons named in the enclosed
form of proxy will vote FOR the appointment of Haskell &amp; White LLP as auditors of the Corporation until the end of the next
annual meeting of the Shareholders and the authorization of the directors to fix their remuneration, unless a Shareholder has specified
in the proxy that his or her Common Shares are to be withheld from voting in respect thereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Advisory Vote on Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Dodd-Frank Wall Street Reform and Consumer
Protection Act of 2010 enables the Corporation&rsquo;s Shareholders to vote to approve, on an advisory or non-binding basis, the
compensation of our named executive officers as disclosed in this Circular in accordance with SEC rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For information on the Corporation&rsquo;s
executive compensation programs and how they reflect the Compensation Committee&rsquo;s philosophy and are linked to the Corporation&rsquo;s
performance, see &ldquo;Compensation Discussion and Analysis&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are asking for Shareholder approval of the
compensation of our named executive officers as disclosed in this Circular in accordance with SEC rules, which disclosures include
the disclosures under &ldquo;Compensation Discussion and Analysis&rdquo;, the compensation tables and the narrative discussion
following the compensation tables. This vote is not intended to address any specific item of compensation, but rather the overall
compensation of our named executive officers and the policies and practices described in this Circular (the &ldquo;<B>Advisory
Vote on Executive Compensation Resolution</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This vote is advisory and therefore not binding
on the Corporation, the Board or the Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is the text of the advisory vote
on executive Compensation resolution to be considered at the Meeting (the &ldquo;<B>Advisory Executive Compensation Resolution</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RESOLVED, that the compensation
paid to the Corporation&rsquo;s named executive officers, as disclosed in this Circular pursuant to Item 402 of Regulation S-K,
including the &ldquo;Compensation Discussion and Analysis&rdquo;, the compensation tables and narrative discussion be, and hereby
is, APPROVED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The Board unanimously recommends that Shareholders
vote FOR the Advisory Executive Compensation Resolution. The persons named in the enclosed form of proxy will vote FOR the Advisory
Executive Compensation Resolution, unless a Shareholder has specified in the proxy that his or her Common Shares are to be withheld
from voting in respect thereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SPECIAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 9, 2016, the Canadian Securities
Administrators substantively amended the regulatory framework that governs take-over bids, including amending both Multilateral
Instrument 62-104 &ndash; Take-Over Bids and Issuer Bids and National Policy 62-203 &ndash; Take-Over Bids and Issuer Bids (the
&ldquo;<B>Regulatory Amendments</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: black">The Corporation
is proposing to adopt a shareholder rights plan agreement (the &ldquo;<B>Rights Plan</B>&rdquo;) in the form attached hereto as
Schedule &ldquo;B&rdquo;. In light of the Regulatory Amendments, the Rights Plan was adopted to ensure, to the extent possible,
that all shareholders of the Corporation are treated fairly and equally in connection with any take-over bid or other acquisition
of control of the Corporation. The Rights Plan between the Corporation and </FONT>Computershare Trust Company of Canada <FONT STYLE="color: black">(as
rights agent) will be implemented if approved by Corporation&rsquo;s shareholders at the Meeting (the &ldquo;<B>Effective Date</B>&rdquo;).
Correspondingly, the Corporation is presenting the Rights Plan to the shareholders for their ratification, confirmation and approval
at the Meeting. If the Rights Plan is not approved at the Meeting, it shall be of no further force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Purpose of Rights Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The intended purpose of the Rights Plan is
to ensure, to the extent possible, that all shareholders of the Corporation are treated fairly and equally in connection with any
take-over bid or other acquisition of control of the Corporation (the &ldquo;<B>Purpose</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Rights Plan is not being adopted in response
to, or in anticipation of, any offer or take-over bid. The Rights Plan does not reduce the duty of the Board to act honestly, in
good faith and in the best interests of the Corporation, and to act on that basis if any offer or take-over bid is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Summary of the Rights Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholder rights plans, including the Rights
Plan, are complex legal documents with various intricacies as to their mechanics and relevant terms and conditions. The following
is a generally stated and non-exhaustive summary of the principal terms of the Rights Plan and is intended to provide shareholders
with a reasonable understanding of the mechanics of the Rights Plan and how the Rights Plan will help achieve the aforesaid Purpose.
This summary is qualified in its entirety by the full text of the Rights Plan, a copy of which is attached hereto as Schedule &ldquo;B&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Generally stated, the Rights Plan is designed
to address the Purpose by requiring any potential transaction that will result in a person (an &ldquo;<B>Acquiring Person</B>&rdquo;)
owning, in the aggregate, 20% or more of the outstanding Common Shares (inclusive of any Common Shares held by the Acquirer, its
associates and affiliates, and any person acting jointly or in concert with any of them (collectively, the &ldquo;<B>Acquirer Group</B>&rdquo;))
to be structured as a formal take-over bid that satisfies certain minimum requirements relating primarily to the manner in which
the bid must be made, the minimum number of days the bid must remain open, and the minimum number of shares that must be acquired
under the bid. Non-compliant transactions may, through the operation of the Rights Plan and the rights issued thereunder, result
in the Acquirer Group&rsquo;s Common Share position in the Corporation being substantially diluted. Consequentially, the Rights
Plan incentivizes the Acquirer to structure its proposed transaction in a manner that complies with the minimum requirements prescribed
by the Rights Plan, thereby helping fulfill the Purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Key mechanics of the Rights Plan include the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Issuance of Rights</U>: One right (a &ldquo;<B>Right</B>&rdquo;) is issued and attached to each
Common Share. This includes all Common Shares issued as of the Effective Date and all Common Shares issued after the Effective
Date but prior to the Separation Time (defined below).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Exercise of Rights &ndash; Dilution of Acquirer</U>: The Rights will only become exercisable
in the event that an Acquirer acquires, or announces its intention to acquire, Common Shares that would take the aggregate shareholdings
of the Acquirer Group to 20% or more of the Corporation&rsquo;s issued and outstanding Common Shares (a &ldquo;<B>Flip-in Event</B>&rdquo;).
On the eighth trading day following the Flip-in Event (the &ldquo;<B>Separation Time</B>&rdquo;), each Right will permit shareholders,
other than members of the Acquirer Group, to purchase additional Common Shares at a substantial discount to the then current market
price (generally stated, each Right will permit a shareholder to acquire 12 additional Common Share for each Right at a price per
Common Share equal to 50% of the market price of the Common Shares at the time of the Flip-in Event).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><U>Avoiding Dilution</U></B><U> &ndash; Conducting a Permitted Bid</U>: A Flip-in Event, however,
will not occur if the Acquiring Person conducts a take-over bid that meets the requirements of a &ldquo;Permitted Bid&rdquo;. The
principal requirements necessary for a take-over bid to constitute a Permitted Bid are: (a) it must be a formal take-over bid made
by way of a take-over bid circular; (b) it must be made to all of the shareholders of the Corporation and not just a subset of
shareholders; (c) it must remain open for at least 105 days; and (d) it must contain an irrevocable condition that it cannot close
unless more than 50% of the Common Shares held by shareholders other than the Acquiring Group have tendered their shares to the
bid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net effect of the key mechanics of the
Rights Plan is that in the absence of conducting a Permitted Bid, the Acquiring Person will risk having the Common Share position
of the Acquirer Group be substantially diluted through the exercise of the Rights by the other shareholders. By encouraging the
use of Permitted Bids in this manner, the Rights Plan helps achieve its Purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other general terms of the Rights Plan include
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Transferability of Rights</U>: Until the Separation Time, the Rights will be transferable only
together with the Common Shares to which they are attached and will be represented by the same certificates as such Common Shares.
After the Separation Time, separate certificates evidencing the Rights will be mailed to holders of such Rights as of the Separation
Time and the Rights shall trade separately from the Common Shares. The Rights do not carry any of the rights attaching to the Common
Shares and no holder of any Rights shall be entitled to vote, receive dividends, or be deemed to be a holder of any Common Shares
by virtue of holding such Rights alone.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Waiver of Application of Rights Plan</U>: The Board may, prior to the occurrence of a Flip-in
Event, waive the application of the Rights Plan in respect of, among other things, a particular Flip-in Event resulting from a
take-over bid made by way of a take-over bid circular to all holders of the Common Shares. In such circumstances, such waiver shall
also be deemed to be a waiver in respect of any other Flip-in Event occurring under a take-over bid made by way of a take-over
bid circular to all holders of Common Shares prior to the expiry of the first mentioned take-over bid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Redemption of Rights</U>: The Board may, with the approval of a majority of shareholders, at
any time prior to the occurrence of a Flip-in Event which has not been waived, elect to redeem all but not less than all, the outstanding
Rights at a price of CAD$0.000001 per Right.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Anti-Dilution Adjustments</U>: The exercise price of the Rights, the redemption price of the
Rights, the number and kind of securities subject to purchase upon exercise of each Right, and the number of Rights outstanding
are subject to adjustment from time to time to prevent dilution in the event of dividends, subdivisions, consolidations or other
changes in the outstanding Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Amendments</U>: The Rights Plan may be amended to correct any clerical or typographical error
or to maintain the validity of the Rights Plan as a result of any changes in applicable legislation or applicable rules or policies
of securities regulatory authorities or stock exchanges, without the approval of the holders of the Common Shares or Rights. Prior
to the Separation Time, the Corporation may, with the prior consent of the holders of Common Shares, supplement, amend, vary or
rescind any of the provisions of the Rights Plan in order to effect any changes. After the Separation Time, but before the Expiration
Time (defined below), the Corporation may only supplement, amend, vary or rescind any of the provisions of the Rights Plan with
the prior consent of the holders of the Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Expiration Time</U>: For the purposes of the Rights Plan, its expiration time (the &ldquo;<B>Expiration
Time</B>&rdquo;) is the close of business on that date which the Rights Plan is terminated. The Rights Plan will terminate on the
earliest of: (i) the date of the termination of the Meeting if the Rights Plan is not ratified and confirmed by the Corporation&rsquo;s
shareholders at the Meeting; (ii) the date of termination of the Corporation&rsquo;s annual and special meeting of its shareholders
in 2020 if the Rights Plan is not reconfirmed by the shareholders at such meeting; (iii) the date of termination of the Corporation&rsquo;s
annual and special meeting of its shareholders in 2023 if the Rights Plan is not reconfirmed by the shareholders at such meeting;
or (iv) the close of business on the ninth anniversary of the Effective Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Shareholder Rights Plan Resolution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: black">The resolution approving
the Rights Plan must be passed by </FONT>a majority <FONT STYLE="color: black">of votes cast by the holders of Common Shares present
in person or represented by proxy at the Meeting. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The Board unanimously recommends that Shareholders
vote FOR the adoption of the Rights Plan.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholders will be asked at the Meeting to
consider, and, if deemed advisable, to approve, confirm and adopt, with or without variation, the following ordinary resolution
which ratifies, confirms and approves the Rights Plan and its implementation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&lsquo;&lsquo;<B>BE IT HEREBY RESOLVED </B>as
an ordinary resolution of the shareholders that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: windowtext">1.</FONT></TD><TD STYLE="text-align: justify">the Corporation&rsquo;s shareholder rights plan (the &ldquo;<B>Rights Plan</B>&rdquo;), as created,
evidenced and governed by that certain Shareholder Rights Plan Agreement to be executed between the Corporation and Computershare
Trust Company of Canada (as rights agent), and the operation thereof in accordance with its terms, be, and are hereby, confirmed
and approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: windowtext">2.</FONT></TD><TD STYLE="text-align: justify">the board of directors of the Corporation (the &ldquo;<B>Board</B>&rdquo;) is hereby authorized
to cause all measures to be taken, such further agreements to be entered into, and such further documents to be executed as may
be deemed necessary or advisable by the Board to give effect to and fully carry out the intent of this resolution; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: windowtext">3.</FONT></TD><TD STYLE="text-align: justify">each director and officer of the Corporation be and is hereby authorized and directed, for and
on behalf of the Corporation, to sign and execute all such documents, and to do all such acts and things as such director or officer
determines, in their discretion, to be necessary or advisable in order to properly implement and give effect to the terms of this
resolution, such determination to be conclusively evidenced by the execution and delivery of such documents or the doing of any
such act or thing.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXECUTIVE COMPENSATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Compensation Discussion and Analysis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This discussion relates to the Named Executive
Officers listed in the Summary Compensation Table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Mandate of the Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It is the task of the Compensation Committee
to periodically review Fennec&rsquo;s compensation structure with respect to its Named Executive Officers, including its Chief
Executive Officer, to ensure that Fennec continues to attract and retain qualified and experienced individuals to its management
team and to motivate these individuals to perform to the best of their ability and in Fennec&rsquo;s best interests. The Compensation
Committee determines the compensation of the Named Executive Officers, evaluates and approves the compensation plans, policies
and programs of the Corporation and recommends to the Board from time to time other incentive compensation plans that it determines
should be considered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In reviewing executive compensation, the Compensation
Committee relies on the advice of the Chief Executive Officer regarding other executive officers and allows him to participate
in the Committee&rsquo;s deliberations on those executive officers. The Chief Executive Officer, however, is not allowed to participate
in the Committee&rsquo;s deliberations on his compensation. The Compensation Committee may not delegate any of its responsibilities
to another entity or to an individual without the approval of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>General Compensation Philosophy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The key components of executive officer compensation
are salaries, cash incentive awards and stock options. Fennec&rsquo;s policy with respect to the compensation of Named Executive
Officers is to establish annual goals with respect to corporate development and the individual areas of responsibility of each
Named Executive Officers and then to review total compensation with respect to the achievement of these goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Salary and Non-Equity Incentive Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It is Fennec&rsquo;s policy that the base salaries
paid to its Named Executive Officers reflect, in addition to the criteria set out above, the individual&rsquo;s responsibility,
experience and achievements. Each year the Compensation Committee sets a series of objectives for each executive and for the executive
team as a whole to determine the opportunity for cash incentive awards. These objectives are prioritized and assigned potential
values in light of overall company objectives, including with respect to scientific, clinical, regulatory, intellectual property,
business and corporate development, and financial objectives. The Compensation Committee reviews both base salaries and cash incentive
awards on at least an annual basis to ensure that the relevant criteria are satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The annual compensation considerations also
include the awarding of stock options. The granting of options to the Named Executive Officers under the Corporation&rsquo;s Amended
and Restated Stock Option Plan, as amended from time to time (the &ldquo;<B>Stock Option Plan</B>&rdquo;) serves three primary
purposes: (1) to recognize significant performance during the past year; (2) to provide long-term incentives for future efforts,
since the value of the options is directly dependent on the market valuation of the Corporation; and (3) to retain individuals,
as the options typically vest over time. When determining whether and how many new option grants will be made, the Compensation
Committee takes into account the amount and terms of any outstanding options. The Compensation Committee generally considers the
granting of options twice annually to all eligible employees, including executive officers. The Committee, in its discretion, may
grant options at other times during a fiscal year to a Named Executive Officer for performance or other reasons. Fennec does not
require its Named Executive Officers to own a specific number of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Analysis of Named Executive Officer Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee is charged with
annually reviewing and approving corporate goals and objectives relevant to each of the Named Executive Officer&rsquo;s compensation,
evaluating each officer&rsquo;s performance in light of those goals and objectives, and fixing and determining each Named Executive
Officer&rsquo;s level of salary and award of cash incentive payments and options based on this evaluation. In determining the long-term
incentive component of each Named Executive Officer&rsquo;s compensation, the Compensation Committee considers the Corporation&rsquo;s
performance and relative shareholder return, the value of similar incentive awards to other similarly situated executive officers
at companies in the comparator group, the awards given to the Named Executive Officer in past years, and such other factors as
the Compensation Committee considers relevant. Specifically, the Compensation Committee&rsquo;s review and evaluation includes
measurement of the following areas:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the achievement of corporate objectives, such as financings, partnerships and other business development,
and consideration of those achievements in light of budgetary constraints and other challenges facing the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Corporation&rsquo;s financial condition;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Corporation&rsquo;s share price and market capitalization; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the advancement of our product candidates, both preclinical and clinical.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Compensation Committee Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee has reviewed and
discussed the Compensation Discussion and Analysis contained in this Circular with management and, based on that review and discussion,
the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this
Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<tr style="vertical-align: top">
    <TD STYLE="width: 15%; text-align: justify"><font style="font-size: 10pt">Submitted by:</font></td>
    <TD STYLE="width: 85%; text-align: justify"><font style="font-size: 10pt">THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Chris Rallis, Chair</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Marco Brughera</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Khalid Islam</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Compensation Committee Interlocks and Insider
Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chris Rallis, Marco Brughera and Khalid Islam
are the current members of the Compensation Committee. None of these individuals was at any time during 2016 or at any other time
an officer or employee of ours. No interlocking relationship exists between any member of our Compensation Committee and any member
of any other company&rsquo;s board of directors or compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board has determined that each member of
the Compensation Committee is &ldquo;independent&rdquo; under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets out certain information
respecting the compensation paid for the fiscal years ended December 31, 2016, December 31, 2015 and December 31, 2014 to our Chief
Executive Officer and to our Chief Financial Officers, who were the only executives officer whose compensation exceeded $100,000
for the fiscal year ended December 31, 2016 (collectively, the &ldquo;<B>Named Executive Officers</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name and Principal Position</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Salary (USD$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Bonus (USD$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><b>Option Awards</b><br> <b>(USD$)<sup>(1)</sup></b></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total (USD$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: justify">Rostislav Raykov, CEO</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">2016</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">215,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">156,885</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">371,885</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2014</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,462</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">199,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">418,212</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Robert Andrade, CFO<sup>(2)</sup></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">177,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">268,933</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">446,433</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,791</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2014</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Krysia Lynes, Former Interim CFO<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2014</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,573</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Represents the aggregate grant date fair value computed in accordance with FASB ASC Topic 718.&nbsp;Dollar
value amounts for 2016 are based on individual grants to each of, Mr. Raykov and Mr. Andrade of 150,000 and 75,000 options, respectively,
on July 5, 2016, at an exercise price of $2.45 per common share, respectively, and will expire on July 5, 2023, respectively. One-third
of these options shall vest as of grant the grant date and be exercisable one year after the grant date (the &ldquo;Vesting Commencement
Date&rdquo;). The remaining two-thirds of the options shall vest monthly at a rate of 1/36<SUP>th</SUP> of the remaining grant
and shall be exercisable as of the last day of each following month after the Vesting Commencement Date. As of the third anniversary
of the grant date, all of the options shall be vested.&nbsp;Dollar value amounts for 2014 are based on individual grants to Mr.
Raykov of 83,333 and 25,000 options on January 24, 2014 and December 31, 2014, at an exercise price of $1.59 and $2.69 per common
share, respectively, which will expire on January 24, 2021 and December 31, 2021, respectively. All options vested in full on the
date of grant.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Mr. Andrade served as the Chief Financial Officer of Fennec from September 2009 until August 2013.
He re-joined as the Corporation&rsquo;s Chief financial officer in November 2015.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Ms. Lynes served as the Interim Chief Financial Officer of Fennec until November 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Rostislav Raykov</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Raykov has been employed by Fennec since
July 2009.&nbsp;Pursuant to an employment agreement dated May 3, 2010 between Mr. Raykov and Fennec, Mr. Raykov is employed as
Fennec&rsquo;s Chief Executive Officer and: (a) received an initial annual salary in the amount of $140,000, subject to annual
adjustment by our Board of Directors, (b) upon approval of the Stock Option Plan, was granted options to purchase up to 5.0% of
our Common Shares estimated by us to be outstanding upon completion of the 2010 Rights Offering, and (c) may receive annual bonuses
at the sole discretion of the Board.&nbsp;If Mr. Raykov&rsquo;s employment terminates due to a change of control of Fennec, Mr.
Raykov&rsquo;s remaining unvested options shall immediately vest and be fully exercisable. If Mr. Raykov is dismissed from employment
by us for any reason other than &ldquo;for cause,&rdquo; we are obligated to pay Mr. Raykov severance compensation equal to twelve
months of salary. The initial term of the agreement was for one year and the agreement automatically extends for additional one-year
periods unless terminated by either party in accordance with the agreement. If Mr. Raykov was terminated without cause on December
31, 2016, the Corporation would be required to pay Mr. Raykov $250,000 in in severance payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Robert Andrade</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Andrade has been employed by Fennec since
November 2015. Mr. Andrade is employed as Fennec&rsquo;s Chief Financial Officer.&nbsp;Pursuant to an employment agreement dated
November 13, 2015, Mr. Andrade (a) receives an initial annual salary in the amount of $165,000, and (b) may receive annual bonuses
at the sole discretion of the Board.&nbsp; If Mr. Andrade&rsquo;s employment terminates due to a change of control of the Fennec,
Mr. Andrade&rsquo;s remaining unvested options shall immediately vest and be fully exercisable. If Mr. Andrade is dismissed from
employment by us for any reason other than &ldquo;for cause,&rdquo; we are obligated to pay Mr. Andrade severance compensation
equal to six months of salary. If Mr. Andrade was terminated without cause on December 31, 2016, the Corporation would be required
to pay Mr. Andrade $95,000 in in severance payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to their employment agreements,
Mr. Raykov and Mr. Andrade, are a party to a confidentiality and intellectual property agreement with the Corporation.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the employment agreements for each of Mr.
Andrade and Mr. Raykov &ldquo;for cause&rdquo; is generally defined as (1) material breach of the terms of the employment or intellectual
property agreements; (2) failure to perform the duties inherent in the Employee&rsquo;s position in good faith and in a reasonable
and appropriate manner; or (3) acts of fraud or embezzlement or other intentional misconduct which adversely affects the Corporation's
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Payments on Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides details regarding
the estimated incremental payments from the Corporation to each of the current NEOs assuming termination without cause on December
31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>Severance <sup>(1)</sup></b></font></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Estimated Bonus</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Value of benefits</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Rostislav Raykov<BR> Chief Executive Officer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Robert Andrade<BR> Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">95,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: windowtext">(1)</FONT></TD><TD STYLE="text-align: justify">Severance payments are calculated based on the annualized salary and short term incentives described
herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Equity Grants, Exercises and Holdings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth information
concerning the number and value of unexercised options held by each Named Executive Officer as of December 31, 2016. All executive
awards, with the exception of those expiring 07/05/2023, vest and are exercisable immediately. The current Stock Option Plan provides
for grants denominated in US and CAD dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">Number of Options</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Granted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercisable</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Option Exercise<BR>
Price</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Expiration Date</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: justify">Rostislav Raykov</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">150,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">USD$</TD><TD STYLE="width: 15%; text-align: right"> 2.45</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">07/05/2023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">USD$</TD><TD STYLE="text-align: right"> 2.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/31/2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">USD$</TD><TD STYLE="text-align: right">1.59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">01/24/2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">USD$</TD><TD STYLE="text-align: right">0.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">08/23/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">USD$</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/20/2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">CAD$</TD><TD STYLE="text-align: right">1.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">08/18/2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">CAD$</TD><TD STYLE="text-align: right">2.43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">08/18/2017</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Robert Andrade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">USD$</TD><TD STYLE="text-align: right">2.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">07/05/2023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">CAD$</TD><TD STYLE="text-align: right"> 1.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">08/18/2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">CAD$</TD><TD STYLE="text-align: right">2.43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">08/18/2017</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Executive Incentive Plan Awards &ndash;
Value Vested or Earned During the Year</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table details the value of executive
options on the vesting date that vested during 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of Options<BR> Vested During Year</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><b>Option-Based Awards</b><br> <b>Value Vested During the Year</b><br> <b>(USD$)<font style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></font></b></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Non-Equity Incentive Plan<BR> Compensation &ndash; Value Earned<BR> During the Year (USD$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: center">Rostislav Raykov</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">50,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Robert Andrade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: right; padding-left: 0.25in">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">75,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The value of the vested option-based awards
represents the aggregate dollar value that would have been realized if the options under the option-based award had been exercised
on the vesting date. The dollar value was computed by determining the difference between the closing market price of the Common
Shares on the OTC at the deemed exercise on the vesting date and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Termination Benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event of his termination with us other
than for cause, we will be obligated to pay Mr. Raykov a one-time severance payment of $250,000. In the event of his termination
with us other than for cause, we will be obligated to pay Mr. Andrade a one-time severance payment of $95,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Director Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the compensation
earned by the Corporation's non-executive directors for the year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Fees paid in<BR>
 Cash</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Stock Awards</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><b>Option Awards<sup>(1)(2)</sup></b></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify">Dr. Islam</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">100,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">46,484</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">146,484</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Mr. Brughera</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,740</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Mr. Haigh</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,742</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Mr. Rallis</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">33,750</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">32,538</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">66,288</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: right">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">166,250</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">173,004</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">339,254</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20.4pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.4pt"></TD><TD STYLE="width: 18pt">(1)</TD><TD STYLE="text-align: justify">Represents the aggregate grant date fair value computed in accordance with FASB ASC Topic 718.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.4pt"></TD><TD STYLE="width: 18pt">(2)</TD><TD STYLE="text-align: justify">Detail of grants are presented in the following table:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Date of Grant</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of Options Granted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Option Exercise Price $USD</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; text-align: justify">Mr. Rallis</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">June 6, 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">14,344</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.44</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Dr. Islam</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 6, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Mr. Haigh</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 6, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Mr. Brughera</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">December 30, 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">35,545</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">2.11</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: right; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; padding-bottom: 2.5pt">80,627</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Equity Grants, Exercises and Holdings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth information
concerning the number and value of unexercised options held by each Named Executive Officer as of December 31, 2016. All executive
awards vest and are exercisable immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Director Outstanding Equity Awards at December
31, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number&nbsp;of&nbsp;Securities</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Underlying&nbsp;Unexercised</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options&nbsp;(#)&nbsp;Exercisable</b></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Option</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise&nbsp;Price&nbsp;(USD$)</b></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Option</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Expiration&nbsp;</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Date</b></P></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>Value of</b></font><br> <font style="font-size: 10pt"><b>Unexercised in-</b></font><br> <font style="font-size: 10pt"><b>the-Money</b></font><br> <font style="font-size: 10pt"><b>Options (USD$)<font style="font-family: Times New Roman, Times, Serif"><sub>(1)</sub></font></b></font></TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Adrian Haigh</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">133,333</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.31</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center; padding-left: 5.4pt">04/25/2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">12/31/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">06/09/2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Chris Rallis</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">11/18/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,133</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">04/04/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,833</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.54</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">05/17/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,814</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,111</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">08/17/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,778</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,762</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">11/20/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,166</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">04/03/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">05/17/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">08/13/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,145</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">08/23/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,666</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">01/24/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,729</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">04/25/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">05/15/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">08/04/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">11/07/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">12/31/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">03/16/2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">05/11/2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,127</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">08/03/2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,062</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">11/10/2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,696</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,344</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">06/09/2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Khalid Islam</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">04/25/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">12/31/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">12/11/2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">06/09/2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Marco Brughera</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">12/30/2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,066</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Calculated using the closing price of the Corporation&rsquo;s common
shares on December 30, 2016 USD$2.14 on the OTC which was the last trading day for the year 2016.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Director Incentive Plan Awards &ndash; Value
Vested During the Year</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table details the value of director
options on the vesting date that vested during 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of Options<BR> Vested During Year</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><b>Option-Based Awards</b><br> <b>Value Vested During the Year</b><br> <b>(USD$)<font style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></font></b></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Non-Equity Incentive Plan<BR> Compensation &ndash; Value Earned<BR> During the Year (USD$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: center">Adrian Haigh</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">10,246</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">615</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Chris Rallis</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,344</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">861</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Khalid Islam</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,230</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Marco Brughera</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,066</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: right">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">80,627</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,771</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The value of the vested option-based awards
represents the aggregate dollar value that would have been realized if the options under the option-based award had been exercised
on the vesting date. The dollar value was computed by determining the difference between the closing market price of the Common
Shares on the OTC at the deemed exercise on the vesting date and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The annual compensation considerations for
non-executive directors also include the awarding of stock options. We believe that granting of options to the non-executive directors
serves three primary purposes: (1) to recognize the significant time and effort commitments during the past year; (2) to provide
long-term incentives for future efforts since the value of the options is directly dependent on the market valuation of the Corporation;
and (3) to retain quality individuals. When determining whether and how many new option grants will be made, the Compensation Committee
takes into account the amount and terms of any outstanding options. Fennec does not require its non-executive directors to own
a specific number of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #010101">Chris A. Rallis
</FONT>entered into an Independent Director Agreement with the Corporation, dated as of August 25, 2011, which provides for (i)
cash compensation in the form of USD$2,000 for each meeting of the Board attended and USD$500 for each committee meeting attended
(other than committee meeting held before or after a Board meeting held on the same day), and (ii) non-cash compensation in the
form of a grant of options to purchase shares of the Corporation&rsquo;s Common Shares having an aggregate value equal to $5,000
(with price per share and exercise price based on the value of the Corporation&rsquo;s Common Shares as of the date of grant) per
board meeting attended. The options immediately vest when granted and are otherwise subject to the terms and conditions of the
Stock Option Plan. The Independent Director Agreements also provide for the reimbursement of such director&rsquo;s reasonable travel
and related expenses incurred in the course of attending board meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of Adrian Haigh and Khalid Islam has entered
into an Independent Director Agreement with the Corporation, dated as of April 25, 2014, which provides for (i) cash compensation
in the form of USD$2,000 for each meeting of the Board attended and USD$500 for each committee meeting attended (other than committee
meeting held before or after a Board meeting held on the same day), and (ii) non-cash compensation in the form of a grant of options
to purchase 133,000 shares of the Corporation&rsquo;s Common Shares. Such options shall vest: (i) as to 66,666 common shares, on
the grant date; and (ii) as to 66,666 common shares, upon and subject to the Corporation obtaining PUMA for STS in the EU, provided
they then remain on the Board at the time of such approval and that they have played a vital or precipitating part in obtaining
such EU orphan drug designation, as reasonably determined by non-interested Board members. If the vesting conditions referred to
in (ii) above have not occurred by December 31, 2017, the option to acquire the 66,666 common shares referred to in (ii) above
shall be terminated and of no further force or effect. The Independent Director Agreements also provide for the reimbursement of
such director&rsquo;s reasonable travel and related expenses incurred in the course of attending board meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2015, fees payable to the non-executive
directors was increased to $2,500 per board meeting attended, with all other conditions set forth above remaining the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July of 2016, the Board resolved to align
the compensation paid to all its members to that of companies in similar industries and market capitalizations. The July 2016 resolution
replaced all previous member agreement. Each non-management member receives an annual base retainer of $30,000. The Chairman of
the Board shall receive an additional annual fee of $50,000 and includes all activities of the Chairman. The Chair of the Audit
Committee receives an additional annual fee of $7,500. Chair of any other Committee shall receive an additional annual fee of $5,000.
These annual base retainer and annual cash fees are to be paid quarterly and are in lieu of any per-meeting fees. Board members
shall also be reimbursed for any out of pocket disbursements for attending Board or Committee meetings or any other meeting at
the Company&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OTHER INFORMATION REGARDING MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Stock Option Plan as last ratified by Shareholders
on June 8, 2016 was adopted to develop the interest and incentive of eligible employees, directors and other service providers
of the Corporation in the Corporation's growth and development by giving eligible Participants (as defined below) an opportunity
to purchase Common Shares on a favourable basis, thereby advancing the interests of the Corporation, enhancing the value of the
Common Shares for the benefit of all Shareholders and increasing the ability of the Corporation to attract and retain skilled and
motivated individuals in the service of the Corporation. The maximum number of Common Shares that may be issued under the Stock
Option Plan is a rolling maximum equal to 25% of the issued and outstanding Common Shares from time to time (as of May 19, 2017,
this maximum percentage equals 3,426,827 Common Shares). As of May 19, 2017 options for an aggregate of 2,482,711 Common Shares
have been granted and remain issued and outstanding under the Stock Option Plan (representing approximately 18% of the currently
issued and outstanding Common Shares), options for 68,739 Common Shares have been exercised under the Stock Option Plan (representing
approximately 0.5% of the currently issued and outstanding Common Shares) since June 8, 2016, and the Stock Option Plan has 1,011,616
unallocated options (representing approximately 7.4% of the currently issued and outstanding Common Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Within the above aggregate limit of 25% of
the issued and the issued and outstanding Common Shares from time to time, the Stock Option Plan contains no limits on the number
or percentage of such options that may be granted to insiders of the Corporation or to any one person. The Board currently has
the right, in its sole discretion, to alter, amend or discontinue the Stock Option Plan from time to time and at any time. However,
no such amendment or discontinuation may alter or impair the rights or increase the obligations under the Stock Option Plan of
Participants without the consent of the Participants. Further, any amendment to the Stock Option Plan is subject to prior regulatory
approval. The Stock Option Plan&rsquo;s amending procedures explicitly provide that shareholder approval is not required to implement
any amendments, save and except for amendments related to (i) the maximum number of Common Shares or any other shares of the Corporation
which are reserved for issuance under the Stock Option Plan (and under any other share compensation arrangement of the Corporation);
(ii) a reduction in the exercise price for options held by insiders; and (iii) an extension to the term of options held by insiders.
Examples of the amendments that may be made by the Board without shareholder approval include, without limitation, amendments related
to (a) the vesting provisions of the Stock Option Plan or any option granted under the Stock Option Plan, (b) the early termination
provisions of the Stock Option Plan or any option granted under the Stock Option Plan, (c) the addition of any form of financial
assistance by the Corporation for the acquisition by all or certain categories of Participants, and the subsequent amendment of
any such provision which is more favourable to such Participants, (d) the addition or modification of a cashless exercise feature,
payable in cash or Common shares, which provides for a full deduction of the number of underlying Common Shares from the Stock
Option Plan reserve, (e) changing the maximum percentage of Common Shares which are reserved for issuance under the Stock Option
Plan to a maximum number of Common Shares not exceeding the number of Common Shares which then represents the maximum percentage
previously approved by the Corporation&rsquo;s security holders; (f) the suspension or termination under applicable laws (including,
without limitation, the rules, regulations and policies of the TSX); and/or (g) general housekeeping matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Participation in the Stock Option Plan shall
be limited to directors, employees and service providers who are designated from time to time by the Compensation Committee (each,
a &ldquo;<B>Participant</B>&rdquo;). Board nominees or other associates or affiliates of the Corporation&rsquo;s largest shareholder,
Southpoint Capital Advisors, are not eligible to participate in the Stock Option Plan. Subject to the terms of the Stock Option
Plan, the Compensation Committee determines the Participants designated to participate in the Stock Option Plan, the number of
Common Shares such Participant is entitled to purchase and the price at which the Common Shares may be purchased and the applicable
vesting period. The option price at which the Common Shares may be purchased under the Stock Option Plan is the fair market value
of the Common Shares of the Corporation at the time of grant, which under the Stock Option Plan is the closing price of the Common
Shares on the TSX on the trading day immediately preceding the date of grant (if the Common Shares are then listed on the TSX).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options granted under the Stock Option Plan
must be exercised within a period of seven (7) years from the date of grant, failing which the Participant's right to purchase
such Common Shares lapses. The Stock Option Plan provides that should the expiry date of any vested stock option of a Stock Option
Plan participant fall on, or within nine (9) trading days immediately following, a Black-Out Period, the expiry date of such a
vested stock option will automatically be the date that is ten (10) trading days from the date the relevant Black-Out Period ends.
Unless otherwise determined by the Compensation Committee and specifically set forth in the stock option agreement executed by
the Participant, options vest and may be exercised by the Participant as to one-third on each of the first, second and third anniversaries
of the date of grant. The Compensation Committee may, however, in its sole discretion by written notice to any Participant, accelerate
the vesting of all or any of the options of a Participant. The Participant's rights under the options granted under the Stock Option
Plan are not assignable or transferable by the Participant. The Corporation does not currently have any arrangements in place for
financial assistance to facilitate the purchase of securities by Participants under the Stock Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Participant&rsquo;s right to exercise options
ceases following any of the following events (each of which, a &ldquo;<B>Participant Termination Date</B>&rdquo;): (i) if an employee,
such Participant&rsquo;s employment with the Corporation or any of its subsidiaries is terminated for any reason; (ii) if a director,
such Participant ceases to be a director on the Board for any reason; or (iii) if a service provider, such Participant ceases to
provide services to the Corporation. In such case, the Participant, or the Participant's legal representative, as the case may
be, may only exercise such options that are then vested any time prior to the earlier of: the original expiry date of such option,
or within 30 days of the Participant Termination Date, or if specifically approved by the Board, such later date which may not
be more than three (3) years following the Participant Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For U.S. federal income tax purposes, an optionee
who is granted an incentive stock option under the Stock Option Plan will generally not recognize taxable income either at the
time the option is granted or upon its exercise, although the exercise will increase the optionee&rsquo;s alternative minimum taxable
income by an amount equal to the difference, if any, between the fair market value of the shares at the time of exercise and the
option's exercise price, and therefore may subject the optionee to the alternative minimum tax. Upon the sale or exchange of the
shares more than two years after grant of the option and more than one year after exercising the option, any gain or loss will
be treated as long-term capital gain or loss. If these holding periods are not satisfied, the optionee will recognize ordinary
income at the time of sale or exchange equal to the difference between the exercise price and the lower of (i) the fair market
value of the shares at the date of the option&rsquo;s exercise or (ii) the sale price of the shares. Fennec will be entitled to
a deduction in the same amount as the ordinary income recognized by the optionee. Any gain or loss recognized on such a premature
disposition of the shares in excess of the amount treated as ordinary income will be characterized as long-term or short-term capital
gain or loss, depending on the optionee&rsquo;s holding period with respect to such shares. Options that do not qualify as incentive
stock options under the Stock Option Plan are referred to as nonstatutory options. Generally, an optionee will not recognize any
taxable income at the time he or she is granted a nonstatutory option. Upon its exercise, however, the optionee will generally
recognize taxable ordinary income measured as the excess of the then fair market value of the shares acquired over the exercise
price of the option. Any taxable income recognized in connection with an option exercise by an optionee who is also one of our
employees will be subject to tax withholding by us. Fennec will be entitled to a tax deduction in the same amount as the ordinary
income recognized by the optionee with respect to shares acquired upon exercise of a nonstatutory option. Upon resale of such shares
by the optionee, any difference between the sales price received and the fair market value for the shares on the date of exercise
of the option will be treated as long-term or short-term capital gain or loss, depending on the optionee&rsquo;s holding period
with respect to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Directors&rsquo; and Officers&rsquo; Liability
Insurance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fennec has liability insurance for its directors
and officers. The aggregate annual premium for that insurance is approximately $42,000 no part of which is payable by the directors
and officers of the Corporation. The insurance coverage under the policy for each loss is limited to an annual aggregate of $2,500,000
for each policy year. The policy is subject to a $250,000 retention for any non securities claim, $750,000 for securities claims
and $1,500,000 for merger objection suits and there shall be no retention for any non-indemnifiable claim(s) made against a director
or officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><BR>
Indebtedness of Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 13(k) of the Securities Exchange Act
of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), prohibits Fennec from making or arranging an extension of credit to
its directors or executive officers in the form of a personal loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No individual, who is or was a director, executive
officer or employee of Fennec, nor any proposed nominee for election as a director of Fennec, nor any associate of any one of them:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">is or, at any time since the beginning of Fennec&rsquo;s most recent completed financial period,
has been indebted to Fennec or any of its subsidiaries; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">was indebted to another entity, which indebtedness is, or was at any time during Fennec&rsquo;s
most recent completed financial period, the subject of a guarantee, support agreement, letter of credit or other similar arrangement
or understanding provided by Fennec or any of its subsidiaries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Interest of Informed Persons in Material
Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the BCBCA and our articles,
directors who have a material interest in any person who is a party to a material contract or a proposed material contract with
Fennec are required to disclose that interest and abstain from voting on any resolution to approve that contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the knowledge of Fennec, except as disclosed
below, no informed person or proposed nominee for election as a director of Fennec and no associate or affiliate of the foregoing
persons has or has had any material interest, direct or indirect, in any transaction since the commencement of Fennec&rsquo;s last
completed financial period or in any proposed transaction which has materially affected or would materially affect Fennec or any
of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with regulations of the SEC,
Fennec must disclose in this Circular any transaction or series of transactions in Fennec&rsquo;s last two completed fiscal years
to which Fennec was a party and in which any director or executive officer of Fennec, or any of their immediate family members
had a direct or indirect material interest, if the amount involved exceeds the lesser of $120,000 or one (1) percent of the average
of the Corporation&rsquo;s total assets at year end for the last two completed fiscal years (a &ldquo;<B>Related Party Transaction</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Performance Graph</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following line graph compares the percentage change, from December 31, 2011 to December 31, 2016, in cumulative total shareholder
return for $100 (CAD$ for TSX and US$ for AMEX) invested in our </FONT>Common Shares<FONT STYLE="font-family: Times New Roman, Times, Serif">
with cumulative total return of the AMEX Composite, the AMEX Biotechnology Index and the S&amp;P/TSX Composite Total Return Index.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="pg28img1_def14a.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides certain information
with respect to securities authorized for issuance under equity incentive plans as of December 31, 2016 (share amounts are in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">Plan Category</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">(a)<BR> Number&nbsp;of&nbsp;securities&nbsp;to&nbsp;be&nbsp;issued<BR> upon&nbsp;exercise&nbsp;of&nbsp;outstanding<BR> options&nbsp;warrants&nbsp;and&nbsp;rights&nbsp;(*)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">(b)<BR> Weighted-average&nbsp;exercise&nbsp;price&nbsp;of<BR> outstanding&nbsp;options,&nbsp;warrants&nbsp;and<BR> rights</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">(c)<BR> Number&nbsp;of&nbsp;securities&nbsp;remaining<BR> available&nbsp;for&nbsp;future&nbsp;issuance&nbsp;under<BR> equity&nbsp;compensation&nbsp;plans<BR> (excluding&nbsp;securities&nbsp;reflected&nbsp;in<BR> Column&nbsp;(a))</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: justify">Equity compensation plan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,428,449</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><font style="font-size: 10pt">USD $ 1.92</font></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">983,192</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">approved by shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">999,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">CAD $ 2.38</font></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: right">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,427,450</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">983,192</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">* The Corporation&rsquo;s current stock option
plans allow for the issuance of stock options denominated in both U.S. dollars and Canadian dollars.&nbsp;&nbsp;This table presents
the number and weighted-average exercise price of outstanding options by the currency associated with the original grants.&nbsp;At
December 31, 2016 we had 1,428,449 stock options denominated in U.S. dollars with a weighted-average exercise price of $1.92 and
999,001 stock options denominated in CAD dollars with a weighted-average exercise price of CAD$2.38.&nbsp;&nbsp;At December 31,
2016, we had 983,192 stock options available for future issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPORT ON CORPORATE GOVERNANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fennec believes that good corporate governance
is important to ensure that Fennec is managed for the long-term benefit of its shareholders. In connection with Fennec&rsquo;s
commitment to comply with the standards of applicable securities legislation, Fennec has continued to review Fennec&rsquo;s corporate
governance practices and policies and has compared them to developing practices and regulation in Canada and the United States.
In particular, Fennec has considered developing rules and guidelines for corporate governance practices and policies, and related
disclosures, promulgated by the Canadian Securities Administrators, the SEC as well as the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2004, Fennec&rsquo;s Board adopted
a Mandate of the Board of Directors, Corporate Governance Guidelines and a Code of Business Conduct and Ethics applicable to all
officers, directors and employees of Fennec. The Board also (i) restated the charter of the Audit Committee, (ii) established a
separate Governance Committee and adopted a written charter for the committee, (iii) restated the charter of the Compensation Committee,
and (iv) appointed an Independent Chairman of the Board. Each of the various committee charters and other corporate governance
documents are regularly reviewed with a view to determining if any updates are necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Set out below is a description of certain corporate
governance practices of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Shareholder Communications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholders who wish to communicate with members
of the Board of Directors, including the independent directors individually or as a group, may send correspondence to them care
of the Chief Executive at our principal executive offices. Such communication will be forwarded to the intended recipient(s). Fennec
currently does not intend to have the Chief Executive screen this correspondence, but it may change this policy if directed by
the Board due to the nature or volume of the correspondence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors is composed of a majority
of independent directors. The Board applies the definition of independence found in Canadian National Instrument 58-101 and National
Policy 58-201. The Board has determined that four of the current five directors are &ldquo;independent&rdquo;, being Messrs. Rallis,
Brughera, Haigh and Islam. Only one director has a material relationship with the Corporation and are therefore is not independent.
Mr. Raykov, Chief Executive Officer of the Corporation is considered to have a material relationship with the Corporation by virtue
of his executive officer position. Fennec is of the view that the composition of its Board reflects a diversity of background and
experience that are important for effective corporate governance. Other directorships held by Board members are described in this
Circular under the heading &ldquo;Ordinary Matters &ndash; Election of Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the financial year ended December 31,
2016, the Board devoted a portion of six meetings to discuss in the absence of directors who are not &ldquo;independent,&rdquo;
and certain of the Committees also conducted executive sessions where all participants were independent directors. In order to
facilitate open and candid discussion among its independent directors, the Corporate Governance Guidelines provide that independent
directors should meet at least annually without the presence of management or non-independent directors, that the Chairman or Lead
Independent Director is authorized to call additional meetings of the independent directors and that the Chairman or Lead Independent
Director is authorized to act as the presiding director at such meetings and to develop the agenda for such meetings. In addition,
each Board member is free to suggest the inclusion of items on any Board or Committee meeting agenda and suggest pre-meeting materials
to either the Chair of the Board or the Lead Independent Director. At any meeting of the Board, each Board member is also free
to raise subjects that are not on the agenda for that meeting. Furthermore, each Board committee, the Chairman and the Lead Independent
Director, on behalf of the independent directors as a group, have the authority to hire legal, accounting, financial or other advisors
as they may deem necessary in their best judgment, without the need to obtain the prior approval of any officer of the Corporation.
The Chief Financial Officer of the Corporation will arrange for payment of the invoices of any such third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Directors&rsquo; Attendance</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the fiscal year ended December 31, 2016,
the Board met on nine occasions, the Audit Committee met on five occasions, the Compensation Committee met on seven occasions,
and the Governance Committee met on six occasions. The following table sets forth the attendance of directors at meetings of the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 70%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Director</b></font></td>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 28%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Attendance at </B><BR>
        <B>Board Meetings</B></P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Adrian Haigh</font></td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">9/9</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Chris Rallis</font></td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">9/9</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Khalid Islam</font></td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">9/9</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Marco Brughera</font></td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">3/3</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Steve Skolsky</font></td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">3/3</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board expects management to be responsible
for the day-to-day operations of and to implement the approved strategic business plan within the context of authorized budgets
and corporate policies and procedures. Management is expected to report regularly to the Board in a comprehensive, accurate, and
timely fashion on Fennec&rsquo;s business and affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fennec does not have a formal written policy
regarding attendance of Board members at annual meetings of the shareholders. Fennec, however, strongly encourages all directors
to attend such meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Mandate of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board has the overall responsibility for
the strategic planning and general management of Fennec&rsquo;s business and affairs. In fulfilling its responsibilities, the Board
is responsible for, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify; text-indent: -0.2in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">adoption of a strategic plan;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">approval of the annual operating and capital expenditure budgets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">identification of the principal risks of the business and ensuring the implementation of the appropriate
systems to manage these risks;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">succession planning, including appointing and monitoring senior management;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">adoption of a communications policy;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">approval of acquisitions, dispositions, investments and financings that exceed certain prescribed
limits;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">integrity of the internal control and management information systems; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">development of clear position descriptions for directors, including the Chair of the Board, the
Chair of each Board committee and, together with the CEO, a clear position description for the CEO.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board discharges its responsibilities directly
and through committees that have specific areas of responsibility. The frequency of Board meetings and the nature of items discussed
during the meetings depend on the opportunities or risks that Fennec faces. The Board, directly and through its committees, has
adopted a process whereby it assesses the risk factors that must be identified and managed to ensure Fennec&rsquo;s long-term viability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board mandate generally describes the Board&rsquo;s
expectation of management and provides a list of specific matters for which management must obtain Board approval prior to implementation.
The Board mandate also provides that the Board annually establish performance objectives for the CEO, which responsibility has
been delegated to the Compensation Committee. In addition, the Board receives regular updates from management concerning the Corporation&rsquo;s
progress toward achieving corporate goals. The Board has also delegated to the Compensation Committee responsibility for evaluating
the CEO&rsquo;s compensation, which evaluation includes review of the CEO&rsquo;s performance against annual performance objectives
for the year and input from the Chairman, Lead Independent Director as well as other directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board Mandate is attached as Schedule &ldquo;A-1&rdquo;
to this Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Position Descriptions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board Mandate and the Governance Committee
Charter provide that the Board is responsible for the development of clear position descriptions for directors, including the Chair
of the Board and the chair of each board committee; and, together with the Chief Executive Officer, a clear position description
for the Chief Executive Officer, which includes delineating management&rsquo;s responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Board Leadership Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 9, 2015, Khalid Islam was elected
Chairman of the Board. The Board determined that in the best interest of the Corporation the most effective leadership structure
at this time is to separate the roles of Chairman and Chief Executive Officer. As an independent director, Dr. Islam is responsible
for overseeing and ensuring the independence of and separation between management and the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risk Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors has an active role,
as a whole and also at the committee level, in overseeing the identification and management of our principal risks. The Board of
Directors regularly receives reports from senior management on areas of material risk to our Corporation<B>, </B>including our
credit, liquidity, operational, legal and regulatory risks. In carrying out its responsibilities under its charter, the Audit Committee
reviews our major financial risk exposures and the steps management has taken to monitor and control such exposures, and it also
meets periodically with management to discuss policies with respect to risk assessment and risk management. In addition, the Compensation
Committee oversees the management of risks relating to our executive and non-executive compensation plans and arrangements, and
the Governance Committee manages risks associated with the independence of the Board of Directors and potential conflicts of interest.
While each committee oversees certain risks and the management of such risks, the entire Board of Directors is regularly informed
through committee reports about such risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ethical Business Conduct</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2004, Fennec&rsquo;s Board adopted
a Mandate of the Board of Directors, Corporate Governance Guidelines and a Code of Business Conduct and Ethics (the &ldquo;<B>Code</B>&rdquo;)
applicable to all officers, directors and employees of Fennec. You can access the Code in the corporate governance section of Fennec&rsquo;s
website at <B><U>www.fennecpharma.com</U>. </B>Fennec undertakes to provide any person without charge, upon request, a copy of
such code by writing to Attn: Code of Ethics Request, Fennec Pharmaceuticals Inc., 68 TW Alexander Drive, PO Box 13628, Research
Triangle Park, North Carolina 27709<FONT STYLE="font-variant: small-caps">. </FONT>Fennec is committed to adhering to applicable
legal requirements and maintaining the highest standards of conduct and integrity. The Code is intended to promote those goals
in conjunction with the Corporation&rsquo;s Insider Trading Policy, Disclosure Policy and Audit Committee Complaint Procedures.
The Code sets out the legal and ethical standards of conduct for personnel of Fennec and addresses topics such as: reporting obligations
and procedures; honest and ethical conduct and conflicts of interest; compliance with applicable laws and Corporation policies
and procedures; confidentiality of corporate information; use of corporate assets and opportunities; public disclosure and books
and records; and non-retaliation. The Board is not aware of any conduct of a director or officer that constitutes a departure from
the Code and, as a result, since the beginning of Fennec&rsquo;s fiscal year ended December 31, 2016, there have been no material
change reports filed that pertain to such a departure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Code provides that the Governance Committee
shall monitor and periodically evaluate compliance with the Code and its application to the Corporation&rsquo;s business. In addition,
the Code sets out the procedures adopted by the Audit Committee for the receipt, retention and treatment of complaints and concerns
regarding accounting, internal accounting control, or auditing matters. In each case, the Code provides that the Corporation will
not discipline, discriminate against or retaliate against any employee who reports a complaint or concern in good faith, whether
or not the information is ultimately proven to be correct, or who cooperates in any investigation or inquiry thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to ensure independent judgment in
considering transactions or agreements in which a director or officer has a material interest, the Code contains a process that
must be followed regarding the disclosure, consultation and approval of transactions involving potential conflicts of interest.
As a first step, officers and directors must disclose such matters to the Chief Executive Officer and to the Chair or any other
disinterested member of the Governance Committee charged with reviewing conflicts of interest. The Board has adopted rules for
what activities constitute conflicts of interest and potential conflicts of interest, as well as procedures for determining whether
a relationship or transaction constitutes a conflict of interest, the current versions of which are attached as appendices to the
Code. Following disclosure, any officer or director must avoid or terminate any activity that involves an actual or reasonably
apparent conflict of interest unless it is determined at the appropriate level that the activity is not a conflict of interest
or is otherwise not harmful to the Corporation or improper. Disinterested members of the Governance Committee shall make any such
determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the BCBCA and our articles,
directors who have a material interest in any person who is a party to a material contract or a proposed material contract with
us are required to disclose that interest and abstain from voting on any resolution to approve that contract. In addition, no director,
director nominee or officer may enter into any transaction or relationship that is disclosable by such person or the Corporation
pursuant to the BCBCA or by the Corporation pursuant to SEC rules without the prior approval of the disinterested members of the
Governance Committees, and no such person may directly or indirectly approve, or represent the Corporation or the other party in
arranging, the terms of any transaction between the Corporation and a party with which he/she has any relationship of a type that
is disclosable by such person or the Corporation pursuant to the BCBCA or by the Corporation pursuant to SEC rules. All transactions
between the Corporation and a party with which a director, officer or employee has such a relationship shall be on an arm&rsquo;s
length basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Orientation and Continuing Education</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Responsibility for the oversight of orientation
for new directors and continuing education programs for all directors with respect to the Corporation&rsquo;s business and financial
matters, corporate governance and other appropriate subjects is assigned to the Governance Committee under its charter. In this
regard, the Governance Committee&rsquo;s duties include ensuring the adequacy of the orientation and education program for new
members of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Governance Committee is also responsible
for arranging continuing education for directors in order to ensure that directors maintain the skill and knowledge necessary to
meet their obligations as directors. Given the Corporation&rsquo;s limited resources, to date, no formal external continuing education
programs have been sponsored by the Corporation but members of the Board are free to attend such programs as they determine necessary
and in the Corporation&rsquo;s best interest. The Corporation also provides directors with the opportunity to meet with senior
management of the Corporation, including the Chief Financial Officer, as well as external advisors, at any time and such personnel
and advisers are regularly invited to present at Board meetings or in connection with Board retreats to provide updates in legal,
accounting, governance and other business developments. Some meetings are held at the Corporation&rsquo;s premises, allowing directors
the opportunity to gain additional insight into the Corporation&rsquo;s operations. In addition, analyst reports and other information
relating to the Corporation&rsquo;s business and the industry in which it operates are presented at Board meetings and strategy
sessions and industry-related articles of interest are distributed to Board members from time to time. Pursuant to each Committee
charter, directors are permitted to obtain advice and assistance from internal or external advisors, including for the purposes
of continuing education and developments relevant to board responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Nomination of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board does not have a nominating committee.
Nominations to the Board are largely the result of recruitment efforts of the Chairman of the Board. Potential nominees are discussed
with the Board as a whole. The Board feels that the current approach is appropriate. <FONT STYLE="font-family: Times New Roman, Times, Serif">The
full Board of Directors assumed the functions of a nominating committee. The Board of Directors believes that such action was appropriate
because it believes that, in doing so, it gains access to the expertise and insight of its management and non-independent directors
on the operations of the Corporation as they relate to an evaluation of a director candidate. The final determination to nominate
a candidate is made by our independent directors, acting separately. The Board has not adopted a formal charter regarding the nominations
process; but has adopted resolutions formalizing the nominations process</FONT><B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Chairman of the Board has the ongoing responsibility
of assessing the effectiveness of the Board as a whole, the committees of the Board and the contribution of individual directors.
Evaluation criteria include such factors as the attendance record of individual Board members and the effectiveness of their participation
at Board meetings. Annually, the Chairman of the Board prepares and approves the list of nominees to be presented at the Annual
Meetings of the Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Term Limits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation has not adopted term limits
for directors of the Corporation. The Board believes that the need to have experienced directors who are familiar with the business
of the Corporation must be balanced with the need for renewal, fresh perspectives and a healthy skepticism when assessing management
and its recommendations. In addition, as mentioned above the Board undertakes an assessment process that evaluates its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While term limits can help ensure the Board
gains fresh perspective, imposing this restriction means the Board would lose the contributions of longer serving directors who
have developed a deeper knowledge and understanding of the Corporation over time. The Board believes that term limits have the
disadvantage of losing the contribution of directors who have been able to develop, over a period of time, increasing insight into
the Corporation and its operations and thereby provide an increasing contribution to the Board as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Board and Senior Management Diversity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation believes that an effectively
functioning Board is critical to its success, and that its Board must have the flexibility to adopt director election and composition
practices that suit its unique needs and circumstances. The Corporation seeks the most qualified persons, regardless of gender
or other characteristics unrelated to expertise and performance. Accordingly, the Corporation does not have written policies or
set targets with respect to representation of women on the Board or as members of its senior management team. Such policies, while
well intended, may create arbitrary and technical impediments to the selection of the most qualified persons. This approach enables
the Corporation to make decisions regarding the composition of its Board and senior management team based on what is in the best
interests of the Corporation and its shareholders. The Corporation has no female executive officer and there are no women on the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Short-Selling</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Corporation&rsquo;s Insider
Trading Policy, which is applicable to its directors, officers and other employees, no such person may engage in short-selling
of the Corporation&rsquo;s securities or any trading in exchange-traded options with respect to the Corporation&rsquo;s securities.
Any director or executive officer who wishes to enter into another type of hedging arrangement must consult with the Compliance
Officer as legal restrictions and/or public disclosures may be required. In addition, margin loans using the Corporation&rsquo;s
securities and other pledges of such securities present the risk that the pledgee will foreclose and sell the securities at a time
when the Corporation&rsquo;s personnel are prohibited from trading, with possibly serious collateral consequences. For this reason,
such an arrangement may be risky and should not be undertaken without the prior written approval of the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board is responsible for establishing director
and executive officer compensation and reviews such compensation at least as often as annually. The Board believes that directors
should be fairly compensated for undertaking the responsibilities associated with serving as a director. At the same time, director
compensation should be consistent with market practices generally. The Board delegates to the Compensation Committee responsibility
for periodically assessing market practices for director and executive officer compensation. In addition, the Compensation Committee
evaluates director compensation in the context of evaluating director recruitment and retention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee operates under a
written charter adopted by the Board. The Compensation Committee is currently composed entirely of independent directors: Mr. Rallis
(Chair), Mr. Brughera and Dr. Islam. The Compensation Committee held seven meetings in the fiscal year ending December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to director compensation, the Compensation
Committee of the Board determines the compensation to be paid to Fennec&rsquo;s executive officers and periodically reviews Fennec&rsquo;s
compensation structure to ensure that Fennec continues to attract and retain qualified and experienced individuals to Fennec&rsquo;s
management team and motivate these individuals to perform to the best of their ability and in Fennec&rsquo;s best interests. Among
other things, the Compensation Committee considers compensation levels of comparable positions in similarly sized organizations
in the biotechnology industry. The Compensation Committee also administers the Stock Option Plan and approves new stock option
grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board has created audit, compensation,
and governance committees to ensure that the Board functions independently of management. It is also customary practice for directors
(i) to regularly receive detailed information describing Fennec&rsquo;s performance, and (ii) when necessary, to speak directly
with management regarding additional information required on particular matters of interest. Moreover, directors have access to
information independent of management through Fennec&rsquo;s external auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Audit Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On behalf of the Board, the Audit Committee
of the Board retains, oversees and evaluates Fennec&rsquo;s independent auditors, reviews the financial reports and other financial
information provided by Fennec, including audited financial statements, and discusses the adequacy of disclosure with management
and the auditors. The Audit Committee also reviews the performance of the independent auditors in the annual audit and in assignments
unrelated to the audit, assesses the independence of the auditors, and reviews their fees. The Audit Committee is also responsible
for reviewing Fennec&rsquo;s internal controls over financial reporting and disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee operates under a written
charter adopted by the Board. Multilateral Instrument 52-110 &ndash; Audit Committees requires certain disclosures be cross-referenced
with respect to the Audit Committee when soliciting proxies from Shareholders for the purpose of electing directors. The Corporation
is relying on the exemption found in Part 7 of the Multilateral Instrument applicable to U.S. Listed Issuers. The Audit Committee
met four times during the fiscal year ended December 31, 2016. As required by the rules of the SEC and Canadian securities laws,
the Audit Committee is composed entirely of independent directors, each of whom the Board has determined is &ldquo;financially
literate&rdquo; for purposes of the applicable laws: Mr. Rallis (Chair), Mr. Haigh and Dr. Islam. In addition, the Board has determined
that Mr. Rallis qualifies as an &ldquo;audit committee financial expert,&rdquo; as defined in Item 407(d)(5) of Regulation S-K
promulgated by the SEC. A copy of the Corporation&rsquo;s Audit Committee Charter is included as Schedule &ldquo;A-2&rdquo; to
this Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Audit Committee Report</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee has (1)&nbsp;reviewed and
discussed the audited financial statements with management, (2)&nbsp;discussed with Deloitte LLP, our independent registered public
accounting firm, the matters required to be discussed by the Statement on Auditing Standards No.&nbsp;61, and (3)&nbsp;received
the written disclosures and the letter from Deloitte LLP required by the Independence Standards Board Standard No.&nbsp;1, and
has discussed their independence with the independent registered public accounting firm. Based upon these discussions and reviews,
the Audit Committee recommended to the Board that the audited financial statements be included in the Corporation&rsquo;s Annual
Report on Form 10-K for the fiscal year ended December&nbsp;31, 2016 that we filed with the SEC on March 29, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deloitte LLP served as our independent registered
public accounting firm and audited our consolidated financial statements for the year ended December&nbsp;31, 2016. Though the
Audit Committee does not have formal pre-approval policies and procedures in place, it has pre-approved all of the services performed
by Deloitte LLP as discussed below, as required by SEC regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Audit Fees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the aggregate
fees for professional services and other services rendered by our independent auditors, Deloitte LLP in fiscal year 2016 and 2015
(in US dollars):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Fiscal&nbsp;Year <BR>Ended 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Fiscal&nbsp;Year <BR>Ended 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: justify"><font style="font-size: 10pt">Audit Fees<sup>(1)</sup></font></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">65,902</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">92,035</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Audit-Related Fees<sup>(2)</sup></font></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Tax Fees<sup>(3)</sup></font></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,026</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><font style="font-size: 10pt">All Other Fees<sup>(4)</sup></font></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,370</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,104</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">77,298</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">104,984</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><I>Audit Fees</I> include fees for the standard audit work that needs to be performed each year
in order to issue an opinion on the consolidated financial statements of the Corporation.&nbsp;It also includes fees for services
that can only be provided by the Corporation&rsquo;s auditor such as auditing of non-recurring transactions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><I>Audit-Related Fees</I> include fees assurance and related services that are reasonably related
to the performance of the audit or review and are traditionally performed by the independent accountant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Tax Fees include fees for periodic tax consultations and compliance services in various local,
regional and national tax jurisdictions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">All Other Fees include fees for products and services other than Audit Fees, Audit Related Fees
and Tax Fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee does not have formal pre-approval
policies and procedures; however, prior to the engagement by the registrant, the Audit Committee approved all of the services performed
by Deloitte LLP as required by SEC regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<tr style="vertical-align: top">
    <TD STYLE="width: 15%; text-align: justify"><font style="font-size: 10pt">Submitted By:</font></td>
    <TD STYLE="width: 85%; text-align: justify"><font style="font-size: 10pt">THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Chris A. Rallis, Chair</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adrian J. Haigh</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Khalid Islam</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Governance Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Governance Committee of the Board develops,
recommends and oversees the effectiveness of Fennec&rsquo;s corporate governance guidelines. In addition, the Governance Committee
oversees the orientation and education of directors and the process of evaluating the Board and its committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Governance Committee of the Board is charged
with nominating activities, including determining desired Board skills and attributes for directors, conducting appropriate and
necessary evaluations of the backgrounds and qualifications of possible director candidates, and recommending director nominees
for approval by the Board or the Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Governance Committee is currently composed
three independent directors: Mr. Haigh (Chair), Mr. Brughera and Dr. Islam. The Governance Committee held six meetings in the fiscal
year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Retention of Outside Advisors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fennec&rsquo;s Corporate Governance Guidelines
provide that the Board, each Board committee, the Chairman and the Lead Independent Director, on behalf of the independent directors
as a group, shall have the authority to hire legal, accounting, financial or other advisors as they may deem necessary in their
best judgment, without the need to obtain the prior approval of any officer of the Corporation. The Corporation will arrange for
payment of the invoices of any such third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 16(a) Beneficial Ownership Reporting
Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently do not have any securities registered
under Section&nbsp;12 of the Exchange Act, as amended. Accordingly, our directors, officers, and stockholders beneficially owning
more than 10% of our Common Shares are not required to comply with the reporting requirements of Section&nbsp;16(a) of the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>SHAREHOLDER
PROPOSALS FOR NEXT YEAR&rsquo;S ANNUAL MEETING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BCBCA permits certain eligible shareholders
of the Corporation to submit shareholder proposals to the Corporation, which proposals may be included in a management proxy circular
relating to an annual meeting of shareholders. Shareholders having proposals that they desire to present at the next year&rsquo;s
annual meeting of shareholders should, if they desire that such proposals be included in the Corporation&rsquo;s proxy circular
relating to such meeting, submit such proposals in time to be received by Fennec not later than February 28, 2018. To be so included,
all such submissions must comply with the requirements of the SEC&rsquo;s Rule 14a-8 and you should pay close attention to that
rule. Proposals should be mailed to the Secretary at Fennec Pharmaceuticals Inc., PO Box 13628, 68 TW Alexander Drive, Research
Triangle Park, NC 27709.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -0.5in"><FONT STYLE="font-variant: small-caps"><B>ADDITIONAL
INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial information for the financial year
ended December 31, 2016 is provided in the Corporation&rsquo;s consolidated financial statements and management&rsquo;s discussion
and analysis (&ldquo;<B>MD&amp;A</B>&rdquo;), which are included in the Annual Report. Security holders who wish to be added to
the mailing list for the annual and interim financial statements and MD&amp;A should complete the appropriate sections of the proxy
or contact the undersigned at PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, North Carolina 27709.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation&rsquo;s Annual Report on Form
10-K for the fiscal period ended December 31, 2016 (including the consolidated financial statements and MD&amp;A) and other information
relating to the Corporation is available on SEDAR at <U>www.sedar.com</U> and at <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>APPROVAL OF THE BOARD OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The contents of this Circular and its sending
to Shareholders have been approved by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>DATED</B> at Research Triangle Park, North
Carolina this 19<SUP>th</SUP> day of May, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; text-align: justify">&nbsp;</td>
    <td style="width: 50%; text-align: justify"><font style="font-size: 10pt"><b>BY ORDER OF THE BOARD OF DIRECTORS</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b><i>/s/ Rostislav Raykov</i></b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Rostislav Raykov</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Chief Executive Officer</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE &ldquo;A-1&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Mandate of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>A.&#9;Responsibilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors (the &ldquo;<B>Board</B>&rdquo;)
of Fennec Pharmaceuticals Inc. (the &ldquo;<B>Company</B>&rdquo;) is responsible for the stewardship of the Company. All directors
shall act honestly and in good faith with a view to the best interests of the Company and exercise the care, diligence and skill
that a reasonably prudent person would exercise in comparable circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board retains plenary authority and power
to do all lawful acts and things as are not by law or otherwise directed or required to be exercised or done by the shareholders
of the Company or in some other manner. In carrying out its responsibilities, the Board of Directors (or the committees of the
Board of Directors duly constituted by the Board of Directors to the extent such delegation is permitted by law and is specifically
made by the Board of Directors) shall have the following specific responsibilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the adoption of a corporate strategic plan that includes the periodic review and approval of business
plans, which take into account, among other things, the opportunities and risks of the business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the identification of the principal risks of the Company&rsquo;s business and ensuring the implementation
of appropriate systems to manage these risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">the adoption of processes for succession planning, the periodic review of succession plans for
key members of senior management, including the Chief Executive Officer (the &ldquo;<B>CEO</B>&rdquo;), and the appointment and
training of, and monitoring the performance and compensation of senior management, including officers of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">the adoption of a communications policy and the periodic review of such policy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">the establishment of adequate systems of internal controls and management information systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">the adoption of corporate governance guidelines or principles applicable to the Company, including
with respect to: (i) the size and composition of the Board; (ii) the orientation of new directors; (iii) the provision of continuing
education to directors; (iv) the compensation and tenure of directors; (v) the periodic assessment (at least annually) of the performance
of the Board, its committees and directors, this Mandate, the Charter for each committee of the Board; and (vi) the position description(s)
applicable to each individual director, as well as the competencies and skills each individual director is expected to bring to
the Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">the oversight of the maintenance by management of practices and processes to ensure compliance
with applicable laws and appropriate ethical standards, including the adoption by management of corporate policies and procedures
and the adoption of a written code of business conduct and ethics applicable to directors, officers and employees of the Company
containing standards that are reasonably designed to deter wrongdoing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">to the extent feasible, satisfying itself as to the integrity of the CEO and other senior officers
and that the CEO and other senior officers create a culture of integrity throughout the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">the submission of matters or questions requiring the approval of shareholders to the shareholders
for approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">the approval of the submission to the shareholders of any amendment to the articles of the Company
or the approval of any adoption, amendment or repeal of any articles or bylaws of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify">the recommendation of candidates for election or appointment to the Board of Directors, including
the review of nominations recommended by shareholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify">the approval of the annual objectives of the Company and the Chief Executive Officer, and the assessment
of the performance of the Company and the Chief Executive Officer against the approved objectives;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify">the approval of an annual operating budget for the Company and its subsidiaries on a consolidated
basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify">the authorization of the issuance of securities of the Company as required in accordance with applicable
laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify">the declaration of dividends on shares of the Company or the approval of the purchase, redemption
or other acquisition of shares issued by the Company as required in accordance with applicable laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify">the oversight of the reliability and integrity of accounting principles and practices followed
by management, financial statements and other financial reporting, and disclosure practices followed by management;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify">the oversight of the qualifications and independence of the independent auditors of the Company
and the approval of the terms of their audit and non-audit service engagements as required in accordance with applicable laws and
the requirements of any stock exchanges on which the Company lists its securities and of securities regulatory authorities, as
adopted or in force or amended from time to time, and the assessment of the performance of the independent auditors, the filling
of a vacancy in the office of the independent auditor between shareholders' meetings, and the recommendation of the annual appointment
or, if appropriate, the removal, of the independent auditors of the Company to the shareholders of the Company for their approval
in accordance with applicable laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify">the approval of the annual audited consolidated financial statements of the Company and, as required
in accordance with applicable laws, the approval of the quarterly unaudited consolidated financial statements of the Company and
overview of the accounting principles and practices followed by management;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify">the approval of prospectuses, annual information forms, annual reports on Form 20-F, 40-F or 10-K
or other applicable form, as the case may be, and proxy circulars and proxy statements sent to shareholders of the Company and
the review of managements' discussion and analyses of financial condition and results of operations, and other material disclosure
documents as determined by the Board of Directors from time to time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify">the establishment and periodic review of the Company&rsquo;s measures for receiving feedback from
security holders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: justify">the development of clear position descriptions for directors, including the Chair of the Board,
a &ldquo;Lead Independent Director&rdquo; and the chair of each board committee; and, together with the CEO, a clear position description
for the CEO, which includes delineating management&rsquo;s responsibilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">22.</TD><TD STYLE="text-align: justify">the oversight of the management of environmental risks and practices, charitable activities and
other social responsibility matters; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">23.</TD><TD STYLE="text-align: justify">to the extent not otherwise referred to above, the review and approval of all proposed transactions
and matters described below under the heading &ldquo;B. Decisions Requiring Prior Approval of the Board&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">and, where applicable, in accordance with the
requirements of the <I>Canada Business Corporations Act</I>, the stock exchanges on which the Company lists its securities and
securities regulatory authorities, as adopted or in force or amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In discharging its duties and responsibilities,
the Board of Directors is expected to be fully diligent in its oversight to avoid fraud or abuse. Accordingly, the Board may conduct
such examinations, investigations or inquiries, and engage such special legal, accounting or other advisors, at the expense of
the Company, at such time or times and on such terms and conditions as the Board of Directors considers appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>B.</B></TD><TD STYLE="text-align: justify"><B>Decisions Requiring Prior Approval of the Board</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to such other approvals as required
by applicable law or the stock exchanges on which the Company lists its securities and securities regulatory authorities, the Board
(or the committees of the Board duly constituted by the Board to the extent such delegation is permitted by law and is specifically
made by the Board of Directors) shall review and approve:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the strategic plan, financial plans and operating budget of the Company on at least an annual basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the quarterly and annual financial statements of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">all material capital expenditures not part of the approved operating budget, all mergers and acquisitions,
and all material investments and dispositions of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">all material borrowings and banking arrangements of the
Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">all financing by the Company including the issuance of debt, equity and derivative instruments;
for greater certainty, this includes the approval of all off-balance sheet financings by the Company or by special purpose entities
or affiliates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">the purchase and redemption of securities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify">any changes to the articles or by-laws of the Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.</TD><TD STYLE="text-align: justify">the hiring and, if necessary, the termination of the Chief Executive Officer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.55pt"></TD><TD STYLE="width: 35.45pt">9.</TD><TD STYLE="text-align: justify">the compensation paid to senior management and directors, including the issuance of stock options
and non &ndash; arm&rsquo;s length consulting arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.55pt"></TD><TD STYLE="width: 35.45pt">10</TD><TD STYLE="text-align: justify">any other material matters outside the ordinary course of the Company's business including all
major strategic and policy decisions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">11.</TD><TD STYLE="text-align: justify">any other matter specified by the Board as requiring its
approval.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>C.</B></TD><TD STYLE="text-align: justify"><B>Expectations of Management</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CEO, through the Senior management, is
responsible for the day-to-day operations of the Company and for providing the Board, directly or through the Chair of the Board,
the appropriate committee or the Lead Independent Director, with timely, complete and accurate information on such operations.
The Board expects management to propose and, after Board approval, implement the Company's strategic plan and to be accountable
for the Company's financial and competitive performance. The Board expects the Company's resources to be managed in a manner consistent
with enhancing the value of the Company and with consideration for ethics and corporate social responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board may request that certain members
of senior management attend all or any portion of a Board or committee meeting and may schedule presentations by managers who can
provide additional insight based on their personal involvement in the matter or their particular expertise. Each director shall
have complete access to any member of senior management. The Chief Financial Officer and the General Counsel of the Company shall
each have access to meet separately with the Audit Committee and Governance Committee respectively, the Chairman and Lead Independent
Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board may reasonably rely on the information
provided to them by the Company&rsquo;s senior management personnel and outside advisors and auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>D.</B></TD><TD STYLE="text-align: justify"><B>Measures for Receiving Shareholder Feedback</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR>
The Company has developed a Disclosure Policy to facilitate consistent disclosure practices aimed at informative, timely and broad
dissemination of material information to the market in compliance with applicable securities laws and the rules and policies of
any exchange on which the Company&rsquo;s securities are listed. The Disclosure Policy Committee established under the Disclosure
Policy is responsible for overseeing and monitoring communications with, and responses to inquiries from, both institutional and
individual investors and the financial community consistent with the objectives of the Company&rsquo;s Disclosure Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Company spokespersons as appointed by the Disclosure
Policy Committee from time to time are available to shareholders by telephone, fax and e-mail and the Company maintains up-to-date
material of interest to shareholders and investors on the Company&rsquo;s web site at www.Fennecpharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>E.</B></TD><TD STYLE="text-align: justify"><B>General.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors shall review and assess
the adequacy of the mandate of the Board on an annual basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nothing in this Mandate is intended, or may
be construed, to impose on any member of the Board a standard of care or diligence that is in any way more onerous or extensive
than the standard required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE &ldquo;A-2&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Audit Committee Charter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Purpose</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purpose of the Audit Committee (the &ldquo;Committee&rdquo;)
of the Board of Directors (the &ldquo;Board&rdquo;) of Fennec Pharmaceuticals Inc. (together with its subsidiaries, the &ldquo;Company&rdquo;)
is to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Assist the Board in fulfilling its responsibility to oversee the
Company&rsquo;s accounting and financial reporting processes and audits of the Company&rsquo;s financial statements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Review the financial reports and other financial information provided
by the Company, the Company&rsquo;s disclosure controls and procedures, and its internal accounting and financial controls;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Assume direct responsibility for the appointment, compensation, retention
(and where appropriate, replacement), and oversight of the work of the outside auditor in preparing or issuing an audit report
or related work;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Oversee the independence of the outside auditor and approve all auditing
services and permitted non-audit services provided by the outside auditor;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Receive direct reports from the outside auditor and resolve any disagreements
between management and the outside auditor regarding financial reporting; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Carry out the specific responsibilities set forth below in furtherance
of this stated purpose.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Committee Membership and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Resources and Authority</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In discharging its oversight role, the Committee
is granted all responsibilities and authority required by MI 52-110 and SEC Rule 10A-3, including without limitation the authority
to investigate any matter brought to its attention with full access to all books, records, facilities and personnel of the Company
and the authority to engage independent legal, accounting or other advisors to obtain such advice and assistance as the Committee
determines necessary to carry out its duties. The Committee may request any officer or employee of the Company or the Company's
outside counsel to attend a meeting of the Committee or to meet with any member of, or consultants to, the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company shall provide the Committee all
appropriate funding, as determined by the Committee, for payment of compensation to any such advisors and any outside auditor,
as well as for any ordinary administrative expenses of the Committee that it determines are necessary or appropriate in carrying
out its responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Key Responsibilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Committee&rsquo;s role is one of oversight,
and it is recognized that the Company&rsquo;s management is responsible for preparing the Company&rsquo;s financial statements
and that the outside auditor is ultimately accountable to the Board and the Committee, as representatives of the stockholders,
and is responsible for auditing those financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following functions shall be the common
recurring activities of the Committee in carrying out its oversight role. The functions are set forth as a guide and may be varied
and supplemented from time to time as appropriate under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Appointment of Outside Auditor. The Committee
shall have direct responsibility for the appointment, compensation, retention (and where appropriate, replacement), and oversight
of the work of any registered public accounting firm selected to be the Company&rsquo;s outside auditor for the purpose of preparing
or issuing an audit report or performing other audit, review or attest services for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Appointment and Performance Evaluation of Chief
Financial Officer and Internal Auditor. The Chair of the Committee shall participate in the identification of candidates for the
positions of Chief Financial Officer and Lead of the Company&rsquo;s internal auditing function, if any, and shall advise management
with respect to the decision to hire a particular candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disclosure Controls and Procedures. The Committee
shall review periodically with management the quality and adequacy of the Company&rsquo;s disclosure controls and procedures. The
Committee must be satisfied that adequate procedures are in place for the review of the Company&rsquo;s public disclosure of financial
information extracted or derived from the Company&rsquo;s financial statements and must periodically assess the adequacy of those
procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Internal Controls. The Committee shall discuss
periodically with management and the outside auditor the quality and adequacy of the Company&rsquo;s internal controls and internal
auditing procedures, if any, including any significant deficiencies in the design or operation of those controls which could adversely
affect the Company&rsquo;s ability to record, process, summarize and report financial data and any fraud, whether or not material,
that involves management or other employees who have a significant role in the Company&rsquo;s internal controls, and discuss with
the outside auditor how the Company&rsquo;s financial systems and controls compare with industry practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting Policies. The Committee shall review
periodically with management and the outside auditor the quality, as well as acceptability, of the Company&rsquo;s accounting policies,
and discuss with the outside auditor how the Company&rsquo;s accounting policies compare with those in the industry and all alternative
treatments of financial information within U.S. and Canadian generally accepted accounting principles that have been discussed
with management, the ramifications of use of such alternative disclosures and treatments and the treatment preferred by the outside
auditor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pre-approval of All Audit Services and Permitted
Non-Audit Services. The Committee shall approve, in advance, all audit services and all permitted non-audit services to be provided
to the Company by the outside auditor; provided that any non-audit services performed pursuant to an exception to the pre-approval
requirement permitted under applicable laws shall not be deemed unauthorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Annual Audit. In connection with the annual
audit of the Company&rsquo;s financial statements, the Committee shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">request from the outside auditor a formal written statement delineating
all relationships between the auditor and the Company consistent with Independence Standards Board Standard No. 1 and such other
requirements as may be established by the Public Company Accounting Oversight Board, discuss with the outside auditor any such
disclosed relationships and their impact on the outside auditor&rsquo;s objectivity and independence, and take appropriate action
to oversee the independence of the outside auditor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approve the selection and the terms of the engagement of the outside
auditor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review with management and the outside auditor the audited financial
statements to be included in the Company&rsquo;s Annual Report filed on the System for Electronic Document Analysis and Retrieval
(&ldquo;SEDAR&rdquo;) and with the SEC, and review and consider with the outside auditor the matters required to be discussed by
Statement on Auditing Standards (SAS) No. 61.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review with management and the outside auditor any press releases
in respect of the audited financial statements before the Company first publicly discloses this information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">perform the procedures set forth below in &ldquo;Financial Reporting
Procedures&rdquo; with respect to the annual financial statements to be reported.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review with management and the outside auditor the Company&rsquo;s
critical accounting policies and practices.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">recommend to the Board whether, based on the reviews and discussions
referred to above, the annual financial statements should be included in the Company&rsquo;s Annual Report filed on SEDAR and with
the SEC.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interim Reports. In connection with the Company&rsquo;s
preparation of its interim financial information to be included in the Company&rsquo;s Quarterly Reports filed on SEDAR and filed
with the SEC, the Committee shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review with the outside auditor the Company&rsquo;s interim financial
information and the matters required to be discussed by SAS No. 61.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">perform the procedures set forth below in &ldquo;Financial Reporting
Procedures&rdquo; with respect to the interim financial information to be reported.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">by action of a majority of the Committee or through the Committee
Chair, review with the outside auditor, prior to filing, the Company&rsquo;s interim financial information to be included in the
Company&rsquo;s Interim Reports filed on SEDAR and filed with the SEC.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">by action of a majority of the Committee or through the Committee
Chair, review with the outside auditor any interim press releases in respect of the interim financial statements before the Company
first publicly discloses this information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial Reporting Procedures. In connection
with the Committee&rsquo;s review of each reporting of the Company&rsquo;s annual or interim financial information, the Committee
shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">discuss with the outside auditor whether all material correcting
adjustments identified by the outside auditor in accordance with U.S. and Canadian generally accepted accounting principles and
the rules of the SEC and CSA are reflected in the Company&rsquo;s financial statements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review with the outside auditor all material communications between
the outside auditor and management, such as any management letter or schedule of unadjusted differences.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review with management and the outside auditor any material financial
or other arrangements of the Company which do not appear on the Company&rsquo;s financial statements and any transactions or courses
of dealing with third parties that are significant in size or involve terms or other aspects that differ from those that would
likely be negotiated with independent parties, and which arrangements or transactions are relevant to an understanding of the Company&rsquo;s
financial statements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">resolve any disagreements between management and the outside auditor
regarding financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hiring Policies. The Committee shall review
and approve the Company&rsquo;s hiring policies regarding partners, employees and former partners and employees of the present
and any former outside auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Charter. The Committee shall review and reassess
at least annually the adequacy of this Charter and recommend any proposed changes to the Board for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reports. The Committee shall report its activities
to the full Board on a regular basis and make such recommendations to the Board with respect to the above and other matters as
the Committee deems necessary or appropriate. The Committee shall also prepare and submit to the appropriate authority or body
any other report required by applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><B>Complaint Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any issue of significant financial misconduct
shall be brought to the attention of the Committee for its consideration. In this connection, the Committee shall establish procedures
for (i) the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls
or auditing matters and (ii) the confidential, anonymous submission by employees of the Company of concerns regarding questionable
accounting or auditing matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SCHEDULE &ldquo;B&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Shareholder Rights Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SHAREHOLDER RIGHTS PLAN AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>DATED AS OF JUNE 27, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>BETWEEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Fennec
Pharmaceuticals INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>COMPUTERSHARE TRUST COMPANY OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CANADA AS RIGHTS AGENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: left"><A HREF="#FPI_001"><b>ARTICLE 1 INTERPRETATION</b></A></td>
    <TD STYLE="text-align: right; vertical-align: bottom"><B>47</B></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 10%; text-align: left; padding-left: 0.25in">1.1</td>
    <TD STYLE="width: 80%; text-align: left"><A HREF="#FPI_002">Certain Definitions</A></td>
    <TD STYLE="width: 10%; text-align: right; vertical-align: bottom">47</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">1.2</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_003">Currency</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">61</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">1.3</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_004">Headings</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">61</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">1.4</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_005">Calculation of Number and Percentage of Beneficial Ownership of Outstanding Voting Shares</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">61</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">1.5</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_006">Acting Jointly or in Concert</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">61</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">1.6</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_007">Generally Accepted Accounting Principles</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">62</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom"><font style="font-size: 10pt; color: blue"><b>&nbsp;</b></font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: left"><A HREF="#FPI_008"><b>ARTICLE 2&nbsp;&nbsp;RIGHTS</b></A></td>
    <TD STYLE="text-align: right; vertical-align: bottom"><B>62</B></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.1</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_009">Legend</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">62</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.2</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_010">Initial Exercise Price; Exercise of Rights; Detachment of Rights</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">63</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.3</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_011">Adjustments to Exercise Price; Number of Rights</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">66</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.4</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_012">Date on Which Exercise Is Effective</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">72</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.5</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_013">Execution, Authentication, Delivery and Dating of Rights Certificates</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">72</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.6</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_014">Registration, Transfer and Exchange</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">72</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.7</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_015">Mutilated, Destroyed, Lost and Stolen Rights Certificates</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">73</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.8</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_016">Persons Deemed Owners of Rights</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">74</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.9</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_017">Delivery and Cancellation of Certificates</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">74</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.10</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_018">Agreement of Rights Holders</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">75</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">2.11</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_019">Rights Certificate Holder Not Deemed a Shareholder</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">76</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom"><font style="font-size: 10pt; color: blue"><b>&nbsp;</b></font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2" style="text-align: left"><A HREF="#FPI_020"><b>ARTICLE 3&nbsp;&nbsp;ADJUSTMENTS TO THE RIGHTS IN THE EVENT OF CERTAIN TRANSACTIONS</b></A></td>
    <TD STYLE="text-align: right; vertical-align: bottom"><B>76</B></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">3.1</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_021">Flip-in Event</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">76</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom"><font style="font-size: 10pt; color: blue"><b>&nbsp;</b></font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: left"><A HREF="#FPI_022"><b>ARTICLE 4&nbsp;&nbsp;THE RIGHTS AGENT</b></A></td>
    <TD STYLE="text-align: right; vertical-align: bottom"><B>78</B></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">4.1</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_023">General</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">78</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">4.2</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_024">Merger, Amalgamation or Consolidation or Change of Name of Rights Agent</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">79</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">4.3</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_025">Duties of Rights Agent</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">79</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">4.4</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_026">Change of Rights Agent</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">82</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">4.5</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_027">Compliance with Anti-Money Laundering Legislation</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">82</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">4.6</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_028">Privacy Legislation</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">82</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">4.7</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_029">Liability</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">83</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: right; vertical-align: bottom"><font style="font-size: 10pt; color: blue"><b>&nbsp;</b></font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2" style="text-align: left"><A HREF="#FPI_030"><b>ARTICLE 5 MISCELLANEOUS</b></A></td>
    <TD STYLE="text-align: right; vertical-align: bottom"><B>83</B></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.1</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_031">Redemption and Waiver</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">83</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.2</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_032">Expiration</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">85</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.3</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_033">Issuance of New Rights Certificates</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">85</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.4</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_034">Supplements and Amendments</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">85</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.5</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_035">Fractional Rights and Fractional Shares</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">87</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%; text-align: left; padding-left: 0.25in">5.6</td>
    <TD STYLE="width: 80%; text-align: left"><A HREF="#FPI_036">Rights of Action</A></td>
    <TD STYLE="width: 10%; text-align: right; vertical-align: bottom">88</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.7</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_037">Regulatory Approvals</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">88</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.8</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_038">Declaration as to Foreign Holders</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">88</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.9</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_039">Notices</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">88</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.10</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_040">Costs of Enforcement</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">89</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.11</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_041">Successors</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">89</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.12</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_042">Benefits of this Agreement</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">89</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.13</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_043">Governing Law</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">90</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.14</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_044">Severability</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">90</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.15</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_045">Effective Time</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">90</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.16</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_046">Determinations and Actions by the Board of Directors</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">91</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.17</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_047">Fiduciary Duties of the Directors</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">91</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.18</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_048">Time of the Essence</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">91</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.19</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_049">Force Majeure</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">91</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">5.20</td>
    <TD STYLE="text-align: left"><A HREF="#FPI_050">Execution in Counterparts</A></td>
    <TD STYLE="text-align: right; vertical-align: bottom">91</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>ATTACHMENTS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>ATTACHMENT 1 &ndash; FORM OF RIGHTS CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SHAREHOLDER RIGHTS PLAN AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>SHAREHOLDER RIGHTS PLAN AGREEMENT</B>,
dated as of June 27, 2017 between Fennec Pharmaceuticals Inc. (the &ldquo;<B>Corporation</B>&rdquo;), a corporation existing under
the laws of British Columbia, and Computershare Trust Company of Canada, a company incorporated under the laws of Canada (the &ldquo;<B>Rights
Agent</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WHEREAS </B>the Board of Directors
has determined that it is in the best interests of the Corporation to adopt a new rights plan to ensure, to the extent possible,
that: (a) all shareholders of the Corporation are treated fairly in connection with any take-over bid for the Corporation; (b)
the shareholders of the Corporation and the Board of Directors have adequate time to consider and evaluate any unsolicited Offer
to Acquire the outstanding Voting Shares; and (c) the Board of Directors has adequate time to identify, develop and negotiate value-enhancing
alternatives, if considered appropriate, to any unsolicited Offer to Acquire the outstanding Voting Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>AND WHEREAS </B>in order to implement
the adoption of a shareholder rights plan as established by this Agreement, the Board of Directors has:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: left">authorized the issuance, effective at the Effective Time, of one Right in respect of each Voting Share
of the Corporation in each case outstanding at the Effective Time (the &ldquo;<B>Record Time</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: left">authorized the issuance of one Right in respect of each Voting Share issued after the Record Time
and prior to the earlier of the Separation Time and the Expiration Time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>AND WHEREAS </B>each Right entitles
the holder thereof, after the Separation Time, to purchase securities of the Corporation pursuant to the terms and subject to the
conditions set forth in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>AND WHEREAS </B>the Corporation
desires to appoint the Rights Agent to act on behalf of the Corporation and the holders of Rights, and the Rights Agent is willing
to so act, in connection with the issuance, transfer, exchange and replacement of Rights, the exercise of Rights and other matters
referred to in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOW THEREFORE</B>, in consideration
of the premises and the respective covenants and agreements set forth herein, and subject to such covenants and agreements, the
parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="FPI_001"></A><B>ARTICLE 1<BR>
INTERPRETATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B><A NAME="FPI_002"></A>1.1</B></TD><TD STYLE="text-align: justify"><B>Certain Definitions</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of this Agreement, the
following terms have the meanings indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B>Acquiring Person</B>&rdquo; means any Person who is the Beneficial owner of 20% or more
of the outstanding Voting Shares; provided, however, that the term &ldquo;<B>Acquiring Person</B>&rdquo; shall not include:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Corporation or any Subsidiary of the Corporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any Person who becomes the Beneficial owner of 20% or more of the outstanding Voting Shares as
a result of one or any combination of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 36pt">(A)</TD><TD STYLE="text-align: justify">an acquisition or redemption by the Corporation of Voting Shares which, by reducing the number
of Voting Shares outstanding, increases the proportionate number of Voting Shares Beneficially owned by such Person to 20% or more
of the Voting Shares then outstanding;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 36pt">(B)</TD><TD STYLE="text-align: justify">Permitted Bid Acquisitions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 36pt">(C)</TD><TD STYLE="text-align: justify">Pro Rata Acquisitions; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 36pt">(D)</TD><TD STYLE="text-align: justify">Exempt Acquisitions,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">provided, however, that if a Person
becomes the Beneficial owner of 20% or more of the outstanding Voting Shares by reason of one or any combination of the operation
of Paragraphs (A), (B), (C) or (D) above and such Person thereafter becomes the Beneficial owner of an additional 1% of the number
of outstanding Voting Shares (other than pursuant to one or more of any combination of Paragraphs (A), (B), (C) or (D) above),
as the case may be, then as of the date such Person becomes the Beneficial owner of such additional Voting Shares, as the case
may be, such Person shall become an &ldquo;<B>Acquiring Person</B>&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="text-align: justify">for a period of 10 calendar days after the Disqualification Date, any Person who becomes the Beneficial
owner of 20% or more of the outstanding Voting Shares as a result of such Person becoming disqualified from relying on Section
1.1(g)(iii)(B) solely because such Person is making or has announced a current intention to make a Take- over Bid, either alone
or by acting jointly or in concert with any other Person. For the purposes of this definition, &ldquo;<B>Disqualification Date</B>&rdquo;
means the first date of a public announcement of facts indicating that any Person is making, or has announced a current intention
to make a Take- over Bid; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 36pt">(iv)</TD><TD STYLE="text-align: justify">an underwriter or member of a banking or selling group that becomes the Beneficial owner of 20%
or more of the Voting Shares in connection with a distribution of securities of the Corporation by the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B>Affiliate</B>&rdquo;, when used to indicate a relationship with a specified company or
corporation, means a Person that directly, or indirectly through one or more controlled intermediaries, controls, or is a company
or corporation controlled by, or is under common control with, such a specified company or corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B>Agreement</B>&rdquo; means this shareholder rights plan agreement dated as of June 27,
2017 between the Corporation and the Rights Agent, as may be amended and/or supplemented from time to time; &ldquo;<B>hereof</B>&rdquo;,
&ldquo;<B>herein</B>&rdquo;, &ldquo;<B>hereto</B>&rdquo; and similar expressions mean and refer to this Agreement as a whole and
not to any particular part of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B>annual cash dividend</B>&rdquo; means cash dividends paid in any fiscal year of the Corporation,
to the extent that such cash dividends do not exceed in the aggregate, the greatest of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">if cash dividends were declared payable by the Corporation on its Common Shares in its immediately
preceding fiscal year, 200% of the aggregate amount of such cash dividends;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if cash dividends were declared payable by the Corporation on its Common Shares in each of its
three immediately preceding fiscal years, 300% of the arithmetic mean of the aggregate amounts of such cash dividends; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">100% of the aggregate consolidated net income of the Corporation, before extraordinary items, for
its immediately preceding fiscal year;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B>Associate</B>&rdquo; means, when used to indicate a relationship with a specified Person,
a spouse of that Person, any Person of the same or opposite sex with whom that Person is living in a conjugal relationship outside
marriage, a child of that Person, or a relative of that Person who has the same residence as that Person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B>BCBCA</B>&rdquo; means the <I>Business Corporations Act</I> (British Columbia), as amended,
and the regulations made thereunder, and any comparable or successor laws or regulations thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">A Person shall be deemed the &ldquo;<B>Beneficial owner</B>&rdquo; of, and to have &ldquo;<B>Beneficial
ownership</B>&rdquo; of, and to &ldquo;<B>Beneficially own</B>&rdquo;,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">any securities as to which such Person or any of such Person&rsquo;s Affiliates or Associates is
the owner at law or in equity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any securities as to which such Person or any of such Person&rsquo;s Affiliates or Associates has
the right to become the owner at law or in equity (provided that such right is exercisable within a period of 60 days, whether
or not on condition or the happening of any contingency or the making of any payment) pursuant to any agreement, arrangement, pledge
or understanding, whether or not in writing (other than customary agreements with and between underwriters and/or banking group
members and/or selling group members with respect to a distribution of securities and other than pledges of securities in the ordinary
course of business), or upon the exercise of any conversion right, exchange right, share purchase right (other than the Rights),
warrant or option; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any securities which are Beneficially owned within the meaning of Sections 1.1(g)(i) or 1.1(g)(ii)
by any other Person with whom such Person is acting jointly or in concert;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">provided, however, that a Person shall
not be deemed the &ldquo;<B>Beneficial owner</B>&rdquo; of, or to have &ldquo;<B>Beneficial ownership</B>&rdquo; of, or to &ldquo;<B>Beneficially
own</B>&rdquo;, any security:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">because such security has been agreed to be deposited with or tendered to such Person pursuant
to a Lock-up Agreement or is otherwise deposited with or tendered to such Person pursuant to any Take-over Bid made by such Person,
made by any of such Person&rsquo;s Affiliates or Associates or made by any other Person referred to in Section 1.1(g)(iii), until
the earlier of such deposited or tendered security being taken up or paid for;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">because such Person, any of such Person&rsquo;s Affiliates or Associates or any other Person referred
to in Section 1.1(g)(iii) holds such security provided that,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">the ordinary business of any such Person (the &ldquo;<B>Investment Manager</B>&rdquo;) includes
the management of investment funds for others (which others, for greater certainty, may include or be limited to one or more employee
benefit plans or pension plans) and such security is held by the Investment Manager in the ordinary course of such business in
the performance of such Investment Manager&rsquo;s duties for the account of any other Person (a &ldquo;<B>Client</B>&rdquo;),
including non- discretionary accounts held on behalf of a Client by a dealer or broker registered under applicable law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">such Person is (i) the manager or trustee (the &ldquo;<B>Manager</B>&rdquo;) of a mutual fund (a
&ldquo;<B>Mutual Fund</B>&rdquo;) that is registered or qualified to issue its securities to investors under the securities laws
of any province of Canada or the laws of the United States and such security is held in the ordinary course of business in the
performance of the Manager&rsquo;s duties with respect to the Mutual Fund, or (ii) a Mutual Fund;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">such Person (the &ldquo;<B>Trust Company</B>&rdquo;) is licensed to carry on the business of a
trust company under applicable laws and, as such, acts as trustee or administrator or in a similar capacity in relation to the
estates of deceased or incompetent Persons (each an &ldquo;<B>Estate Account</B>&rdquo;) or in relation to other accounts (each
an &ldquo;<B>Other Account</B>&rdquo;) and holds such security in the ordinary course of such duties for such Estate Accounts or
for such Other Accounts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">such Person is established by statute for purposes that include, and the ordinary business or activity
of such Person (the &ldquo;<B>Statutory Body</B>&rdquo;) includes, the management of investment funds for employee benefit plans,
pension plans, insurance plans or various public bodies and such security is held in the ordinary course of business in the performance
of such Statutory Body&rsquo;s duties for such investment funds;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">such Person (the &ldquo;<B>Administrator</B>&rdquo;) is the administrator or trustee of one or
more pension funds, plans or related trusts (a &ldquo;<B>Plan</B>&rdquo;) or is a Plan registered or qualified under the laws of
Canada or any Province thereof or the laws of the United States of America or any state thereof or is a Plan and such security
is held in the ordinary course of business in the performance of such Administrator&rsquo;s duties for such Plans; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.5in">(6)</TD><TD STYLE="text-align: justify">such Person is a Crown agent or agency and such security is held in the ordinary course of business
in the performance of such Crown agent&rsquo;s or agency&rsquo;s duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">provided, in any of the above cases,
that the Investment Manager, the Manager, the Mutual Fund, the Trust Company, the Statutory Body, the Administrator, the Plan,
or the Crown agent or agency, as the case may be, is not then making a Take-over Bid or has not then announced an intention to
make a Take-over Bid other than an Offer to Acquire Voting Shares or other securities by means of a distribution by the Corporation
or by means of ordinary market transactions (including pre-arranged trades entered into in the ordinary course of business of such
Person) executed through the facilities of a stock exchange or organized over-the-counter market, alone or by acting jointly or
in concert with any other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">because such Person (1) is a Client of the same Investment Manager as another Person on whose account
the Investment Manager holds such security, (2) has an Estate Account or another Account of the same Trust Company as another Person
on whose account the Trust Company holds such security or (3) is a Plan with the same Administrator as another Plan on whose account
the Administrator holds such security;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">where such Person (1) is a Client of an Investment Manager and such security is owned at law or
in equity by the Investment Manager, or (2) has an Estate Account or an Other Account of a Trust Company and such security is owned
at law or in equity by the Trust Company or (3) is a Plan and such security is owned at law or in equity by the Administrator of
the Plan; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(E)</TD><TD STYLE="text-align: justify">where such Person is a registered holder of such security as a result of carrying on the business
of, or acting as a nominee of, a securities depositary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">&ldquo;<B>Board of Directors</B>&rdquo; means the board of directors of the Corporation or any
duly constituted and empowered committee thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B>Book Entry Form</B>&rdquo; means, in reference to securities, securities that have been
issued and registered in uncertificated form and includes securities evidenced by an advice or other statement and securities which
are maintained electronically on the records of the Corporation&rsquo;s transfer agent but for which no certificate has been issued,
including securities issued and recorded under the Direct Registration System (DRS);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">&ldquo;<B>Book Entry Rights Exercise Procedures</B>&rdquo; has the meaning ascribed thereto in
Section 2.2(c);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">&ldquo;<B>Business Day</B>&rdquo; means any day other than a Saturday, Sunday or a day on which
banking institutions in Toronto are authorized or obligated by law to close;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">&ldquo;<B>Canadian Dollar Equivalent</B>&rdquo; of any amount which is expressed in United States
dollars means, on any date, the Canadian dollar equivalent of any such amount determined by multiplying such amount by the U.S.
- Canadian Exchange Rate in effect on such date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">&ldquo;<B>Canadian - U.S. Exchange Rate</B>&rdquo; means, on any date, the inverse of the U.S.
- Canadian Exchange Rate in effect on such date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">&ldquo;<B>close of business</B>&rdquo; on any given date means the time on such date (or, if such
date is not a Business Day, the time on the next succeeding Business Day) at which the principal transfer office in Toronto of
the transfer agent for the Common Shares of the Corporation (or, after the Separation Time, the principal office in Toronto of
the Rights Agent) is closed to the public; <I>provided, however</I>, that for the purposes of the definitions of &ldquo;<B>Competing
Permitted Bid</B>&rdquo; and &ldquo;<B>Permitted Bid</B>&rdquo;, &ldquo;<B>close of business</B>&rdquo; on any date means 11:59
p.m. (local time, at the place of deposit) on such date (or, if such date is not a Business Day, 11:59 p.m. (local time, at the
place of deposit) on the next succeeding Business Day);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">&ldquo;<B>Common Shares</B>&rdquo; means the common shares in the capital of the Corporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">&ldquo;<B>Competing Permitted Bid</B>&rdquo; means a Take-over Bid that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">is made after a Permitted Bid or another Competing Permitted Bid (each such Permitted Bid or Competing
Permitted Bid being in this definition, the &quot;<B>Prior Bid</B>&quot;) has been made and prior to the expiry, termination or
withdrawal of all such other Prior Bids;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">satisfies all components of the definition of a Permitted Bid other than the requirements set out
in Section (ii)(A) of the definition of a Permitted Bid; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">contains, and the take-up and payment for securities deposited or tendered thereunder are subject
to, an irrevocable and unqualified condition that no Voting Shares shall be taken up or paid for pursuant to the Take-over Bid
prior to the close of business on the last day of the minimum deposit period applicable to such Take-over Bid as required by NI
62-104;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">provided, however, that a Take-over
Bid that qualifies as a Competing Permitted Bid shall cease to be a Competing Permitted Bid at any time and at such time as when
such Take-over Bid ceases to meet any or all of the provisions of this definition, and furthermore, any acquisition of Voting Shares
made pursuant to such Take-over Bid, including any acquisition of Voting Shares made before such Take-over Bid ceased to be a Competing
Permitted Bid, will not be a Permitted Bid Acquisition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">&ldquo;<B>controlled</B>&rdquo; a company is &ldquo;<B>controlled</B>&rdquo; by another Person
or two or more Persons acting jointly or in concert if:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">securities entitled to vote in the election of directors carrying more than 50% of the votes for
the election of directors are held, directly or indirectly, by or on behalf of the other Person or two or more Persons acting jointly
or in concert; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the votes carried by such securities are entitled, if exercised, to elect a majority of the board
of directors of such company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">and &ldquo;<B>controls</B>&rdquo;,
&ldquo;<B>controlling</B>&rdquo; and &ldquo;<B>under common control with</B>&rdquo; shall be interpreted accordingly;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify">&ldquo;<B>Co-Rights Agents</B>&rdquo; has the meaning ascribed thereto in Section 4.1(a);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify">&ldquo;<B>Disposition Date</B>&rdquo; has the meaning ascribed thereto in Section 5.1(a);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD STYLE="text-align: justify">&ldquo;<B>Dividend Reinvestment Acquisition</B>&rdquo; means an acquisition of Voting Shares of
any class pursuant to a Dividend Reinvestment Plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD STYLE="text-align: justify">&ldquo;<B>Dividend Reinvestment Plan</B>&rdquo; means a regular dividend reinvestment or other
program or plan of the Corporation made available by the Corporation to holders of its securities and/or to holders of securities
of a Subsidiary of the Corporation, where such program or plan permits the holder to direct that some or all of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">any dividends paid in respect of shares of any class of the Corporation or a Subsidiary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any proceeds of redemption of shares of the Corporation or a Subsidiary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any interest paid on evidences of indebtedness of the Corporation or a Subsidiary; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">any optional cash payments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">be applied to the purchase of Voting
Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&ldquo;<B>Effective Date</B>&rdquo; means June 27, 2017;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(w)</TD><TD STYLE="text-align: justify">&ldquo;<B>Effective Time</B>&rdquo; means 12:01 a.m. (Eastern time) on the Effective Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">&ldquo;<B>Election to Exercise</B>&rdquo; has the meaning ascribed thereto in Section 2.2(d);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(y)</TD><TD STYLE="text-align: justify">&ldquo;<B>Exempt Acquisition</B>&rdquo; means a share acquisition:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">in respect of which the Board of Directors has waived the application of Section 3.1 pursuant to
the provisions of Sections 5.1(a), 5.1(b) or 5.1(e);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">pursuant to a distribution by the Corporation of Voting Shares or securities convertible into or
exchangeable for Voting Shares (and the conversion or exchange of such securities) pursuant to a public offering or private placement,
provided that the acquiror does not thereby Beneficially Own a greater percentage of the Voting Shares or securities convertible
into or exchangeable for Voting Shares so issued than the percentage of such securities Beneficially Owned by the acquiror immediately
prior to such acquisition; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">pursuant to an amalgamation, plan of arrangement or other statutory procedure having similar effect
which has been approved by the Board of Directors and the holders of Voting Shares by the requisite majority or majorities of the
holders of Voting Shares at a meeting duly called and<FONT STYLE="font-size: 10pt"> </FONT>held for such purpose in accordance
with the provisions of the BCBCA and any other applicable legal requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(z)</TD><TD STYLE="text-align: justify">&ldquo;<B>Exercise Price</B>&rdquo; means the price at which a holder may purchase the securities
issuable upon exercise of one whole Right which, until adjustment thereof in accordance with the terms hereof, shall be the product
of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Market Price per Common Share determined as at the Separation Time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">multiplied by 6;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(aa)</TD><TD STYLE="text-align: justify">&ldquo;<B>Expansion Factor</B>&rdquo; has the meaning ascribed
thereto in Section 2.3(a);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(bb)</TD><TD STYLE="text-align: justify">&ldquo;<B>Expiration Time</B>&rdquo; means the close of
business on that date which is the earliest date of termination of this Agreement as provided for in Section 5.15 or, if this
Agreement is ratified and confirmed pursuant to Section 5.15(b) and subsequently reconfirmed pursuant to Section 5.15(c) at the
Corporation&rsquo;s annual and special meeting of shareholders in 2020 and 2023, the close of business on the ninth anniversary
of the Effective Date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(cc)</TD><TD STYLE="text-align: justify">&ldquo;<B>Flip-in Event</B>&rdquo; means a transaction
in or pursuant to which any Person becomes an Acquiring Person;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(dd)</TD><TD STYLE="text-align: justify">&ldquo;<B>holder</B>&rdquo; has the meaning ascribed thereto
in Section 2.8;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(ee)</TD><TD STYLE="text-align: justify">&ldquo;<B>Independent Shareholders</B>&rdquo; means holders
of any Voting Shares, other than:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">any Acquiring Person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any Offeror (other than any Person who pursuant to Section 1.1(g)(iii)(B) is not deemed to Beneficially
own the Voting Shares held by such Person);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any Affiliate or Associate of any Acquiring Person or Offeror;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">any Person acting jointly or in concert with any Acquiring Person or Offeror; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">any employee benefit plan, stock purchase plan, deferred profit sharing plan and any similar plan
or trust for the benefit of employees of the Corporation or a Subsidiary of the Corporation, unless the beneficiaries of the plan
or trust direct the manner in which the Voting Shares are to be voted or withheld from voting or direct whether the Voting Shares
are to be tendered to a Take-over Bid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(ff)</TD><TD STYLE="text-align: justify">&ldquo;<B>Lock-up Agreement</B>&rdquo; means an agreement
between a Person and one or more holders of Voting Shares (each a &ldquo;<B>Locked-up Person</B>&rdquo;), the terms of which are
publicly disclosed and a copy of which agreement is made available to the public (including the Corporation) not later than (i)
the date the Lock-up Bid is publicly announced or (ii) if the Lock-up Bid has been made prior to the date on which such agreement
is entered into then as soon as possible after it is entered into and in any event not later than the date following the date
of such agreement, pursuant to which each Locked-up Person agrees to deposit or tender Voting Shares to a Take-over Bid (the &ldquo;<B>Lock-up
Bid</B>&rdquo;) to be made or made by the Person or any of such Person&rsquo;s Affiliates or Associates or any other Person referred
to in Section 1.1(g)(iii) and which provides:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">that any agreement to deposit or tender to, or to not withdraw Voting Shares from, the Lock-up
Bid is terminable at the option of the Locked-up Person in order to tender or deposit such Voting Shares to another Take- over
Bid or support another transaction:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">where the price or value per Voting Share offered under such other Take-over Bid or transaction
is higher than the price or value per Voting Share offered under the Lock-up Bid; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">if:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">the price or value per Voting Share offered under the other Take-over Bid or transaction exceeds
the price or value per Voting Share offered or proposed to be offered under the Lock-up Bid by as much or more than a specified
amount (the &ldquo;<B>Specified Amount</B>&rdquo;) and the Specified Amount is not greater than 7% of the price or value per Voting
Share that is offered or proposed to be offered under the Lock-up Bid; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">the number of Voting Shares to be purchased under the other Take-over Bid or transaction exceeds
the number of Voting Shares offered to be purchased under the Lock-up Bid by as much or more than a specified number of Voting
Shares (the &ldquo;<B>Specified Number of Shares</B>&rdquo;) and the Specified Number of Shares is not greater than 7% of the number
of Voting Shares offered to be purchased under the Lock-up Bid, at a price or value per Voting Share, as applicable, that is not
less than the price or value per Voting Share offered under the Lock-up Bid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.75in; text-align: justify">and the agreement may contain a right
of first refusal or require a period of delay to give such Person an opportunity to match a higher price or value in another Take-over
Bid or transaction or other similar limitation on a Locked-up Person&rsquo;s right to withdraw Voting Shares from the agreement,
so long as the limitation does not preclude the exercise by the Locked-up Person of the right to withdraw Voting Shares during
the period of the other Take-over Bid or transaction; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">no &ldquo;<B>break-up</B>&rdquo; fees, &ldquo;<B>top-up</B>&rdquo; fees, penalties, expenses or
other amounts that exceed in the aggregate the greater of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the cash equivalent of 2.5% of the price or value payable under the Lock-up Bid to a Locked-up
Person; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">50% of the amount by which the price or value payable under another Take-over Bid or transaction
to a Locked-up Person exceeds the price or value of the consideration that such Locked-up Person would have received under the
Lock-up Bid,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">shall be payable by a Locked-up Person
pursuant to the agreement in the event a Locked-up Person fails to deposit or tender Voting Shares to the Lock-up Bid or withdraw
Voting Shares previously tendered thereto in order to tender to another Take-over Bid or support another transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(gg)</TD><TD STYLE="text-align: justify">&ldquo;<B>Market Price</B>&rdquo; per share of any securities
on any date of determination means the greater of: (i) closing sale price per security of such class of securities on the Trading
Day immediately preceding such date on the Toronto Stock Exchange (or, if the securities are not listed thereon, on such principal
stock exchange on which the securities are listed (as determined by volume of trading), or if the securities are not listed on
any stock exchange, then on the over-the-counter market); and (ii) the volume weighted average price per security of such class
of securities during the five consecutive Trading Days through and including the Trading Day immediately preceding such date on
the Toronto Stock Exchange (or, if the securities are not listed thereon, on such principal stock exchange on which the securities
are listed (as determined by volume of trading), or if the securities are not listed on any stock exchange, then on the over-the-counter
market); provided, however, that if an event of a type analogous to any of the events described in Section 2.3 hereof shall have
caused the sale prices used to determine the Market Price on any Trading Days not to be fully comparable with the sale prices
on such date of determination or, if the date of determination is not a Trading Day, on the immediately preceding Trading Day,
such sale prices so used shall be appropriately adjusted in a manner analogous to the applicable adjustment provided for in Section
2.3 hereof in order to make them fully comparable with the sale prices on such date of determination or, if the date of determination
is not a Trading Day, on the immediately preceding Trading Day. The volume weighted average price per security of any securities
shall be determined by dividing the aggregate sale price of all such securities sold on the said exchange or market, as the case
may be, during the said five consecutive trading days by the total number of such securities so sold. The Market Price shall be
expressed in Canadian dollars and, if initially determined in respect of any day in question in United States dollars, such amount
shall be translated into Canadian dollars on such date at the Canadian Dollar Equivalent thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(hh)</TD><TD STYLE="text-align: justify">&ldquo;<B>NI 51-102</B>&rdquo; means National Instrument
51-102 - <I>Continuous Disclosure Obligations </I>and any comparable or successor laws, instruments or rules thereto;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">&ldquo;<B>NI 62-104</B>&rdquo; means National Instrument
62-104 &ndash; <I>Take-Over Bids and Issuer Bids </I>and any comparable or successor laws, instruments or rules thereto;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(jj)</TD><TD STYLE="text-align: justify">&ldquo;<B>Nominee</B>&rdquo; has the meaning ascribed thereto
in Section 2.2(c);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(kk)</TD><TD STYLE="text-align: justify">&ldquo;<B>Offer to Acquire</B>&rdquo; includes:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">an offer to purchase or a solicitation of an offer to sell Voting Shares of any class or classes,
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">an acceptance of an offer to sell Voting Shares of any class or classes, whether or not such offer
to sell has been solicited,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">or any combination thereof, and the
Person accepting an offer to sell shall be deemed to be making an Offer to Acquire to the Person that made the offer to sell;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(ll)</TD><TD STYLE="text-align: justify">&ldquo;<B>Offeror</B>&rdquo; means a Person who has announced,
and has not withdrawn, an intention to make or who has made, and has not withdrawn, a Take-over Bid, other than a Person who has
completed a Permitted Bid, a Competing Permitted Bid or an Exempt Acquisition;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(mm)</TD><TD STYLE="text-align: justify">&ldquo;<B>Offeror&rsquo;s Securities</B>&rdquo; means Voting
Shares Beneficially owned by an Offeror on the date of the Offer to Acquire;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(nn)</TD><TD STYLE="text-align: justify">&ldquo;<B>Permitted Bid</B>&rdquo; means a Take-over Bid
made by an Offeror that is made by means of a take-over bid circular and which also complies with the following additional provisions:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Take-over Bid is made to all holders of Voting Shares of record other than the Offeror;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Take-over Bid contains, and the take-up and payment for securities tendered or deposited is
subject to, an irrevocable and unqualified condition that no Voting Shares will be taken up or paid for pursuant to the Take-over
Bid</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">prior to the close of business on a date which is not less than 105 days following the date of
the Take-over Bid or such shorter minimum period as the Corporation may announce in a &ldquo;deposit period news release&rdquo;
(defined in NI 62-104), and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">unless at such date more than 50% of the Voting Shares held by Independent Shareholders shall have
been deposited or tendered pursuant to the Take-over Bid and not withdrawn;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">unless the Take-over Bid is withdrawn, the Take-over Bid contains an irrevocable and unqualified
provision that Voting Shares may be deposited pursuant to such Take-over Bid at any time during the period described in Section
1.1(nn)(ii)(A) and that any Voting Shares deposited pursuant to the Take-over Bid may be withdrawn until taken up and paid for;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">unless the Take-over Bid is withdrawn, the Take-over Bid contains an irrevocable and unqualified
provision that in the event that the deposit condition set forth in Section 1.1(nn)(ii)(B) is satisfied the Offeror will make a
public announcement of that fact and the Take-over Bid will remain open for deposits and tenders of Voting Shares for not less
than 10 days from the date of such public announcement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">provided, however, that a Take-over
Bid that qualifies as a Permitted Bid shall cease to be a Permitted Bid at any time and at such time as such Take-over Bid ceases
to meet any or all of the provisions of this definition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(oo)</TD><TD STYLE="text-align: justify">&ldquo;<B>Permitted Bid Acquisition</B>&rdquo; means an
acquisition of Voting Shares of any class made pursuant to a Permitted Bid or a Competing Permitted Bid;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(pp)</TD><TD STYLE="text-align: justify">&ldquo;<B>Person</B>&rdquo; includes an individual, firm,
association, trustee, executor, administrator, legal or personal representative, body corporate, company, trust, partnership,
joint venture, syndicate or other form of unincorporated association, a government and its agencies or instrumentalities, any
entity or group (whether or not having legal personality), any successor (by merger, statutory amalgamation or otherwise) and
any of the foregoing acting in any derivative, representative or fiduciary capacity;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(qq)</TD><TD STYLE="text-align: justify">&ldquo;<B>Pro Rata Acquisition</B>&rdquo; means an acquisition
of Voting Shares by a Person pursuant to:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">a Dividend Reinvestment Acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a stock dividend, stock split or other event in respect of securities of one or more particular
classes or series of the Corporation pursuant to which such Person becomes the Beneficial owner of Voting Shares on the same pro
rata basis as all other holders of securities of the particular class, classes or series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the receipt and/or exercise of rights issued by the Corporation to all the holders of a class of
Voting Shares to subscribe for or purchase Voting Shares, provided that such rights are acquired directly from the Corporation
as part of a rights offering and not from any other Person and provided that the Person does not thereby acquire a greater percentage
of Voting Shares than the Person&rsquo;s percentage of Voting Shares Beneficially owned immediately prior to such receipt or exercise;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">a distribution by the Corporation of Voting Shares, or securities convertible into or exchangeable
for Voting Shares (and the conversion or exchange of such convertible or exchangeable securities) made pursuant to a prospectus
or a distribution by way of private placement by the Corporation, provided that the Person does not thereby acquire a greater percentage
of such Voting Shares of that class, or securities convertible or exchangeable for Voting Shares, than the Person&rsquo;s percentage
of Voting Shares Beneficially owned immediately prior to such acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(rr)</TD><TD STYLE="text-align: justify">&ldquo;<B>Record Time</B>&rdquo; has the meaning set forth
in the recitals to this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(ss)</TD><TD STYLE="text-align: justify">&ldquo;<B>Redemption Price</B>&rdquo; has the meaning set
forth in Section 5.1(b) of this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(tt)</TD><TD STYLE="text-align: justify">&ldquo;<B>Right</B>&rdquo; means a right to purchase a
Common Share, upon the terms and subject to the conditions set forth in this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(uu)</TD><TD STYLE="text-align: justify">&ldquo;<B>Rights Agent</B>&rdquo; means Computershare Trust
Company of Canada, a company incorporated under the laws of Canada or any successor Rights Agent appointed pursuant to Section
4.4;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(vv)</TD><TD STYLE="text-align: justify">&ldquo;<B>Rights Certificate</B>&rdquo; means the certificates
representing the Rights after the Separation Time, which shall be substantially in the form attached hereto as Attachment 1;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(ww)</TD><TD STYLE="text-align: justify">&ldquo;<B>Rights Register</B>&rdquo; and &ldquo;<B>Rights
Registrar</B>&rdquo; have the meanings ascribed thereto in Section 2.6(a);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(xx)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Securities Act </I>(Ontario)</B>&rdquo; means the Securities Act, R.S.O., c. S.5,
as amended, and the regulations and rules thereunder, and any comparable or successor laws or regulations or rules thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(yy)</TD><TD STYLE="text-align: justify">&ldquo;<B>Separation Time</B>&rdquo; means the close of
business on the eighth Trading Day after the earlier of:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Stock Acquisition Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the date of the commencement of or first public announcement of the intent of any Person (other
than the Corporation or any Subsidiary of the Corporation) to commence a Take-over Bid (other than a Permitted Bid or a Competing
Permitted Bid, as the case may be); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the date upon which a Permitted Bid or Competing Permitted Bid ceases to be such;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">or such later date as may be determined
by the Board of Directors, provided that, if any such Take-over Bid expires, is cancelled, terminated or otherwise withdrawn prior
to the Separation Time, such Take-over Bid shall be deemed for the purposes of this definition, never to have been made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(zz)</TD><TD STYLE="text-align: justify">&ldquo;<B>Stock Acquisition Date</B>&rdquo; means the first
date of public announcement (which, for purposes of this definition, shall include, without limitation, a report filed pursuant
to Section 5.2 of NI 62-104 or Section 13(d) of the <I>U.S. Exchange Act</I>) by the Corporation or an Acquiring Person that an
Acquiring Person has become such;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(aaa)</TD><TD STYLE="text-align: justify">&ldquo;<B>Subsidiary</B>&rdquo;: a company is a Subsidiary
of another company if:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">it is controlled by:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">that other, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">that other and one or more companies each of which is controlled by that other, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">two or more companies each of which is controlled by that other, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">it is a Subsidiary of a company that is that other&rsquo;s Subsidiary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(bbb)</TD><TD STYLE="text-align: justify">&ldquo;<B>Take-over Bid</B>&rdquo; means an Offer to Acquire
Voting Shares, or securities convertible into Voting Shares if, assuming that the Voting Shares or convertible securities subject
to the Offer to Acquire are acquired and are Beneficially Owned at the date of such Offer to Acquire by the Person making such
Offer to Acquire, such Voting Shares (including Voting Shares that may be acquired upon conversion of securities convertible into
Voting Shares) together with the Offeror&rsquo;s Securities, constitute in the aggregate 20% or more of the outstanding Voting
Shares on the date of the Offer to Acquire;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(ccc)</TD><TD STYLE="text-align: justify">&ldquo;<B>Trading Day</B>&rdquo;, when used with respect
to any securities, means a day on which the principal Canadian securities exchange on which such securities are listed or admitted
to trading is open for the transaction of business or, if the securities are not listed or admitted to trading on any Canadian
securities exchange, a day on which the principal United States securities exchange on which such securities are listed or admitted
to trading is open for the transaction of business or, if the securities are not listed or admitted to trading on any Canadian
or United States securities exchange, a Business Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(ddd)</TD><TD STYLE="text-align: justify">&ldquo;<B>U.S. - Canadian Exchange Rate</B>&rdquo; means,
on any date:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">if on such date the Bank of Canada sets an average noon spot rate of exchange for the conversion
of one United States dollar into Canadian dollars, such rate; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 114pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in; text-align: justify"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in any other case, the rate for such date for the conversion of one United States dollar into Canadian
dollars calculated in such manner as may be determined by the Board of Directors from time to time acting in good faith;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(eee)</TD><TD STYLE="text-align: justify">&ldquo;<B>U.S. Dollar Equivalent</B>&rdquo; of any amount
which is expressed in Canadian dollars means, on any date, the United States dollar equivalent of such amount determined by multiplying
such amount by the Canadian - U.S. Exchange Rate in effect on such date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(fff)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>U.S. Exchange Act</I></B>&rdquo; means the
United States <I>Securities Exchange Act of 1934</I>, as amended, and the rules and regulations thereunder as now in effect or
as the same may from time to time be amended, re-enacted or replaced;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(ggg)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>U.S. Securities Act</I></B>&rdquo; means the
United States <I>Securities Act of 1933</I>, as amended, and the rules and regulations thereunder as now in effect or as the same
may from time to time be amended, re-enacted or replaced; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(hhh)</TD><TD STYLE="text-align: justify">&ldquo;<B>Voting Shares</B>&rdquo; means the Common Shares
of the Corporation and any other shares in the capital of the Corporation entitled to vote in the election of directors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B><A NAME="FPI_003"></A>1.2</B></TD><TD STYLE="text-align: justify"><B>Currency</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">All sums of
money which are referred to in this Agreement are expressed in lawful money of Canada, unless otherwise specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B><A NAME="FPI_004"></A>1.3</B></TD><TD STYLE="text-align: justify"><B>Headings</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The division
of this Agreement into Articles, Sections, Paragraphs, Subparagraphs or other portions hereof and the insertion of headings, subheadings
and a table of contents are for convenience of reference only and shall not affect the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B><A NAME="FPI_005"></A>1.4</B></TD><TD STYLE="text-align: justify"><B>Calculation of Number and Percentage of Beneficial Ownership
of Outstanding Voting Shares</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">For purposes
of this Agreement, the percentage of Voting Shares of any class Beneficially owned by any Person, shall be and be deemed to be
the product (expressed as a percentage) determined by the formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">100 x A/B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">A = the number
of votes for the election of all directors on the Board of Directors generally attaching to the Voting Shares of that class Beneficially
owned by such Person; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">B = the number
of votes for the election of all directors on the Board of Directors generally attaching to all outstanding Voting Shares of such
class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Where any Person is deemed to
Beneficially own unissued Voting Shares, such Voting Shares shall be deemed to be outstanding for the purpose of calculating the
percentage of Voting Shares owned by such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B><A NAME="FPI_006"></A>1.5</B></TD><TD STYLE="text-align: justify"><B>Acting Jointly or in Concert</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 37.55pt">For purposes
of this Agreement a Person is acting jointly or in concert with every Person who is a party to an agreement, commitment, arrangement
or understanding, whether formal or informal or written or unwritten, with the first Person to acquire or Offer to Acquire any
Voting Shares or securities convertible into Voting Shares (other than (A) customary agreements with and between underwriters and/or
banking group members and/or selling group members with respect to a distribution of securities by the Corporation, (B) pledges
of securities in the ordinary course of business, and (C) Lock-Up Agreements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B><A NAME="FPI_007"></A>1.6</B></TD><TD STYLE="text-align: justify"><B>Generally Accepted Accounting Principles</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Wherever in
this Agreement reference is made to generally accepted accounting principles, such reference shall be deemed to be the recommendations
at the relevant time of the Chartered Professional Accountants of Canada, or any successor institute, applicable on a consolidated
basis (unless otherwise specifically provided herein to be applicable on an unconsolidated basis) as at the date on which a calculation
is made or required to be made in accordance with generally accepted accounting principles. Where the character or amount of any
asset or liability or item of revenue or expense is required to be determined, or any consolidation or other accounting computation
is required to be made for the purpose of this Agreement or any document, such determination or calculation shall, to the extent
applicable and except as otherwise specified herein or as otherwise agreed in writing by the parties, be made in accordance with
generally accepted accounting principles applied on a consistent basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: -5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="FPI_008"></A>ARTICLE 2<BR>
RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_009"></A>2.1</B></TD><TD STYLE="text-align: left"><B>Legend</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">In the event
that certificates for Common Shares are issued after the Record Time but prior to the earlier of the Separation Time and the Expiration
Time, they shall evidence, in addition to the Common Shares, one Right for each Common Share represented thereby and shall have
impressed on, printed on, written on or otherwise affixed to them the following legend:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Until the Separation Time (defined
in the Shareholder Rights Plan Agreement referred to below), this certificate also evidences rights of the holder described in
a Shareholder Rights Plan Agreement, dated as of June 27, 2017 (the &ldquo;<B>Shareholder Rights Plan Agreement</B>&rdquo;), between
Fennec Pharmaceuticals Inc. (the &ldquo;<B>Corporation</B>&rdquo;) and Computershare Trust Company of Canada the terms of which
are incorporated herein by reference and a copy of which is on file at the principal executive offices of the Corporation. Under
certain circumstances set out in the Shareholder Rights Plan Agreement, the rights may expire, may become null and void or may
be evidenced by separate certificates and no longer evidenced by this certificate. The Corporation will mail or arrange for the
mailing of a copy of the Shareholder Rights Plan Agreement to the holder of this certificate without charge as soon as practicable
after the receipt of a written request therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Any Common
Shares issued and registered in Book Entry Form after the Record Time but prior to the earlier of the Separation Time and the Expiration
Time, shall evidence, in addition to the Common Shares, one Right for each Common Share represented by such registration and the
registration record of such Common Shares shall include the foregoing legend, adapted accordingly as the Rights Agent may reasonably
require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">For the avoidance
of doubt, notwithstanding the absence of the foregoing legend, until the close of business on the earlier of the Separation Time
and the Expiration Time, all Common Shares that are issued and outstanding at, or after, the Record Time and prior to the earlier
of the Separation Time and the Expiration Time, shall have one Right attached thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_010"></A>2.2</B></TD><TD STYLE="text-align: justify"><B>Initial Exercise Price; Exercise of Rights; Detachment of Rights</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Subject to adjustment as herein set forth, each Right will entitle the holder thereof, from and
after the Separation Time and prior to the Expiration Time, to purchase one Common Share for the Exercise Price (with the Exercise
Price and number of Common Shares being subject to adjustment as set forth below).<FONT STYLE="font-size: 10pt"> </FONT>Notwithstanding
any other provision of this Agreement, any Rights held by the Corporation or any of its Subsidiaries shall be void.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Until the Separation Time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">the Rights shall not be exercisable and no Right may be exercised; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">each Right will be evidenced by the certificate for the associated Common Share of the Corporation
registered in the name of the holder thereof (which certificate shall also be deemed to represent a Rights Certificate) or by the
Book Entry Form registration for the associated Common Share and will be transferable only together with, and will be transferred
by a transfer of, such associated Common Share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">From and after the Separation Time and prior to the Expiration Time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">the Rights shall be exercisable; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">the registration and transfer of Rights shall be separate from and independent of Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">Promptly following the Separation
Time, the Corporation will determine whether it wishes to issue Rights Certificates or whether it will maintain the Rights in Book
Entry Form. In the event that the Corporation determines to maintain Rights in Book Entry Form, it will put in place such alternative
procedures as are directed by the Rights Agent for the Rights to be maintained in Book Entry Form (the &ldquo;<B>Book Entry Rights
Exercise Procedures</B>&rdquo;), it being hereby acknowledged that such procedures shall, to the greatest extent possible, replicate
in all substantive respects the procedures set out in this Agreement with respect to the exercise of the Rights Certificates and
that the procedures set out in this Agreement shall be modified only to the extent necessary, as determined by the Rights Agent,
to permit the Corporation to maintain the Rights in Book Entry Form. In such event, the Book Entry Rights Exercise Procedures shall
be deemed to replace the procedures set out in this Agreement with respect to the exercise of Rights and all provisions of this
Agreement referring to Rights Certificates shall be applicable to Rights registered in Book Entry Form in like manner as to Rights
in certificated form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">In the event that the Corporation
determines to issue Rights Certificates, it will prepare and the Rights Agent will mail to each holder of record of Common Shares
as of the Separation Time (other than an Acquiring Person, any other Person whose Rights are or become void pursuant to the provisions
of Section 3.1(b) hereof and, in respect of any Rights Beneficially owned by such Acquiring Person which are not held of record
by such Acquiring Person, the holder of record of such Rights (a &ldquo;<B>Nominee</B>&rdquo;)), at such holder&rsquo;s address
as shown by the records of the Corporation (the Corporation hereby agreeing to furnish copies of such records to the Rights Agent
for this purpose):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(x)</TD><TD STYLE="text-align: justify">a Rights Certificate in substantially the form set out in Attachment 1 hereof, appropriately completed,
representing the number of Rights held by such holder at the Separation Time and having such marks of identification or designation
and such legends, summaries or endorsements printed thereon as the Corporation may deem appropriate and as are not inconsistent
with the provisions of this Agreement, or as may be required to comply with any law, rule or regulation or judicial or administrative
order or with any rule or regulation of any self-regulatory organization, stock exchange or quotation system on which the Rights
may from time to time be listed or traded, or to conform to usage; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(y)</TD><TD STYLE="text-align: justify">a description of the Rights,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">provided that a Nominee shall
be sent the materials provided for in (x) and (y) in respect of all Common Shares held of record by it which are not Beneficially
owned by an Acquiring Person. In order for the Corporation to determine whether any Person is holding Common Shares which are Beneficially
owned by another Person the Corporation may require such first mentioned Person to furnish such information and documentation as
the Corporation deems necessary or appropriate in order to make such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(d)</TD><TD STYLE="text-align: justify">Rights may be exercised, in whole or in part, on any Business Day after the Separation Time and
prior to the Expiration Time by submitting to the Rights Agent in the manner specified in the Rights Certificate:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">the Rights Certificate evidencing such Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">an election to exercise such Rights (an &ldquo;<B>Election to Exercise</B>&rdquo;) substantially
in the form attached to the Rights Certificate appropriately completed and executed by the holder or his executors or administrators
or other personal representatives or his or their legal attorney duly appointed by an instrument in writing in form and executed
in a manner satisfactory to the Rights Agent; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="text-align: justify">payment by certified cheque, banker&rsquo;s draft or money order payable to the order of the Corporation
of a sum equal to the Exercise Price multiplied by the number of Rights being exercised and a sum sufficient to cover any transfer
tax or charge which may be payable in respect of the transfer or delivery of Rights Certificates or the registration, in Book Entry
Form, of the Common Shares in a name other than that of the holder of the Rights being exercised.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(e)</TD><TD STYLE="text-align: justify">In the event that the Corporation determines to issue Rights Certificates, then upon receipt of
a Rights Certificate, together with a completed Election to Exercise executed in accordance with Section 2.2(d)(ii), which does
not indicate that such Right is null and void as provided by Section 3.1(b), and payment as set forth in Section 2.2(d)(ii), the
Rights Agent (unless otherwise instructed by the</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">Corporation in the event that
the Corporation is of the opinion that the Rights cannot be exercised in accordance with this Agreement) will thereupon promptly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">direct the transfer agent to register, in the name of the holder of the Rights being exercised
or in such other name as may be designated by such holder, in Book Entry Form the number of such Common Shares to be purchased
(the Corporation hereby irrevocably authorizing its transfer agent to comply with all such requisitions);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">when appropriate, requisition from the Corporation the amount of cash to be paid in lieu of issuing
fractional Common Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="text-align: justify">after receipt of confirmation from the transfer agent that the registration, in Book Entry Form,
referred to in Section 2.2(e)(i) has been made, deliver confirmation of the same to the registered holder of such Rights Certificates
or to the Person in whose name such registration has been made;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(iv)</TD><TD STYLE="text-align: justify">when appropriate, after receipt, deliver the cash referred to in Section 2.2(e)(ii) to or to the
order of the registered holder of such Rights Certificate; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(v)</TD><TD STYLE="text-align: justify">tender to the Corporation all payments received on the exercise of the Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(f)</TD><TD STYLE="text-align: justify">In case the holder of any Rights shall exercise less than all the Rights evidenced by such holder&rsquo;s
Rights Certificate, a new Rights Certificate evidencing the Rights remaining unexercised (subject to the provisions of Section
5.5(a)) will be issued by the Rights Agent to such holder or to such holder&rsquo;s duly authorized assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(g)</TD><TD STYLE="text-align: justify">The Corporation covenants and agrees that it will:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">take all such action as may be necessary and within its power to ensure that all Common Shares
issued upon exercise of Rights shall, at the time of registration in Book Entry Form of such Common Shares (subject to payment
of the Exercise Price), be duly authorized, validly issued, and fully paid and non-assessable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">take all such action as may be necessary and within its power to comply with the requirements of
the BCBCA, the <I>Securities Act</I> (Ontario), the U.S. Securities Act and the U.S. Exchange Act and the securities laws or comparable
legislation of each of the provinces of Canada and any other applicable law, rule or regulation, in connection with the issuance
and delivery of the Rights Certificates and the issuance of any Common Shares upon exercise of Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="text-align: justify">use reasonable efforts to cause all Common Shares issued upon exercise of Rights to be listed on
the principal stock exchanges on which such Common Shares were traded immediately prior to the Stock Acquisition Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(iv)</TD><TD STYLE="text-align: justify">pay when due and payable, if applicable, any and all Canadian and United States federal, provincial,
state and municipal transfer taxes and charges (not including any income or capital taxes of the holder or exercising holder or
any liability of the Corporation to withhold tax) which may be payable in respect of the original issuance or delivery of the Rights
Certificates, or the registration in Book Entry Form of Common Shares to be issued upon exercise of any Rights, provided that the
Corporation shall not be required to pay any transfer tax or charge which may be payable in respect of any transfer involved in
the transfer or delivery of Rights Certificates or the registration in Book Entry Form of Common Shares in a name other than that
of the holder of the Rights being transferred or exercised; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(v)</TD><TD STYLE="text-align: justify">after the Separation Time, except as permitted by Section 5.1 not take (or permit any Subsidiary
to take) any action if at the time such action is taken it is reasonably foreseeable that such action will diminish substantially
or otherwise eliminate the benefits intended to be afforded by the Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_011"></A>2.3</B></TD><TD STYLE="text-align: left"><B>Adjustments to Exercise Price; Number of Rights</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The Exercise
Price, the number and kind of securities subject to purchase upon exercise of each Right and the number of Rights outstanding are
subject to adjustment from time to time as provided in this Section 2.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify">In the event the Corporation shall at any time after the date of the Record Time and prior to the
Expiration Time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 78pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">declare or pay a dividend on the Common Shares payable in Common Shares (or other securities exchangeable
for or convertible into or giving a right to acquire Common Shares or other securities of the Corporation) other than pursuant
to any Dividend Reinvestment Plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 78pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">subdivide or change the then outstanding Common Shares into a greater number of Common Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 78pt"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="text-align: justify">consolidate or change the then outstanding Common Shares into a smaller number of Common Shares;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 78pt"></TD><TD STYLE="width: 36pt">(iv)</TD><TD STYLE="text-align: justify">issue any Common Shares (or other securities exchangeable for or convertible into or giving a right
to acquire Common Shares or other securities of the Corporation) in respect of, in lieu of or in exchange for existing Common Shares
except as otherwise provided in this Section 2.3,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">the Exercise Price and the number
of Rights outstanding, or, if the payment or effective date therefor shall occur after the Separation Time, the securities purchasable
upon exercise of Rights, shall be adjusted as of the payment or effective date in the manner set forth below. If an event occurs
which would require an adjustment under both this Section 2.3 and Section 3.1(a), the adjustment provided for in this Section 2.3
shall be in addition to, and shall be made prior to, any adjustment required under Section 3.1(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">If the Exercise Price and number
of Rights outstanding are to be adjusted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(x)</TD><TD STYLE="text-align: justify">the Exercise Price in effect after such adjustment will be equal to the Exercise Price in effect
immediately prior to such adjustment divided by the number of Common Shares (or other capital stock) that a holder of one Common
Share immediately prior to such dividend, subdivision, change, consolidation or issuance would hold thereafter as a result thereof
(the &ldquo;<B>Expansion Factor</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(y)</TD><TD STYLE="text-align: justify">each Right held prior to such adjustment will become that number of Rights equal to the Expansion
Factor,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">and the adjusted number of Rights
will be deemed to be distributed among the Common Shares with respect to which the original Rights were associated (if they remain
outstanding) and the shares issued in respect of such dividend, subdivision, change, consolidation or issuance, so that each such
Common Share (or other capital stock) will have exactly one Right associated with it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">For greater certainty, if the
securities purchasable upon exercise of Rights are to be adjusted, the securities purchasable upon exercise of each Right after
such adjustment will be the securities that a holder of the securities purchasable upon exercise of one Right immediately prior
to such dividend, subdivision, change, consolidation or issuance would hold thereafter after giving full effect to such dividend,
subdivision, change, consolidation or issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">If, after the Record Time and
prior to the Expiration Time, the Corporation shall issue any shares of capital stock other than Common Shares in a transaction
of a type described in Section 2.3(a)(i) or 2.3(a)(iv), shares of such capital stock shall be treated herein as nearly equivalent
to Common Shares as may be practicable and appropriate under the circumstances and the Corporation and the Rights Agent agree to
amend this Agreement in order to effect such treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify">In the event the Corporation shall at any time after the Record Time and prior to the Separation
Time fix a record date for the issuance of rights, options or warrants to all holders of Common Shares entitling them (for a period
expiring within 45 calendar days after such record date) to subscribe for or purchase Common Shares (or securities convertible
into or exchangeable for or carrying a right to purchase Common Shares) at a price per Common Share (or, if a security convertible
into or exchangeable for or carrying a right to purchase or subscribe for Common Shares, having a conversion, exchange or exercise
price, including the price required to be paid to purchase such convertible or exchangeable security or right per share) less than
the Market Price per Common Share on such record date, the Exercise Price to be in effect after such record date shall be determined
by multiplying the Exercise Price in effect immediately prior to such record date by a fraction:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">the numerator of which shall be the number of Common Shares outstanding on such record date, plus
the number of Common Shares that the aggregate offering price of the total number of Common Shares so to be offered (and/or the
aggregate initial conversion, exchange or exercise price of the convertible or exchangeable securities or rights so to be offered,
including the price required to be paid to purchase such convertible or exchangeable securities or rights) would purchase at such
Market Price per Common Share; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">the denominator of which shall be the number of Common Shares outstanding on such record date,
plus the number of additional Common Shares to be offered for subscription or purchase (or into which the convertible or exchangeable
securities or rights so to be offered are initially convertible, exchangeable or exercisable).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">In case such subscription price
may be paid by delivery of consideration, part or all of which may be in a form other than cash, the value of such consideration
shall be as determined in good faith by the Board of Directors, whose determination shall be described in a statement filed with
the Rights Agent and shall be binding on the Rights Agent and the holders of Rights. Such adjustment shall be made successively
whenever such a record date is fixed, and in the event that such rights, options or warrants are not so issued, or if issued, are
not exercised prior to the expiration thereof, the Exercise Price shall be readjusted to the Exercise Price which would then be
in effect if such record date had not been fixed, or to the Exercise Price which would be in effect based upon the number of Common
Shares (or securities convertible into, or exchangeable or exercisable for Common Shares) actually issued upon the exercise of
such rights, options or warrants, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">For purposes of this Agreement,
the granting of the right to purchase Common Shares (whether from treasury or otherwise) pursuant to a Dividend Reinvestment Plan
or any employee benefit, stock option or similar plans shall be deemed not to constitute an issue of rights, options or warrants
by the Corporation; provided, however, that, in all such cases, the right to purchase Common Shares is at a price per share of
not less than 95% of the current market price per share (determined as provided in such plans) of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(c)</TD><TD STYLE="text-align: justify">In the event the Corporation shall at any time after the Record Time and prior to the Separation
Time fix a record date for the making of a distribution to all holders of Common Shares (including any such distribution made in
connection with a merger or amalgamation) of evidences of indebtedness, cash (other than an annual cash dividend or a dividend
referred to in Section 2.3(a)(a)(i), but including any dividend payable in securities other than Common Shares), assets or rights,
options or warrants (excluding those referred to in Section 2.3(b) hereof), the Exercise Price to be in effect after such record
date shall be determined by multiplying the Exercise Price in effect immediately prior to such record date by a fraction:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">the numerator of which shall be the Market Price per Common Share on such record date, less the
fair market value (as determined in good faith by the Board of Directors, whose determination shall be described in a statement
filed with the Rights Agent and shall be binding on the Rights Agent and the holders of Rights), on a per share basis, of the portion
of the cash, assets, evidences of indebtedness, rights, options or warrants so to be distributed; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">the denominator of which shall be such Market Price per Common Share. Such adjustments shall be
made successively whenever such a record date is fixed, and in the event that such
a distribution is not so made, the Exercise Price shall be adjusted to be the Exercise Price which would have been in effect if
such record date had not been fixed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(d)</TD><TD STYLE="text-align: justify">Notwithstanding anything herein to the contrary, no adjustment in the Exercise Price shall be required
unless such adjustment would require an increase or decrease of at least 1% in the Exercise Price; provided, however, that any
adjustments which by reason of this Section 2.3(d) are not required to be made shall be carried forward and taken into account
in any subsequent adjustment. All calculations under Section 2.3 shall be made to the nearest cent or to the nearest ten-thousandth
of a share. Notwithstanding the first sentence of this Section 2.3(d), any adjustment required by Section 2.3 shall be made no
later than the earlier of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">three years from the date of the transaction which gives rise to such adjustment; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">the Expiration Time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(e)</TD><TD STYLE="text-align: justify">In the event the Corporation shall at any time after the Record Time and prior to the Separation
Time issue any shares of capital stock (other than Common Shares), or rights, options or warrants to subscribe for or purchase
any such capital stock, or securities convertible into or exchangeable for any such capital stock in a transaction referred to
in Sections 2.3(a)(i) or 2.3(a)(iv) above, if the Board of Directors acting in good faith determines that the adjustments contemplated
by Sections 2.3(a), 2.3(b) and 2.3(c) above in connection with such transaction will not appropriately protect the interests of
the holders of Rights, the Board of Directors may determine what other adjustments to the Exercise Price, number of Rights and/or
securities purchasable upon exercise of Rights would be appropriate and, notwithstanding Sections 2.3(a), 2.3(b) and 2.3(c) above,
such adjustments, rather than the adjustments contemplated by Sections 2.3(a), 2.3(b) and 2.3(c) above, shall be made, and the
Corporation and the Rights Agent shall have authority upon receiving such consent to amend this Agreement as appropriate to provide
for such adjustments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(f)</TD><TD STYLE="text-align: justify">Each Right originally issued by the Corporation subsequent to any adjustment made to the Exercise
Price hereunder shall evidence the right to purchase, at the adjusted Exercise Price, the number of Common Shares purchasable from
time to time hereunder upon exercise of a Right immediately prior to such issue, all subject to further adjustment as provided
for herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(g)</TD><TD STYLE="text-align: justify">Irrespective of any adjustment or change in the Exercise Price or the number of Common Shares issuable
upon the exercise of the Rights, the Rights Certificates theretofore and thereafter issued may continue to express the Exercise
Price per Common Share and the number of Common Shares which were expressed in the initial Rights Certificates issued hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(h)</TD><TD STYLE="text-align: justify">In any case in which this Section 2.3 shall require that an adjustment in the Exercise Price be
made effective as of a record date for a specified event, the Corporation may elect to defer until the occurrence of such event
the issuance to the holder of any Right exercised after such record date the number of Common Shares and other securities of the
Corporation, if any, issuable upon such exercise over and above the number of Common Shares and other securities of the Corporation,
if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such adjustment; provided, however, that
the Corporation shall deliver to such holder an appropriate instrument evidencing such holder&rsquo;s right to receive such additional
shares (fractional or otherwise) or other securities upon the occurrence of the event requiring such adjustment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">Notwithstanding anything contained in this Section 2.3 to the contrary, the Corporation shall be
entitled to make such reductions in the Exercise Price, in addition to those adjustments expressly required by this Section 2.3,
as and to the extent that in their good faith judgement the Board of Directors shall determine to be advisable, in order that any:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">consolidation or subdivision of Common Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">issuance (wholly or in part for cash) of Common Shares or securities that by their terms are convertible
into or exchangeable for Common Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="text-align: justify">stock dividends; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22pt"></TD><TD STYLE="width: 36pt">(iv)</TD><TD STYLE="text-align: justify">issuance of rights, options or warrants referred to in this Section 2.3, hereafter made by the
Corporation to holders of its Common Shares, shall not be</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">taxable to such shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 36pt">(j)</TD><TD STYLE="text-align: justify">If, as a result of an adjustment made pursuant to Section 3.1, the holder of any Right thereafter
exercised shall become entitled to receive any securities other than Common Shares, thereafter the number of such other securities
so receivable upon exercise of any Right and the applicable Exercise Price thereof shall be subject to adjustment from time to
time in a manner and on terms as nearly equivalent as may be practicable to the provisions with respect to the Common Shares contained
in the foregoing Sections of this Section 2.3 and the provisions of this Agreement with respect to the Common Shares shall apply
on like terms to any such other securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 36pt">(k)</TD><TD STYLE="text-align: justify">Whenever an adjustment to the Exercise Price or a change in the securities purchasable upon the
exercise of Rights is made pursuant to this Section 2.3, the Corporation shall promptly:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">prepare a certificate setting forth such adjustment and a brief statement of the facts accounting
for such adjustment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">file with the Rights Agent and with each transfer agent for the Common Shares a copy of such certificate;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="text-align: justify">cause notice of the particulars of such adjustment or change to be given to the holders of the
Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">Failure to file such certificate
or to cause such notice to be given as aforesaid, or any defect therein, shall not affect the validity of any such adjustment or
change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_012"></A>2.4</B></TD><TD STYLE="text-align: justify"><B>Date on Which Exercise Is Effective</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Each Person
in whose name a registration in Book Entry Form for Common Shares or other securities, if applicable, or in whose name any certificate
for Common Shares or other securities, if applicable, is made or issued upon the exercise of Rights shall for all purposes be deemed
to have become the holder of record of the Common Shares or other securities, if applicable, represented therein, and such registration
or certificate, as the case may be, shall be dated the date upon which the Rights Certificate evidencing such Rights was duly surrendered
in accordance with Section 2.2(d) (together with a duly completed Election to Exercise) and payment of the Exercise Price for such
Rights (and any applicable transfer taxes and other governmental charges payable by the exercising holder hereunder) was made;
provided, however, that if the date of such surrender and payment is a date upon which the share transfer books of the Corporation
are closed, such Person shall be deemed to have become the record holder of such shares on, and such registration or certificate,
as the case may be, shall be dated, the next succeeding Business Day on which the share transfer books of the Corporation are open.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_013"></A>2.5</B></TD><TD STYLE="text-align: justify"><B>Execution, Authentication, Delivery and Dating of Rights Certificates</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Rights will
be evidenced, in the case of Rights in Book Entry Form, by a statement issued under the Rights Agent&rsquo;s direct registration
system or, alternatively, if the Corporation determines to issue Rights Certificates, by the following procedures:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Rights Certificates shall be executed on behalf of the Corporation by any two directors or
officers of the Corporation. The signature of any of these directors or officers on the Rights Certificates may be manual, facsimile
or scanned copy. Rights Certificates bearing the manual, facsimile or scanned signatures of individuals who were at any time the
proper officers of the Corporation shall bind the Corporation, notwithstanding that such individuals or any of them have ceased
to hold such offices either before or after the countersignature and delivery of such Rights Certificates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Promptly after the Corporation learns of the Separation Time, the Corporation will notify the Rights
Agent of such Separation Time and will deliver Rights Certificates executed by the Corporation to the Rights Agent for countersignature,
and the Rights Agent shall countersign (in a manner satisfactory to the Corporation) and send such Rights Certificates to the holders
of the Rights pursuant to Section 2.2(c) hereof. No Rights Certificate shall be valid for any purpose until countersigned by the
Rights Agent as aforesaid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Each Rights Certificate shall be dated the date of countersignature thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B><A NAME="FPI_014"></A>2.6</B></TD><TD STYLE="text-align: justify"><B>Registration, Transfer and Exchange</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Corporation will cause to be kept a register (the &ldquo;<B>Rights Register</B>&rdquo;) in
which, subject to such reasonable regulations as it may prescribe, the Corporation will provide for the registration and transfer
of Rights. The Rights Agent is hereby appointed registrar for the Rights (the &ldquo;<B>Rights Registrar</B>&rdquo;) for the purpose
of maintaining the Rights Register for the Corporation and registering Rights and transfers of Rights as herein provided and the
Rights Agent hereby accepts such appointment. In the event that the Rights Agent shall cease to be the Rights Registrar, the Rights
Agent will have the right to examine the Rights Register at all reasonable times.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">After the Separation Time and
prior to the Expiration Time, upon surrender for registration of transfer or exchange of any Rights Certificate, and subject to
the provisions of Section 2.6(c), the Corporation will execute, and the Rights Agent will countersign and deliver, in the name
of the holder or the designated transferee or transferees, as required pursuant to the holder&rsquo;s instructions, one or more
new Rights Certificates evidencing the same aggregate number of Rights as did the Rights Certificates so surrendered. Alternatively,
in the case of the exercise of Rights in Book Entry Form, the Rights Agent shall provide the holder or the designated transferee
or transferees with one or more statements issued under the Rights Agent&rsquo;s direct registration system evidencing the same
aggregate number of Rights as did the direct registration system&rsquo;s records for the Rights transferred or exchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">All Rights issued upon any registration of transfer or exchange of Rights Certificates shall be
the valid obligations of the Corporation, and such Rights shall be entitled to the same benefits and subject to the same limitations
under this Agreement as the Rights surrendered upon such registration of transfer or exchange.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Every Rights Certificate surrendered for registration of transfer or exchange shall be duly endorsed,
or be accompanied by a written instrument of transfer in form satisfactory to the Corporation or the Rights Agent, as the case
may be, duly executed by the holder thereof or such holder&rsquo;s attorney duly authorized in writing. As a condition to the issuance
of any new Rights Certificate under this Section 2.6, the Corporation may require the payment of a sum sufficient to cover any
tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the reasonable fees
and expenses of the Rights Agent) connected therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The Corporation shall not be required to register the transfer or exchange of any Rights after
the Rights have been terminated pursuant to the provisions of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_015"></A>2.7</B></TD><TD STYLE="text-align: justify"><B>Mutilated, Destroyed, Lost and Stolen Rights Certificates</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">If any mutilated Rights Certificate is surrendered to the Rights Agent prior to the Expiration
Time, the Corporation shall execute and the Rights Agent shall countersign and deliver in exchange therefor a new Rights Certificate
evidencing the same number of Rights as did the Rights Certificate so surrendered.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If there shall be delivered to the Corporation and the Rights Agent prior to the Expiration Time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">evidence to their reasonable satisfaction of the destruction, loss or theft of any Rights Certificate;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">such security and indemnity as may be reasonably required by them to save each of them and any
of their agents harmless,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">then, in the absence of notice
to the Corporation or the Rights Agent that such Rights Certificate has been acquired by a bona fide purchaser, the Corporation
shall execute and upon the Corporation&rsquo;s request the Rights Agent shall countersign and deliver, in lieu of any such destroyed,
lost or stolen Rights Certificate, a new Rights Certificate evidencing the same number of Rights as did the Rights Certificate
so destroyed, lost or stolen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">As a condition to the issuance of any new Rights Certificate under this Section 2.7, the Corporation
may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto
and any other expenses (including the reasonable fees and expenses of the Rights Agent) connected therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Every new Rights Certificate issued pursuant to this Section 2.7 in lieu of any destroyed, lost
or stolen Rights Certificate shall evidence the contractual<FONT STYLE="font-size: 10pt"> </FONT>obligation of the Corporation,
whether or not the destroyed, lost or stolen Rights Certificate shall be at any time enforceable by anyone, and shall be entitled
to all the benefits of this Agreement equally and proportionately with any and all other Rights duly issued hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_016"></A>2.8</B></TD><TD STYLE="text-align: justify"><B>Persons Deemed Owners of Rights</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The Corporation,
the Rights Agent and any agent of the Corporation or the Rights Agent may deem and treat the Person in whose name a Rights Certificate
(or, prior to the Separation Time, the associated Common Share certificate) is registered as the absolute owner thereof and of
the Rights evidenced thereby for all purposes whatsoever. As used in this Agreement, unless the context otherwise requires, the
term &ldquo;<B>holder</B>&rdquo; of any Rights shall mean the registered holder of such Rights (or, prior to the Separation Time,
of the associated Common Share).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_017"></A>2.9</B></TD><TD STYLE="text-align: justify"><B>Delivery and Cancellation of Certificates</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">All Rights
Certificates surrendered upon exercise or for redemption, registration of transfer or exchange shall, if surrendered to any Person
other than the Rights Agent, be delivered to the Rights Agent and, in any case, shall be promptly cancelled by the Rights Agent.
The Corporation may at any time deliver to the Rights Agent for cancellation any Rights Certificates previously countersigned and
delivered hereunder which the Corporation may have acquired in any manner whatsoever, and all Rights Certificates so delivered
shall be promptly cancelled by the Rights Agent. No Rights Certificate shall be countersigned in lieu of or in exchange for any
Rights Certificates cancelled as provided in this Section 2.9, except as expressly permitted by this Agreement. The Rights Agent
shall, subject to applicable laws, destroy all cancelled Rights Certificates and deliver a certificate of destruction to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_018"></A>2.10</B></TD><TD STYLE="text-align: justify"><B>Agreement of Rights Holders</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Every holder
of Rights, by accepting the same, consents and agrees with the Corporation and the Rights Agent and with every other holder of
Rights that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">such holder of Rights shall be bound by and subject to the provisions of this Agreement, as amended
from time to time in accordance with the terms hereof, in respect of all Rights held;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">prior to the Separation Time, each Right will be transferable only together with, and will be transferred
by a transfer of, the associated Common Share certificate representing such Right;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">after the Separation Time, the Rights Certificates will be transferable only on the Rights Register
as provided herein;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">prior to due presentment of a Rights Certificate (or, prior to the Separation Time, the associated
Common Share certificate) for registration of transfer, the Corporation, the Rights Agent and any agent of the Corporation or the
Rights Agent may deem and treat the Person in whose name the Rights Certificate (or, prior to the Separation Time, the associated
Common Share certificate) is registered as the absolute owner thereof and of the Rights evidenced thereby (notwithstanding any
notations of ownership or writing on such Rights Certificate or the associated Common Share certificate made by anyone other than
the Corporation or the Rights Agent) for all purposes whatsoever, and neither the Corporation nor the Rights Agent shall be affected
by any notice to the contrary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">such holder of Rights has waived his right to receive any fractional Rights or any fractional shares
or other securities upon exercise of a Right (except as provided herein);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">without the approval of any holder of Rights or Voting Shares and upon the sole authority of the
Board of Directors, this Agreement may be supplemented or amended from time to time pursuant to Section 5.4(a) and the last paragraph
of Section 2.3(a); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">that notwithstanding anything in this Agreement to the contrary, neither the Corporation nor the
Rights Agent shall have any liability to any holder of a Right or to any other Person as a result of its inability to perform any
of its obligations under this Agreement by reason of any preliminary or permanent injunction or other order, decree or ruling issued
by a court of competent jurisdiction or by a government, regulatory or administrative agency or commission, or any statute, rule,
regulation or executive order promulgated or enacted by any governmental authority, prohibiting or otherwise restraining performance
of such obligation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_019"></A>2.11</B></TD><TD STYLE="text-align: justify"><B>Rights Certificate Holder Not Deemed a Shareholder</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">No holder,
as such, of any Rights or Rights Certificate shall be entitled to vote, receive dividends or be deemed for any purpose whatsoever
the holder of any Common Share or any other share or security of the Corporation which may at any time be issuable on the exercise
of the Rights represented thereby, nor shall anything contained herein or in any Rights Certificate be construed or deemed to confer
upon the holder of any Right or Rights Certificate, as such, any right, title, benefit or privilege of a holder of Common Shares
or any other shares or securities of the Corporation or any right to vote at any meeting of shareholders of the Corporation whether
for the election of directors or otherwise or upon any matter submitted to holders of Common Shares or any other shares of the
Corporation at any meeting thereof, or to give or withhold consent to any action of the Corporation, or to receive notice of any
meeting or other action affecting any holder of Common Shares or any other shares of the Corporation except as expressly provided
herein, or to receive dividends, distributions or subscription rights, or otherwise, until the Right or Rights evidenced by Rights
Certificates shall have been duly exercised in accordance with the terms and provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="FPI_020"></A>ARTICLE 3<BR>
ADJUSTMENTS TO THE RIGHTS IN THE EVENT OF CERTAIN TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_021"></A>3.1</B></TD><TD STYLE="text-align: justify"><B>Flip-in Event</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Subject to Section 3.1(b) and Section 5.1, in the event that prior to the Expiration Time a Flip-in
Event shall occur, then each Right shall constitute, effective at the<FONT STYLE="font-size: 10pt"> </FONT>close of business on
the eighth Trading Day after the Stock Acquisition Date, the right to purchase from the Corporation, upon exercise thereof in accordance
with the terms hereof, that number of Common Shares having an aggregate Market Price on the date of consummation or occurrence
of such Flip-in Event equal to twice the Exercise Price for an amount in cash equal to the Exercise Price (such right to be appropriately
adjusted in a manner analogous to the applicable adjustment provided for in Section 2.3 in the event that after the consummation
or occurrence or event, an event of a type analogous to any of the events described in Section 2.3 shall have occurred).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding anything in this Agreement to the contrary, upon the occurrence of any Flip-in
Event, any Rights that are or were Beneficially owned on or after the earlier of the Separation Time or the Stock Acquisition Date
by:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">an Acquiring Person (or any Person acting jointly or in concert with an Acquiring Person); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">a transferee of Rights, directly or indirectly, from an Acquiring Person (or any Person acting
jointly or in concert with an Acquiring Person), where such transferee becomes a transferee concurrently with or subsequent to
the Acquiring Person becoming such in a transfer that the Board of Directors has determined is part of a plan, arrangement or scheme
of an Acquiring Person (or any Person acting jointly or in concert with an Acquiring Person), that has the purpose or effect of
avoiding Section 3.1(b)(i),</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">shall become null and void without
any further action, and any holder of such Rights (including transferees) shall thereafter have no right to exercise such Rights
under any provision of this Agreement and further shall thereafter not have any other rights whatsoever with respect to such Rights,
whether under any provision of this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">From and after the Separation Time, the Corporation shall do all such acts and things as shall
be necessary and within its power to ensure compliance with the provisions of Section 3.1, including without limitation, all such
acts and things as may be required to satisfy the requirements of the BCBCA, the <I>Securities Act</I> (Ontario), the U.S. Securities
Act, the U.S. Exchange Act and the securities laws or comparable legislation in each of the provinces of Canada and each of the
states of the United States in respect of the issue of Common Shares upon the exercise of Rights in accordance with this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Any Rights Certificate that would represent Rights Beneficially owned by a Person described in
either Section 3.1(b)(i) or 3.1(b)(ii) or transferred to any nominee of any such Person, and any Rights Certificate that would
be issued upon transfer, exchange, replacement or adjustment of any other Rights Certificate referred to in this sentence, shall
either not be issued upon the instruction of the Corporation in writing to the Rights Agent or contain the following legend:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 114pt; text-align: justify">The Rights represented by this
Rights Certificate were issued to a Person who was an Acquiring Person or an Affiliate or an Associate of an Acquiring Person (as
such terms are defined in the Shareholder Rights Plan Agreement) or a Person who was acting jointly or in concert with an Acquiring
Person or an Affiliate or Associate of an Acquiring Person. This Rights Certificate and the Rights represented hereby are void
or shall become void in the circumstances specified in Section 3.1(b) of the Shareholder Rights Plan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">Provided, however, that the
Rights Agent shall not be under any responsibility to ascertain the existence of facts that would require the imposition of such
legend but shall impose such legend only if instructed to do so by the Corporation in writing or if a holder fails to certify upon
transfer or exchange in the space provided on the Rights Certificate that such holder is not a Person described in such legend.
The issuance of a Rights Certificate without the legend referred to in this Section 3.1(d) shall be of no effect on the provisions
of Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="FPI_022"></A><B>ARTICLE 4<BR>
THE RIGHTS AGENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_023"></A>4.1</B></TD><TD STYLE="text-align: justify"><B>General</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: windowtext">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">The Corporation hereby appoints the Rights Agent to act as agent
for the Corporation and the holders of the Rights in accordance with the terms and conditions of this Agreement, and the Rights
Agent hereby accepts such appointment. The Corporation may from time to time appoint one or more co- Rights Agents (&ldquo;<B>Co-Rights
Agents</B>&rdquo;) as it may deem necessary or desirable, subject to the approval of the Rights Agent. In the event the Corporation
appoints one or more Co-Rights Agents, the respective duties of the Rights Agent and Co- Rights Agents shall be as the Corporation
may determine with the approval of the Rights Agent and the Co-Rights Agents. The Corporation agrees to pay to the Rights Agent
reasonable compensation for all services rendered by it hereunder and, from time to time, on demand of the Rights Agent, its reasonable
expenses and counsel fees and other disbursements reasonably incurred in the execution and administration of this Agreement and
the exercise and performance of its duties thereunder (including the reasonable fees and other disbursements of any expert retained
by the Rights Agent with the approval of the Corporation, such approval not to be unreasonably withheld). The Corporation also
agrees to indemnify the Rights Agent, its officers, directors and employees for, and to hold it harmless against, any loss, liability,</FONT><FONT STYLE="color: red"><B>
</B></FONT><FONT STYLE="color: windowtext">cost, claim, action, damage suit or expense arising directly or indirectly out of its
agency relationship with the Corporation pursuant to the terms and conditions of this Agreement, incurred without gross negligence,
bad faith or willful misconduct on the part of the Rights Agent or its directors, officers, employees and agents,, for anything
suffered, or omitted by the Rights Agent or such persons in connection with the acceptance, execution and administration of this
Agreement, including legal costs and expenses for defending against any claim of liability, which right to indemnification will
survive the termination of this Agreement or the resignation or removal of the Rights Agent. In the event of any disagreement arising
regarding the terms of this Agreement, the Rights Agent shall be entitled, at its option, to refuse to comply with any and all
demands whatsoever until the dispute is settled either by written agreement between the parties to this Agreement or by a court
of competent jurisdiction. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Rights Agent shall be protected and shall incur no liability for or in respect of any action
taken, suffered or omitted by it in connection with its administration of this Agreement in reliance upon any certificate for Common
Shares, Rights Certificate, certificate for other securities of the Corporation, instrument of assignment or transfer, power of
attorney, endorsement, affidavit, letter, notice, direction, consent, certificate, opinion, statement, or other paper or document
believed by it to be genuine and to be signed, executed and, where necessary, verified or acknowledged, by the proper Person or
Persons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">The Corporation shall inform
the Rights Agent in a reasonably timely manner of events which may materially affect the administration of this Agreement by the
Rights Agent and, at any time upon request, shall provide to the Rights Agent an incumbency certificate certifying the then current
officers of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Notwithstanding any other provision of this Agreement, any liability of the Rights Agent, except
as resulting from its gross negligence, bad faith or wilful misconduct, shall be limited, in the aggregate, to the amount of fees
paid by the Corporation to the Rights Agent under this Agreement in the twelve (12) months immediately prior to the Rights Agent
receiving the first notice of the claim.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B><A NAME="FPI_024"></A>4.2</B></TD><TD STYLE="text-align: justify"><B>Merger, Amalgamation or Consolidation or Change of Name of Rights Agent</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Any company into which the Rights Agent may be merged or amalgamated or with which it may be consolidated,
or any company resulting from any merger, amalgamation, statutory arrangement or consolidation to which the Rights Agent is a party,
or any company succeeding to the securityholder services business of the Rights Agent, will be the successor to the Rights Agent
under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto,
provided that such company would be eligible for appointment as a successor Rights Agent under the provisions of Section 4.4 hereof.
In case at the time such successor Rights Agent succeeds to the agency created by this Agreement any of the Rights Certificates
have been countersigned but not delivered, any successor Rights Agent may adopt the countersignature of the predecessor Rights
Agent and deliver such Rights Certificates so countersigned; and in case at that time any of the Rights have not been countersigned,
any successor Rights Agent may countersign such Rights Certificates in the name of the predecessor Rights Agent or in the name
of the successor Rights Agent; and in all such cases such Rights Certificates will have the full force provided in the Rights Certificates
and in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">In case at any time the name of the Rights Agent is changed and at such time any of the Rights
Certificates shall have been countersigned but not delivered, the Rights Agent may adopt the countersignature under its prior name
and deliver Rights Certificates so countersigned; and in case at that time any of the Right Certificates shall not have been countersigned,
the Rights Agent may countersign such Rights Certificates either in its prior name or in its changed name; and in all<FONT STYLE="font-size: 10pt">
</FONT>such cases such Rights Certificates shall have the full force provided in the Rights Certificates and in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B><A NAME="FPI_025"></A>4.3</B></TD><TD STYLE="text-align: justify"><B>Duties of Rights Agent</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The Rights
Agent undertakes the duties and obligations imposed by this Agreement upon the following terms and conditions, all of which the
Corporation and the holders of certificates for Common Shares and Rights Certificates, by their acceptance thereof, shall be bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Rights Agent may retain and consult with legal counsel (who may be legal counsel for the Corporation)
and the opinion of such counsel will be full and complete authorization and protection to the Rights Agent as to any action taken
or omitted by it in good faith and in accordance with such opinion; and the Rights Agent may also consult with such other experts
as the Rights Agent shall consider necessary or appropriate to properly carry out the duties and obligations imposed under this
Agreement (at the Corporation&rsquo;s expense) and the Rights Agent shall be entitled to act and rely in good faith on the advice
of any such expert.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Whenever in the performance of its duties under this Agreement, the Rights Agent deems it necessary
or desirable that any fact or matter be proved or established by the Corporation prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively
proved and established by a certificate signed by Persons believed by the Rights Agent to be two directors or officers of the Corporation
and delivered to the Rights Agent; and such certificate will be full authorization to the Rights Agent for any action taken or
suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Rights Agent will be liable hereunder for its own gross negligence, bad faith or wilful misconduct
and that of its officers, directors and employees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The Rights Agent will not be liable for or by reason of any of the statements of fact or recitals
contained in this Agreement (except as such are made or provided by the Rights Agent) or in the certificates for Common Shares
or the Rights Certificates (except its countersignature thereof) or be required to verify the same, but all such statements and
recitals are and will be deemed to have been made by the Corporation only.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Rights Agent will not be under any responsibility in respect of the validity of this Agreement
or the execution and delivery hereof (except the due authorization, execution and delivery hereof by the Rights Agent) or in respect
of the validity or execution of any certificate for a Common Share or Rights Certificate (except its countersignature thereof);
nor will it be responsible for any breach by the Corporation of any covenant or condition contained in this Agreement or in any
Rights Certificate; nor will it be responsible for any change in the exerciseability of the Rights (including the Rights becoming
void pursuant to Section 3.1(b) hereof) or any adjustment required under the provisions of Section 2.3 hereof or responsible for
the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment
(except with respect to the exercise of Rights after receipt of the certificate contemplated by Section 2.3 describing any such
adjustment); nor will it by any act hereunder be deemed to make any representation or warranty as to the authorization of any Common
Shares to be issued pursuant to this Agreement or any Rights or as to whether any Common Shares will, when issued, be duly and
validly authorized, executed, issued and delivered and fully paid and non- assessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The Corporation agrees that it will perform, execute, acknowledge and deliver or cause to be performed,
executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required
by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">The Rights Agent is hereby authorized and directed to accept instructions in writing with respect
to the performance of its duties hereunder from any individuals believed by the Rights Agent to be any two officers or directors
of the Corporation, and to apply to such individuals for advice or instructions in connection with its duties, and it shall not
be liable for any action taken or suffered by it in good faith in accordance with instructions of any such individual. It is understood
that instructions to the Rights Agent shall, except where circumstances make it impracticable or the Rights Agent otherwise agrees,
be given in writing and, where not in writing, such instructions shall be confirmed in writing as soon as reasonably possible after
the giving of such instructions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">The Rights Agent and any shareholder or stockholder, director, officer or employee of the Rights
Agent may buy, sell or deal in Common Shares, Rights or other securities of the Corporation or become financially interested in
any transaction in which the Corporation may be interested, or contract with or lend money to the Corporation or otherwise act
as fully and freely as though it were not the Rights Agent under this Agreement. Nothing herein shall preclude the Rights Agent
from acting in any other capacity for the Corporation or for any other legal entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform
any duty hereunder either itself or by or through its attorneys or agents, and the Rights Agent will not be answerable or accountable
for any act, default, neglect or misconduct of any such attorneys or agents or for any loss to the Corporation resulting from any
such act, default, neglect or misconduct, provided reasonable care was exercised in the selection and continued employment thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B><A NAME="FPI_026"></A>4.4</B></TD><TD STYLE="text-align: justify"><B>Change of Rights Agent</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The Rights
Agent may resign and be discharged from its duties under this Agreement upon 60 days&rsquo; notice (or such lesser notice as is
acceptable to the Corporation) in writing mailed to the Corporation and to each transfer agent of Common Shares by registered or
certified mail. The Corporation may remove the Rights Agent upon 60 days&rsquo; notice in writing, mailed to the Rights Agent and
to each transfer agent of the Common Shares by registered or certified mail. If the Rights Agent should resign or be removed or
otherwise become incapable of acting, the Corporation will appoint a successor to the Rights Agent. If the Corporation fails to
make such appointment within a period of 60 days after such removal or after it has been notified in writing of such resignation
or incapacity by the resigning or incapacitated Rights Agent, then by prior written notice to the Corporation the resigning or
Rights Agent (at the Corporation&rsquo;s expense) or the holder of any Rights (which holder shall, with such notice, submit such
holder&rsquo;s Rights Certificate, if any, for inspection by the Corporation), may apply to any court of competent jurisdiction
for the appointment of a new Rights Agent. Any successor Rights Agent, whether appointed by the Corporation or by such a court,
shall be a company constituted under the laws of Canada or a province thereof. After appointment, the successor Rights Agent will
be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Rights Agent without
further act or deed; but the predecessor Rights Agent shall deliver and transfer to the successor Rights Agent any property at
the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the purpose.
Not later than the effective date of any such appointment, the Corporation will file notice thereof in writing with the predecessor
Rights Agent and each transfer agent of the Common Shares, and mail a notice thereof in writing to the holders of the Rights in
accordance with Section 5.9. Failure to give any notice provided for in this Section 4.4, however, or any defect therein, shall
not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of any successor Rights
Agent, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B><A NAME="FPI_027"></A>4.5</B></TD><TD STYLE="text-align: justify"><B>Compliance with Anti-Money Laundering Legislation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The Rights
Agent shall retain the right not to act and shall not be liable for refusing to act if, due to a lack of information or for any
other reason whatsoever, the Rights Agent reasonably determines that such an act might cause it to be in non-compliance with any
applicable anti- money laundering or anti-terrorist legislation, regulation or guideline. Further, should the Rights Agent reasonably
determine at any time that its acting under this Agreement has resulted in it being in non-compliance with any applicable anti-money
laundering or anti-terrorist legislation, regulation or guideline, then it shall have the right to resign on 10 days&rsquo; prior
written notice to the Corporation, provided: (i) that the Rights Agent&rsquo;s written notice shall describe the circumstances
of such non-compliance; and (ii) that if such circumstances are rectified to the Rights Agent&rsquo;s satisfaction within such
10 day period, then such resignation shall not be effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_028"></A>4.6</B></TD><TD STYLE="text-align: justify"><B>Privacy Legislation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The parties
acknowledge that federal and/or provincial legislation that addresses the protection of individual&rsquo;s personal information
(collectively, &ldquo;<B>Privacy Laws</B>&rdquo;) applies to obligations and activities under this Agreement. Despite any other
provision of this Agreement, neither party will take or direct any action that would contravene, or cause the other to contravene,
applicable Privacy Laws. The Corporation will, prior to transferring or causing to be transferred personal information to the Rights
Agent, obtain and retain required consents of the relevant individuals to the collection, use and disclosure of their personal
information, or will have determined that such consents either have previously been given upon which the parties can rely or are
not required under the Privacy Laws. The Rights Agent will use commercially reasonable efforts to ensure that its services hereunder
comply with Privacy Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_029"></A>4.7</B></TD><TD STYLE="text-align: justify"><B>Liability</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Notwithstanding
any other provision of this Agreement, and whether such losses or damages are foreseeable or unforeseeable, the Rights Agent shall
not be liable under any circumstances whatsoever for any (a) breach by any other party of securities law or other rule of any securities
regulatory authority, (b) lost profits or (c) special, indirect, incidental, consequential, exemplary, aggravated or punitive losses
or damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.2pt"><B><A NAME="FPI_030"></A>ARTICLE 5<BR>
MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_031"></A>5.1</B></TD><TD STYLE="text-align: justify"><B>Redemption and Waiver</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Board of Directors shall waive the application of Section 3.1 in respect of the occurrence
of any Flip-in Event if the Board of Directors has determined, following a Stock Acquisition Date and prior to the Separation Time,
that a Person became an Acquiring Person by inadvertence and without any intention to become, or knowledge that it would become,
an Acquiring Person under this Agreement and, in the event that such a waiver is granted by the Board of Directors, such Stock
Acquisition Date shall be deemed not to have occurred. Any such waiver pursuant to this Section 5.1(a) must be on the condition
that such Person, within 14 days after the foregoing determination by the Board of Directors or such earlier or later date as the
Board of Directors may determine (the &ldquo;<B>Disposition Date</B>&rdquo;), has reduced its Beneficial ownership of Voting Shares
such that the Person is no longer an Acquiring Person. If the Person remains an Acquiring Person at the close of business on the
Disposition Date, the Disposition Date shall be deemed to be the date of occurrence of a further Stock Acquisition Date and Section
3.1 shall apply thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Board of Directors acting in good faith may, prior to a Flip-in Event having occurred, upon
prior written notice delivered to the Rights Agent, determine to waive the application of Section 3.1 to a Flip-in Event that may
occur by reason of a Take-over Bid made by means of a take-over bid circular to all holders of record of Voting Shares (which for
greater certainty shall not include the circumstances described in Section 5.1(a)), provided that if the Board of Directors waives
the application of Section 3.1 to a particular Flip-in Event pursuant to this Section 5.1(b), the Board of Directors shall be deemed
to have waived the application of Section 3.1 to any other Flip-in Event occurring by reason of any Take-over Bid which is made
by means of a Take-over Bid circular to all holders of Voting Shares prior to the expiry of any Take-over Bid (as the same may
be extended from time to time) in respect of which a waiver is, or is deemed to have been granted, under this Section 5.1(b).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">In the event that prior to the occurrence of a Flip-in Event a Person acquires, pursuant to a Permitted
Bid, a Competing Permitted Bid or an Exempt Acquisition under Section 5.1(b), outstanding Voting Shares, then the Board of Directors
shall, immediately upon the consummation of such acquisition without further formality be deemed to have elected to redeem the
Rights at a redemption price of $0.000001 per Right appropriately adjusted in a manner analogous to the applicable adjustment provided
for in Section 2.3 if an event of the type analogous to any of the events described in Section 2.3 shall have occurred (such redemption
price being herein referred to as the &ldquo;<B>Redemption Price</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Subject to the prior consent of the holders of Voting Shares (obtained as described in Section
5.4(b)), the Board of Directors may, at any time prior to the occurrence of a Flip-in Event, elect to redeem all but not less than
all of the then outstanding Rights at the Redemption Price appropriately adjusted in a manner analogous to the applicable adjustments
provided for in Section 2.3, which adjustments shall only be made in the event that an event of the type analogous to any of the
events described in Section 2.3 shall have occurred.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Board of Directors may, prior to the close of business on the tenth Trading Day following a
Stock Acquisition Date or such later Business Day as they may from time to time determine, upon prior written notice delivered
to the Rights Agent, waive the application of Section 3.1 to the related Flip-in Event, provided that the Acquiring Person has
reduced its Beneficial ownership of Voting Shares (or has entered into a contractual arrangement with the Corporation, acceptable
to the Board of Directors, to do so within 10 calendar days of the date on which such contractual arrangement is entered into or
such other date as the Board of Directors may have determined) such that at the time the waiver becomes effective pursuant to this
Section 5.1(e) such Person is no longer an Acquiring Person. In the event of such a waiver becoming effective prior to the Separation
Time, for the purposes of this Agreement, such Flip-in Event shall be deemed not to have occurred.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Where a Take-over Bid that is not a Permitted Bid Acquisition is withdrawn or otherwise terminated
after the Separation Time has occurred and prior to the occurrence of a Flip-in Event, the Board of Directors may elect to redeem
all the outstanding Rights at the Redemption Price. Upon the Rights being redeemed pursuant to this Section 5.1(f), all the provisions
of this Agreement shall continue to apply as if the Separation Time had not occurred and Rights Certificates representing the number
of Rights held by each holder of record of Common Shares as of the Separation Time had not been mailed to each such holder and
for all purposes of this Agreement the Separation Time shall be deemed not to have occurred and the Corporation shall be deemed
to have issued replacement Rights to the holders of its then outstanding Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">If the Board of Directors is deemed under Section 5.1(c) to have elected or elects under Sections
5.1(d) or 5.1(f) to redeem the Rights:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">the right to exercise the Rights will thereupon, without further action and without notice, terminate
and the only right thereafter of the holders of Rights shall be to receive the Redemption Price; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">within 10 calendar days after such election or deemed election, the Corporation shall give notice
of redemption to the holders of the then outstanding Rights by mailing such notice to each such holder at his last address as it
appears upon the applicable registry books of the Rights Agent or, prior to the Separation Time, on the registry books of the transfer
agent for the Voting Shares. Any notice which is mailed in the manner herein provided shall be deemed given, whether or not the
holder receives the notice. Each such notice of redemption will state the method by which the payment of the Redemption Price will
be made.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt; text-align: justify">Notwithstanding anything herein,
if the Board of Directors is deemed under Section 5.1(c) to have elected or elects under Sections 5.1(d) or 5.1(f) to redeem the
Rights, and the aggregate Redemption Price payable to a holder of Rights in respect of all Rights held by such holder is less than
$10, such holder of Rights shall be deemed to have waived any entitlement to receive all or any portion of such aggregate Redemption
Price and the Corporation shall have no obligation to pay all or any portion of the aggregate Redemption Price to any such holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">The Corporation shall give prompt written notice to the Rights Agent of any waiver of the application
of Section 3.1 pursuant to this Section 5.1.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_032"></A>5.2</B></TD><TD STYLE="text-align: justify"><B>Expiration</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">No Person shall
have any rights whatsoever pursuant to this Agreement or in respect of any Right after the Expiration Time, except the Rights Agent
as specified in Section 4.1(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_033"></A>5.3</B></TD><TD STYLE="text-align: justify"><B>Issuance of New Rights Certificates</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Notwithstanding
any of the provisions of this Agreement or of the Rights to the contrary, the Corporation may, at its option, issue new Rights
Certificates evidencing Rights in such form as may be approved by the Board of Directors to reflect any adjustment or change in
the number or kind or class of securities purchasable upon exercise of Rights made in accordance with the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_034"></A>5.4</B></TD><TD STYLE="text-align: justify"><B>Supplements and Amendments</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">At any time, the Corporation may, by resolution of the Board of Directors, amend this Agreement
to correct any clerical or typographical errors or to maintain the validity of this Agreement as a result of any changes in applicable
legislation or applicable rules or policies of securities regulatory authorities or stock exchanges, and such amendments shall
be in force immediately after such a resolution is passed by the Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Subject to Section 5.4(a), prior to the Separation Time, the Corporation may, by resolution of
the Board of Directors, and with the prior consent of the holders of Voting Shares obtained as set forth below, supplement, amend,
vary or rescind any of the provisions of this Agreement and the Rights (whether or not such action would materially adversely affect
the interests of the holders of Rights generally). Such consent is deemed to have been given if the action requiring such consent
is approved by the affirmative vote of a majority of the votes cast by Independent Shareholders represented in person or by proxy
and entitled to be voted at a meeting of the holders of Voting Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Subject to Section 5.4(a), after the Separation Time, the Corporation may, by resolution of the
Board of Directors, and with the prior consent of the holders of Rights obtained as set forth below, supplement, amend, vary or
rescind any of the provisions of this Agreement and the Rights (whether or not such action would materially adversely affect the
interests of the holders of Rights generally). Such consent is deemed to have been given if the action requiring such consent is
approved by the affirmative vote of a majority of the votes cast by the holders of Rights represented in person or by proxy and
entitled to be voted at a meeting of the holders of Rights. For the purposes of this Agreement, each outstanding Right (other than
Rights which are void pursuant to the provisions of this Agreement) will be entitled to one vote, and the procedures for the calling,
holding and conduct of the meeting will be those, as nearly as may be, which are provided for in the Corporation&rsquo;s articles,
the BCBCA and any other applicable law, rule or regulation with respect to meetings of shareholders of the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Any amendments made by the Corporation to this Agreement pursuant to Section 5.4(a) which maintain
the validity of this Agreement as a result of any changes in applicable legislation or applicable rules or policies of securities
regulatory authorities or stock exchanges shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">if made before the Separation Time, be submitted to the shareholders of the Corporation at the
next meeting of shareholders and the shareholders may, by a vote of the majority referred to in Section 5.4(b), confirm or reject
such amendment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">if made after the Separation Time, be submitted to holders of Rights at a meeting to be called
for on a date not later than immediately following the next meeting of shareholders of the Corporation and the holders of Rights
may, by a vote of the majority referred to in Subsection 5.4(c), confirm or reject such amendment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58pt; text-align: justify">Any such amendment shall be effective
from the date of the resolution of the Board of Directors adopting such amendment, until it is confirmed or rejected in accordance
with this Section 5.4(d) or until it ceases to be effective (as described below) and, where such amendment is confirmed, it continues
in effect in the form so confirmed. If such amendment is rejected by shareholders or holders of Rights or is not submitted to shareholders
or holders of Rights as required, then such amendment shall cease to be effective from and after the termination of the meeting
at which it was rejected or to which it should have been but was not submitted or from and after the date of the meeting of holders
of Rights that should have been but was not held, and no subsequent resolution of the Board of Directors to amend this Agreement
to substantially the same effect shall be effective until confirmed by shareholders or holders of Rights, as the case may be. For
greater certainty, if such amendment shall cease to be effective as aforesaid, the relevant portions of this Agreement affected
by such amendment shall revert to their respective form as constituted immediately prior to such amendment, subject to such other
amendments thereto as may have been properly made in accordance with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Notwithstanding anything in this Section 5.4 to the contrary, no such supplement or amendment shall
be made to the provisions of Article 4 except with the written concurrence of the Rights Agent to such supplement or amendment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The Corporation shall give notice in writing to the Rights Agent of any supplement, amendment,
variation or rescission of any provision of this Agreement pursuant to this Section 5.4 within five Business Days of the date of
any such supplement, amendment, variation or rescission, provided that failure to give such notice, or any defect therein shall
not affect the validity of any such supplement, amendment, variation or rescission.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_035"></A>5.5</B></TD><TD STYLE="text-align: justify"><B>Fractional Rights and Fractional Shares</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Corporation shall not be required to issue fractions of Rights or to distribute Rights Certificates
which evidence fractional Rights and the Corporation shall not be required to pay any amount to a holder of record of Rights Certificates
in lieu of such fractional Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Corporation shall not be required to issue fractions of Common Shares upon exercise of Rights
or to distribute certificates which evidence fractional Common Shares. In lieu of issuing fractional Common Shares, the Corporation
shall be entitled to pay to the registered holders of Rights Certificates, at the time such Rights are exercised as herein provided,
an amount in cash equal to the fraction of the Market Price of one Common Share that the fraction of a Common Share that would
otherwise be issuable upon the exercise of such Right is of one whole Common Share at the date of such exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Rights Agent shall have no obligation to make any payments in lieu of issuing fractions of
Common Shares pursuant to Section 5.5(b) unless and until the Corporation shall have provided to the Rights Agent the amount of
cash to be paid in lieu of issuing such fractional Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: -5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: -5pt"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: -5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_036"></A>5.6</B></TD><TD STYLE="text-align: justify"><B>Rights of Action</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Subject to
the terms of this Agreement, all rights of action in respect of this Agreement, other than rights of action vested solely in the
Rights Agent, are vested in the respective holders of the Rights. Any holder of Rights, without the consent of the Rights Agent
or of the holder of any other Rights, may, on such holder&rsquo;s own behalf and for such holder&rsquo;s own benefit and the benefit
of other holders of Rights, enforce, and may institute and maintain any suit, action or proceeding against the Corporation to enforce
such holder&rsquo;s right to exercise such holder&rsquo;s Rights or Rights to which such holder is entitled in the manner provided
in such holder&rsquo;s Rights Certificate and in this Agreement. Without limiting the foregoing or any remedies available to the
holders of Rights, it is specifically acknowledged that the holder of Rights would not have an adequate remedy at law for any breach
of this Agreement and will be entitled to specific performance of the obligations under, and injunctive relief against actual or
threatened violations of the obligations of any Person subject to, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_037"></A>5.7</B></TD><TD STYLE="text-align: justify"><B>Regulatory Approvals</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Any obligation
of the Corporation or action or event contemplated by this Agreement shall be subject to the receipt of any requisite approval
or consent from any governmental or regulatory authority, and without limiting the generality of the foregoing, necessary approvals
of any stock exchange shall be obtained, such as approvals relating to the issuance of Common Shares upon the exercise of Rights
under Section 2.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_038"></A>5.8</B></TD><TD STYLE="text-align: justify"><B>Declaration as to Foreign Holders</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">If in the opinion
of the Board of Directors (who may rely upon the advice of counsel) any action or event contemplated by this Agreement would require
compliance by the Corporation with the securities laws or comparable legislation of a jurisdiction outside Canada or the United
States, the Board of Directors acting in good faith shall take such actions as it may deem appropriate to ensure such compliance.
In no event shall the Corporation or the Rights Agent be required to issue or deliver Rights or securities issuable on exercise
of Rights to persons who are citizens, residents or nationals of any jurisdiction other than Canada or the United States, in which
such issue or delivery would be unlawful without registration of the relevant Persons or securities for such purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 36pt"><B><A NAME="FPI_039"></A>5.9</B></TD><TD STYLE="text-align: justify"><B>Notices</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Notices or demands authorized or required by this Agreement to be given or made by the Rights Agent
or by the holder of any Rights to or on the Corporation shall be sufficiently given or made if delivered, sent by overnight or
same-day courier (until another address is filed in writing with the Rights Agent) or sent by email, as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 114pt; text-align: justify">Fennec Pharmaceuticals Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 114pt; text-align: justify">PO Box 13628</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 114pt; text-align: justify">68 TW Alexander Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 114pt; text-align: justify">Research Triangle Park, NC 27709</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 114pt; text-align: justify">Attention: Controller&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt; text-align: justify">Email: mgowland@fennecpharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify">Notices or demands authorized or required by this Agreement to be given or made by the Corporation
or by the holder of any Rights to or on the Rights Agent shall be sufficiently given or made if delivered, sent by overnight or
same-day courier (until another address is filed in writing with the Corporation), or sent by facsimile, as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.05pt; text-align: justify">Computershare Trust Company
of Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt; text-align: left">100 University Avenue, 8<SUP>th</SUP>
Floor<BR>
Toronto, ON M5J 2Y1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt; text-align: left">Attention:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Manager, Client
Services</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt; text-align: left">Fax Number:&#9;&nbsp;&nbsp;&nbsp;416-981-9800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 36pt">(c)</TD><TD STYLE="text-align: justify">Notices or demands authorized or required by this Agreement to be given or made by the Corporation
or the Rights Agent to or on the holder of any Rights shall be sufficiently given or made if delivered or sent by overnight or
same-day courier, addressed to such holder at the address of such holder as it appears upon the register of the Rights Agent or,
prior to the Separation Time, on the register of the Corporation for its Common Shares. Any notice which is sent in the manner
herein provided shall be deemed given, whether or not the holder receives the notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 36pt">(d)</TD><TD STYLE="text-align: justify">Any communication or notice hereunder may only be sent via overnight or same- day courier or email
to the applicable address first set out herein, and will be deemed to have been properly delivered on the next business day after
sending via overnight or same-day courier or email. Addresses for communication and notice may be updated from time to time in
writing delivered to the other party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_040"></A>5.10</B></TD><TD STYLE="text-align: justify"><B>Costs of Enforcement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The Corporation
agrees that if it fails to fulfil any of its obligations pursuant to this Agreement, then it will reimburse the holder of any Rights
for the costs and expenses (including legal fees) incurred by such holder to enforce his rights pursuant to any Rights or this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_041"></A>5.11</B></TD><TD STYLE="text-align: justify"><B>Successors</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">All the covenants
and provisions of this Agreement by or for the benefit of the Corporation or the Rights Agent shall bind and enure to the benefit
of their respective successors and assigns hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_042"></A>5.12</B></TD><TD STYLE="text-align: justify"><B>Benefits of this Agreement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Nothing in
this Agreement shall be construed to give to any Person other than the Corporation, the Rights Agent and the holders of the Rights
any legal or equitable right, remedy or claim under this Agreement; further, this Agreement shall be for the sole and exclusive
benefit of The Corporation, the Rights Agent and the holders of the Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_043"></A>5.13</B></TD><TD STYLE="text-align: justify"><B>Governing Law</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">This Agreement
and each Right issued hereunder shall be deemed to be a contract made under the laws of the Province of Ontario and for all purposes
shall be governed by and construed in accordance with the laws of such Province applicable to contracts to be made and performed
entirely within such Province.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_044"></A>5.14</B></TD><TD STYLE="text-align: justify"><B>Severability</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">If any term
or provision hereof or the application thereof to any circumstance shall, in any jurisdiction and to any extent, be invalid or
unenforceable, such term or provision shall be ineffective only as to such jurisdiction and to the extent of such invalidity or
unenforceability in such jurisdiction without invalidating or rendering unenforceable or ineffective the remaining terms and provisions
hereof in such jurisdiction or the application of such term or provision in any other jurisdiction or to circumstances other than
those as to which it is specifically held invalid or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_045"></A>5.15</B></TD><TD STYLE="text-align: justify"><B>Effective Time</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify">This Agreement is effective and in full force and effect in accordance with its terms from and
after the Effective Time. This Agreement and all outstanding Rights shall terminate and be void and of no further force and effect
on and from the Expiration Time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify">If this Agreement is not ratified and confirmed by a resolution passed by a majority of the votes
cast by all holders of Voting Shares who vote in respect of such ratification and confirmation (other than any holder who does
not qualify as an Independent Shareholder, with respect to all Voting Shares Beneficially owned by such Person) at a meeting of
holders of Common Shares to be held not later than six months from the date of this Agreement (the &ldquo;<B>Ratification Meeting</B>&rdquo;),
then this Agreement and any then outstanding Rights shall, without further formality, terminate and be void and of no further force
or effect as at the earlier of six months from the date of this Agreement and the termination of the meeting of holders of Common
Shares at which this Agreement is not confirmed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 36pt">(c)</TD><TD STYLE="text-align: justify">This Agreement must be reconfirmed by a resolution passed by a majority of the votes cast by all
holders of Voting Shares who vote in respect of such reconfirmation (other than any holder who does not qualify as an Independent
Shareholder, with respect to all Voting Shares Beneficially owned by such Person) at the Corporation&rsquo;s annual and special
meeting of shareholders in 2020 and 2023. If this Agreement is not so reconfirmed or is not presented for reconfirmation at such
annual meeting, this Agreement and all outstanding Rights shall terminate and be void and of no further force and effect on and
from the date of termination of the annual meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 36pt">(d)</TD><TD STYLE="text-align: justify">Notwithstanding anything in Sections 5.15(a), (b) or (c) to the contrary, termination of this Agreement
and all outstanding Rights pursuant to Sections 5.15(a), (b) or (c) shall not occur if a Flip-in Event has occurred (other than
a Flip-in Event which has been waived pursuant to Section 5.1(a), 5.1(b) or 5.1(e) hereof), prior to the date upon which this Agreement
would otherwise terminate pursuant to Sections 5.15(a), (b) or (c), as the case may be.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_046"></A>5.16</B></TD><TD STYLE="text-align: justify"><B>Determinations and Actions by the Board of Directors</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">All actions,
calculations and determinations (including any omissions with respect to the foregoing) which are done or made by the Board of
Directors for the purposes of this Agreement, in good faith, shall not subject the Board or any director of the Corporation to
any liability to the holders of the Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_047"></A>5.17</B></TD><TD STYLE="text-align: justify"><B>Fiduciary Duties of the Directors</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Nothing contained
herein shall be construed to suggest or imply that the Board of Directors shall not be entitled to recommend that holders of the
Voting Shares reject or accept any Take-over Bid or take any other action including the commencement, prosecution, defence or settlement
of any litigation and the solicitation of additional or alternative Take-over Bids or other proposals to shareholders that the
directors believe are necessary or appropriate in the exercise of their fiduciary duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_048"></A>5.18</B></TD><TD STYLE="text-align: justify"><B>Time of the Essence</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Time shall be of the essence in
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_049"></A>5.19</B></TD><TD STYLE="text-align: justify"><B>Force Majeure</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">No party shall
be liable to the other, or held in breach of this Agreement, if prevented, hindered, or delayed in the performance or observance
of any provision contained herein by reason of act of God, riots, terrorism, acts of war, epidemics, earthquakes, or any other
similar causes beyond the reasonable control of the affected party (including, but not limited to, mechanical, electronic or communication
interruptions, disruptions or failures beyond the reasonable control of the affected party). Performance times under this Agreement
shall be extended for a period of time equivalent to the time lost because of any delay that is excusable under this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"><B><A NAME="FPI_050"></A>5.20</B></TD><TD STYLE="text-align: justify"><B>Execution in Counterparts</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">This Agreement
may be executed in any number of counterparts and may be executed and delivered by facsimile and each of such counterparts and
facsimiles shall for all purposes be deemed to be an original, and all such counterparts and facsimiles shall together constitute
one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><B>IN WITNESS
WHEREOF</B>, the parties hereto have caused this Agreement to be duly executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><B>FENNEC PHARMACEUTICALS INC.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: left">By:</TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify"><B>COMPUTERSHARE TRUST COMPANY OF CANADA</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: left">By:</TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: left">By:</TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ATTACHMENT 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FENNEC PHARMACEUTICALS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SHAREHOLDER RIGHTS PLAN AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Form of Rights Certificate]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-decoration: underline; text-align: left"><U STYLE="text-decoration: none">Certificate No. ___________</U></TD>
    <TD STYLE="width: 50%; text-align: right">Rights</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: -0.5pt"><B>THE RIGHTS
ARE SUBJECT TO TERMINATION ON THE TERMS SET FORTH IN THE SHAREHOLDER RIGHTS PLAN AGREEMENT. UNDER CERTAIN CIRCUMSTANCES (SPECIFIED
IN SECTION 3.1(b) OF THE SHAREHOLDER RIGHTS PLAN AGREEMENT), RIGHTS BENEFICIALLY OWNED BY AN ACQUIRING PERSON OR CERTAIN RELATED
PARTIES, OR TRANSFEREES OF AN ACQUIRING PERSON OR CERTAIN RELATED PARTIES, MAY BECOME VOID.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rights Certificate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">This certifies
that <FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT>, or registered assigns, is the registered holder of
the number of Rights set forth above, each of which entitles the registered holder thereof, subject to the terms, provisions and
conditions of the Shareholder Rights Plan Agreement, dated as of June 27, 2017, as the same may be amended or supplemented from
time to time (the &ldquo;<B>Shareholder Rights Plan Agreement</B>&rdquo;), between Fennec Pharmaceuticals Inc., a corporation duly
existing under the laws of British Columbia (the &ldquo;<B>Corporation</B>&rdquo;) and Computershare Trust Company of Canada, a
company incorporated under the laws of Canada (the &ldquo;<B>Rights Agent</B>&rdquo;) (which term shall include any successor Rights
Agent under the Shareholder Rights Plan Agreement), to purchase from the Corporation at any time after the Separation Time (as
such term is defined in the Shareholder Rights Plan Agreement) and prior to the Expiration Time (as such term is defined in the
Shareholder Rights Plan Agreement), one fully paid common share of the Corporation (a &ldquo;<B>Common Share</B>&rdquo;) at the
Exercise Price referred to below, upon presentation and surrender of this Rights Certificate with the Form of Election to Exercise
(in the form provided hereinafter) duly executed and submitted to the Rights Agent at its principal office in any of the city of
Toronto or any other city as may be designated by the Corporation from time to time. The Exercise Price shall initially be $<FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;
</FONT>(Cdn.) per Right and shall be subject to adjustment as provided in the Shareholder Rights Plan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">This Rights
Certificate is subject to all of the terms and provisions of the Shareholder Rights Plan Agreement, which terms and provisions
are incorporated herein by reference and made a part hereof and to which Shareholder Rights Plan Agreement reference is hereby
made for a full description of the rights, limitations of rights, obligations, duties and immunities thereunder of the Rights Agent,
the Corporation and the holders of the Rights Certificates. Copies of the Shareholder Rights Plan Agreement are on file at the
registered office of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">This Rights
Certificate, with or without other Rights Certificates, upon surrender at any of the offices of the Rights Agent designated for
such purpose, may be exchanged for another</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Rights Certificate or Rights Certificates
of like tenor evidencing an aggregate number of Rights equal to the aggregate number of Rights evidenced by the Rights Certificate
or Rights Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">If this Rights
Certificate shall be exercised in part, the registered holder shall be entitled to receive, upon surrender hereof, another Rights
Certificate or Rights Certificates for the number of whole Rights not exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">No holder of
this Rights Certificate, as such, shall be entitled to vote or receive dividends or be deemed for any purpose the holder of Common
Shares or of any other securities which may at any time be issuable upon the exercise hereof, nor shall anything contained in the
Shareholder Rights Plan Agreement or herein be construed to confer upon the holder hereof, as such, any of the Rights of a shareholder
of the Corporation or any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting
thereof, or to give or withhold consent to any corporate action, or to receive notice of meetings or other actions affecting shareholders
(except as provided in the Shareholder Rights Plan Agreement), or to receive dividends or subscription rights, or otherwise, until
the Rights evidenced by this Rights Certificate shall have been exercised as provided in the Shareholder Rights Plan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">This Rights
Certificate shall not be valid or obligatory for any purpose until it shall have been countersigned by the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">WITNESS the facsimile signature of
the proper officers of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: left"><B>FENNEC PHARMACEUTICALS INC.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: left">By:</TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: left"><B>COMPUTERSHARE TRUST COMPANY OF CANADA</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: left">By:</TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: left; text-indent: -5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APPENDIX A TO RIGHTS CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM OF ASSIGNMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(To be executed by the registered holder
if such holder desires to transfer the Rights Certificate.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 9%; text-align: left">FOR VALUE RECEIVED</TD>
    <TD NOWRAP STYLE="width: 91%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 14%; text-align: left">hereby sells, assigns and transfers unto</TD>
    <TD NOWRAP STYLE="width: 86%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(Please print name and address of transferee.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">the Rights represented by this
Rights Certificate, together with all right, title and interest therein, and does hereby irrevocably constitute and appoint _____________________________________________,
as attorney, to transfer the within Rights on the books of Fennec Pharmaceuticals Inc., with full power of substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: left">Dated:</TD>
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Signature <FONT STYLE="font-size: 10pt">(Signature must correspond to name as written upon the face of this Rights Certificate in every particular, without alteration or enlargement or any change whatsoever.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Signature Guaranteed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The signature on this election must correspond
with the name as written upon the face of the certificate(s), in every particular, without alteration or enlargement, or any change
whatsoever and must be guaranteed by a major Canadian Schedule 1 chartered bank or a member of an acceptable Medallion Signature
Guarantee Program (STAMP, SEMP, MSP). The Guarantor must affix a stamp bearing the actual words &ldquo;Signature Guaranteed&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the USA, signature guarantees must be
done by members of a &ldquo;Medallion Signature Guarantee Program&rdquo; only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature guarantees are not accepted from
Canadian Imperial Bank of Commerce (CIBC), or any Treasury Branches, Credit Union or Caisses Populares, unless they are members
of the Stamp Medallion Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(To be completed if true.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The undersigned
party transferring Rights hereunder, hereby represents, for the benefit of all holders of Rights and Voting Shares, that the Rights
evidenced by this Rights Certificate are not, and, to the knowledge of the undersigned, have never been, beneficially owned by
an Acquiring Person or an Affiliate or Associate thereof or a Person acting jointly or in concert with an Acquiring Person or an
Affiliate or Associate thereof. Capitalized terms shall have the meaning ascribed thereto in the Shareholder Rights Plan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Signature <FONT STYLE="font-size: 10pt">(Signature must correspond to name as written upon the face of this Rights Certificate in every particular, without alteration or enlargement or any change whatsoever.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">(please print name of signatory)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left">Signature Guaranteed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(To be attached to each Rights
Certificate.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left; text-indent: -0.5pt"><B>NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In the event the certification
set forth above is not completed, Fennec Pharmaceuticals Inc. will deem the Beneficial owner of the Rights evidenced by this Rights
Certificate to be an Acquiring Person or an Affiliate or Associate thereof. No Rights Certificates shall be issued in exchange
for a Rights Certificate owned or deemed to have been owned by an Acquiring Person or an Affiliate or Associate thereof, or by
a Person acting jointly or in concert with an Acquiring Person or an Affiliate or Associate thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The signature on this certificate
must correspond with the name as written upon the face of the certificate(s), in every particular, without alteration or enlargement,
or any change whatsoever and must be guaranteed by a major Canadian Schedule 1 chartered bank or a member of an acceptable Medallion
Signature Guarantee Program (STAMP, SEMP, MSP). The Guarantor must affix a stamp bearing the actual words &ldquo;Signature Guaranteed&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left">In the USA, signature guarantees must
be done by members of a &ldquo;Medallion Signature Guarantee Program&rdquo; only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Signature guarantees are not accepted
from Canadian Imperial Bank of Commerce (CIBC), or any Treasury Branches, Credit Union or Caisses Populares,<I> </I>unless they
are members of the Stamp Medallion Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APPENDIX B TO RIGHTS CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM OF ELECTION TO EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(To be exercised by the registered holder
if such holder desires to exercise the Rights Certificate.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left; text-indent: -0.5pt"><B>TO: FENNEC
PHARMACEUTICALS INC. and COMPUTERSHARE TRUST COMPANY OF CANADA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby
irrevocably elects to exercise ____________________ whole Rights represented by the attached Rights Certificate to purchase the
Common Shares or other securities, if applicable, issuable upon the exercise of such Rights and requests that certificates for
such securities be issued in the name of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">(Name)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">(Address)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">(City and Province)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left">Social Insurance Number, Social Security Number or other taxpayer identification number.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If such number of Rights shall not be all
the Rights evidenced by this Rights Certificate, a new Rights Certificate for the balance of such Rights shall be registered in
the name of and delivered to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">(Name)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">(Address)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">(City and Province)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left">Social Insurance Number, Social Security Number or other taxpayer identification number.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify">Dated:</TD>
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Signature <FONT STYLE="font-size: 10pt">(Signature must correspond to name as written upon the face of this Rights Certificate in every particular, without alteration or enlargement or any change whatsoever.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left">Signature Guaranteed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The signature on this election
must correspond with the name as written upon the face of the certificate(s), in every particular, without alteration or enlargement,
or any change whatsoever and must be guaranteed by a major Canadian Schedule 1 chartered bank or a member of an acceptable Medallion
Signature Guarantee Program (STAMP, SEMP, MSP). The Guarantor must affix a stamp bearing the actual words &ldquo;Signature Guaranteed&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In the USA, signature guarantees
must be done by members of a &ldquo;Medallion Signature Guarantee Program&rdquo; only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Signature guarantees are not accepted
from the Canadian Imperial Bank of Commerce (CIBC), or any Treasury Branches, Credit Union or Caisses Populares, unless they are
members of the Stamp Medallion Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(To be completed if true.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The undersigned party exercising
Rights hereunder, hereby represents, for the benefit of all holders of Rights and Voting Shares, that the Rights evidenced by this
Rights Certificate are not, and, to the knowledge of the undersigned, have never been, Beneficially owned by an Acquiring Person
or an Affiliate or Associate thereof or a Person acting jointly or in concert with an Acquiring Person or an Affiliate or Associate
thereof. Capitalized terms shall have the meaning ascribed thereto in the Shareholder Rights Plan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Signature <FONT STYLE="font-size: 10pt">(Signature must correspond to name as written upon the face of this Rights Certificate in every particular, without alteration or enlargement or any change&nbsp;&nbsp;whatsoever.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">(please print name of signatory) </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left">Signature Guaranteed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(To be attached to each Rights
Certificate.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left; text-indent: -0.5pt"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left; text-indent: -0.5pt"><B>NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In the event the certification
set forth above is not completed, Fennec Pharmaceuticals Inc. will deem the Beneficial owner of the Rights evidenced by this Rights
Certificate to be an Acquiring Person or an Affiliate or Associate thereof. No Rights Certificates shall be issued in exchange
for a Rights Certificate owned or deemed to have been owned by an Acquiring Person or an Affiliate or Associate thereof, or by
a Person acting jointly or in concert with an Acquiring Person or an Affiliate or Associate thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The signature on this certificate
must correspond with the name as written upon the face of the certificate(s), in every particular, without alteration or enlargement,
or any change whatsoever and must be guaranteed by a major Canadian Schedule 1 chartered bank or a member of an acceptable Medallion
Signature Guarantee Program (STAMP, SEMP, MSP). The Guarantor must affix a stamp bearing the actual words &ldquo;Signature Guaranteed&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In the USA, signature guarantees
must be done by members of a &ldquo;Medallion Signature Guarantee Program&rdquo; only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Signature guarantees are not accepted
from Canadian Imperial Bank of Commerce (CIBC), or any Treasury Branches, Credit Union or Caisses Populares, unless they are members
of the Stamp Medallion Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE &ldquo;C&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FENNEC PHARMACEUTICALS INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Change of Auditor Reporting Package</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation&rsquo;s auditors, Deloitte
LLP, resigned at their own initiative as of May 15, 2017. The Audit Committee of the Board of Directors conducted a competitive
selection process and approved the appointment of Haskell &amp; White LLP as the Corporation&rsquo;s successor auditors on May
15, 2017. For purposes of complying with National Instrument 51-102 Continuous Disclosure Obligations of the Canadian Securities
Administrators, and for complying with the requirements of Schedule 14A, a copy of the Corporation&rsquo;s disclosure in regard
to the change of auditor in the U.S. is attached as Schedule &ldquo;C&rdquo; and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders will be asked to vote for
the appointment of Haskell &amp; White LLP as auditors of the Corporation, to hold office until the next annual meeting of Shareholders
of the Corporation or until a successor is duly elected or appointed, at a remuneration to be fixed by the Board of Directors.
Approval of the ordinary resolution requires the affirmative vote of a majority of the votes cast in respect thereof by holders
of Common Shares represented at the Meeting. The person designated in the enclosed form of proxy intends to vote FOR the appointment
of Haskell &amp; White LLP<B> </B>as auditors of the Corporation, unless instructed otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Board unanimously recommends that
Shareholders vote FOR the appointment of Haskell &amp; White LLP as auditors of the Corporation at the Meeting. The persons named
in the enclosed form of proxy will vote FOR the appointment of Haskell &amp; White LLP as auditors of the Corporation until the
end of the next annual meeting of the Shareholders and the authorization of the directors to fix their remuneration, unless a
Shareholder has specified in the proxy that his or her Common Shares are to be withheld from voting in respect thereof.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Current Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Date of Report
(Date of earliest event reported): May 17, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Fennec Pharmaceuticals Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>001-32295</B><BR>
(Commission File Number)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 48%; text-align: center"><FONT STYLE="font-size: 10pt"><B>British Columbia</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 48%; text-align: center"><FONT STYLE="font-size: 10pt"><B>20-0442384</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of</FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation) </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification<BR>
No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 48%; text-align: center"><FONT STYLE="font-size: 10pt"><B>PO Box 13628, 68 TW<BR>
Alexander Drive,</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Research Triangle Park, NC</B></FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center"><FONT STYLE="font-size: 10pt"><B>27709</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code:</B> (<B>919) 636-4530</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: left">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: left">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: left">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 4.01</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Changes in Registrant&rsquo;s Certifying Accountant</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) The Audit Committee (the &ldquo;Committee&rdquo;)
of the Board of Directors of Fennec Pharmaceuticals Inc. (the &ldquo;Company&rdquo;) recently conducted a competitive selection
process to determine the Company&rsquo;s independent registered public accounting firm for the fiscal year ending December 31,
2017. This search began after Deloitte LLP (&ldquo;Deloitte&rdquo;) advised the Company it would resign as of May 15, 2017. The
Committee invited several independent public accounting firms to participate in this process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reports of Deloitte on the Company&rsquo;s
consolidated financial statements for the fiscal years ended December 31, 2016 and 2015 did not contain an adverse opinion or disclaimer
of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. In connection with the audits
of the Company's consolidated financial statements for the fiscal years ended December 31, 2016 and 2015, and in the subsequent
interim period through May 15, 2017, there were no disagreements with Deloitte on any matters of accounting principles or practices,
financial statement disclosure or auditing scope and procedures which, if not resolved to the satisfaction of Deloitte, would have
caused Deloitte to make reference to the matter in their report. There were no reportable events (as that term is described in
Item 304(a)(1)(v) of Regulation S-K of the Securities Act of 1933, as amended) during the two fiscal years ended December 31, 2016
and 2015, or in the subsequent period through May 15, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has provided a copy of the
foregoing disclosures to Deloitte and requested that Deloitte furnish it with a letter addressed to the Securities and Exchange
Commission stating whether Deloitte agrees with the above statements. A copy of Deloitte&rsquo;s letter, dated May 17, 2017, is
filed as Exhibit 16.1 to this Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) The Committee approved the appointment
of Haskell &amp; White LLP as the Company&rsquo;s independent registered public accounting firm on May 15, 2017, for the fiscal
year ending December 31, 2017. During the two most recent fiscal years and in the subsequent interim period through May 15, 2017,
the Company has not consulted with Haskell &amp; White LLP with respect to the application of accounting principles to a specified
transaction, either completed or proposed, or the type of audit opinion that would have been rendered on the Company&rsquo;s consolidated
financial statements, or any other matters set forth in Item 304(a)(2)(i) or (ii) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 12%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
    <TD NOWRAP STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 86%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exhibit 16.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Letter from Deloitte LLP to the Securities and Exchange Commission dated May 17, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Dated:&nbsp;May 17, 2017</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Fennec Pharmaceuticals Inc.</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Rostislav Raykov</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rostislav Raykov</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: justify">May 17, 2017</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Securities and Exchange Commission</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Washington, D.C. 20549-7561</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dear Sirs/Madams:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We have read Item 4.01 of Fennec Pharmaceuticals
Inc.'s Form 8-K dated May 17, 2017, and have the following comments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: windowtext">1.</FONT></TD><TD STYLE="text-align: left">We agree with the statements made in section (a) of Item 4.01.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: windowtext">2.</FONT></TD><TD STYLE="text-align: left">We have no basis on which to agree or disagree with the statements made in section (b) of Item 4.01.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yours truly,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ Deloitte LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chartered Professional Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensed Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="proxy01_def14a.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 107 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="proxy02_def14a.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 108; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>pg28img1_def14a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg28img1_def14a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!@@*+ P$1  (1 0,1 ?_$ .H  0 " @,! 0$
M       &!P4( P0) @$* 0$  04! 0$             !0,$!@<( @$)$
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MX \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X
M\Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q
M0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0G
MH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:
M*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^
MSVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SV
MGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGY
MG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG
M'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F
M*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$
M]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#
M17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17
MV>T_,X \Q0GH:*^SVGYG 'F*$]#17V>T_,X \Q0GH:*^SVGYG 'F*$]#17V>
MT_,X \Q0GH:*^SVGYG (!YIBO/78\V1_8]O^X['@VW9[CV!\1W/9[OIW7?\
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M!Y^U\<-&;$)"'TY";=:;9>U.\(P,5--FE/G)"/J4/VHD5&I3!%G15323,),
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M,8H@)A$0+1$ $! 0 0$.@@/E 0'Z0$/N@. 4GKOC7QZU'/VJU:NTEJS7UDO
M+%MTY3Z+7*_*6!)RN9TY;23R,CVZR[-PZ,*JB CW)U?KF*)O+@'-JWCGH+1\
MC9)?3FF-8ZOE+@N"]GD:'2J_5WDX<%CN"DD7,.P:*KMDW"ACD1$>Z(<PF H"
M(C@$DD=2:NF)RX665U[39*P;!IZ&OKU-/J[%NI*WT5KYR!O4+([7;'6F*XB$
MPZ[+-<3H!XA3ZOUAZ@=6*TOJ*"4UJM"ZSHT2KIJ)E(+4RD=68AF;7$--QC>%
MF(NEB@U3&NL96):)-W";7NRK(D I@$ P"#I<2>+J&SAW2CQYTREMD7XRW\1$
M]<50EM"7$_>&F0F2Q8/"S1E/K"\ WB1-Y>WU\N 6FVUU0F=BN5M:TRLH6?8D
M?#1-]GTX2/"6N4776;V.@HZS/?#]_-,8AA(N$6Z3@5"))+'*4 *80$"(I\?-
M%(ZM<Z/0T_K9OIQZ8YG>KF]-@$*$Y,K,$L"AEJLBQ)#*&/.)E=B(H]1<%!3[
MX ' )9,:YH-AL=)M\[3*S+VG6JDPKKZPR,,P=S%*4L$:6&G#UB060.YA32T2
M0K9P+<Q.]1 "&Z@'3 /JNZ[H=1L%TM=6IU;KUFV-)1\Q?I^'AV,?+W*5B8Y.
M(BY&ROVJ*;F9>1\6D5NBHN8YDT0[)1 /)@$/?<>=$R=2N5"D=/ZX?4K8EM=7
MZ]U5U3X->!M]W?2#&6>6VPQBC(S25L;B4BVS@SQ8IEQ60(?M=HH" $9FN(O%
MFQWW^*<_QUTM-;*&<C[,-]E-:U)];AL42=HK&3@V!S%*28RS!5@B9)QWG>D,
MD00, E# +70UY1&U\?[2;T^MH;(E*RTIDC>DH=B2UOJDPD%99E6W4Z5$)%>$
M:2:QW";8R@I%5,)@#KY< K&Q<4^,MOV2SW%:M :>L6U&"[1TUV#,Z\JTC;"/
M& %+'OCS3J,5>KOX\I"@W74,99 "E[!B]D.@%BFUAK@]QG=AGHM34O5GJC:B
M6.W*0,:>PSM+9N7+QK5)>5,W%Y(5]!T\54*T5.9 #J&'L^4< P-)T/I;6SJM
M/M?ZJH-,>TVH/]?U)U6JM#P[BMT>4G"V61J,(LR:HJ1M=>V @/5&B0E0.Y %
M!+VO+@&>H^K];ZS]I UU0J?10N%A>6VUA4:[$UXMCM$B5,K^P318IHU"2F'A
M4B@HX5[2I^GE' *^FN*_&FQ[.8[IL&@]036VHURU?,MC2>O:L]N"$@Q[(L)(
M)UQ&*/SRC 4R]PY,<5T.P7L'+V2] /BU\4^,MZV(QVY=- :?M6SXY1FNTOL_
MKRK2MI3<1P%".<J3#R,6>.'4<4A0;JJ&.H@!2@02]D.@%@2&JM:2UDL5PE*#
M49&U6ZE!K>TV%[7XQU+V+7X+O77L7-/UFQW$E6/$23@XLEC';B98X]GZPX!B
MHC1VFZ^EK%"#U=0XA'2S>3::C2C:O#LT]:MIJ,-#3"-)(W:)EKB<I$G%NX!K
MW??)")3=0' .@TX]:)8Q&OX!GI[6S:$U1:'%VUE%(TV!(PH%O=O)"0=6:H-@
M8]U7YQP_EG*QW+8$U3*K'.)NT/7 ,R&G-3 WV*S-K2BJ,]NR!I7:;-:K0R[/
M8LD>,:0QWUU:K,U&]D<FB6"#83NRJB**1"_04 P",ZQXT<>=*P]C@-2:1U;K
MB&N":J-KCJ=2*] M[*W515;':3I8]@B:69@W743*BN)TB$4,4I0 P@($.KO"
M7A[491A-U7B_H:N3$7+PL]'R<)JRFQCYG-5QX$C 2B#IG$(K)OH9^ +ME 'M
M(J@!RB!@ < NR6UQ09ZZ5+8TU3*U*7ZAM9UC2[F^AF#FS59E9VJ;*Q,X*:50
M-(1K6;:)%3=)I*%(L4H 8!P#$LM-:FCJY?J@PUO26=6VK*VB=V776U;BD8:^
M35V;%9V^5MD<FU*UG7]F:D!-\JY*H=R0  XB& 8^VZ%TG?:%7-6W;4^O;9K:
MH'@#U6B6&IPLM5*Z>JLQCJV:&@GK-:.CA@X\PH->Z3+W*(B0O0HB& ?.T]!:
M/WBVA&6Y=1:XVFTK:CQ6OMK_ $Z!MB$(I(IMDGYXM*;8O",1>)LD2J]V!>V"
M1.O7LAT F%&H=)UC5(>BZYJ5=HM+KZ*[>"JE3AV$!7H=!R[</W*4;$1B#9BS
M37?.U5C@F0H&54,8?*81P#'535FM*+4WU"IM!J%8I$FYGWDE482O1<?6Y!U:
MW;I_9EWT*W:DCW9[ \?+*/.\3-X@ZIA/VNT. 0+5?%GC7HZ<EK-IS0VI-86*
M=(HC+3M&H-:K<N];JJ=\JT/(Q<<V=D8JK !S($.5$Q@ 1+U .@$X5U-K!>P7
M>V*T"H*6?9=<8T_8-A- 1HS-TJL8U>LHZO6:1\/XJ9AV+.2<))-US'3(18Y0
M  $< Q\EI#3DQJYKI&5U?0Y#3S*+AX1GK%W5H=:C-(FON&CN#CFU9.T&)0:1
M#I@BJW(5( 142*8O00 < B;GBIQF>['0W [T!IYUM9M-LK,WV.OKRK*W9&Q1
MI&Z;"=2LQXP9<DLS(U3!-P"O>D[LO0WD# +,4UW0UKVGM!6G5M78R545HJ=Y
M4AF![42F+R83*U6+-F0&0"!5E@!R9KWG<BM]<2]?+@%-R_#+B38*[6:E/<:=
M'357I9IXU1KTKK*H2$/6?:F5-.V,(*/=Q*K:*)-S1A=.2HE(59P/;, F\N 6
M&&CM-EKVNJD75M!)5]134+9-65Y.JPR<+KN?KB3E& F:9&D9E:5V2ADGBI6R
MS4B1T04,!1#J. =#;O'K16_F47';NU!KG:[.#<*.H5*_5"#LXQ"ZX$!P>,6E
M6;E9@#H$R@J5(Q2J@4O; >@= ,HKI74"T3KV!/K"A>8]2S<99=7PQ*I")16O
M;!#(N6\3-4V/29$:5R2CD'JQ45FA$CI@J;H(=H< QTAQ^T;+3%CL$GJ+73^<
MN%KI-ZM4JZJ,(L_L5TUL)1H%KF7)V8JR-AIHD 8UVJ)EV@@'=F+@$E5U?K=;
M83;;2M"IZFT6=?5JC38AZ[$FNK>LKKBY5@$;,+7SPG$*.#"<6X+=UVA'R>4>
MH$ZP!@# & , 8 P!@# & , 8 P"N_P!>?S$_IW@&7HG[GU[]G)?A&P"6X P!
M@# & , 8 P!@# & , 8 P!@# //#8'+J3JO,BH:K;V:AH:G8S=-TYL.#>KL/
MX@K[AW'7IFV:_E(0AI5-Z6N5Y&-@HQXF#10'#FXHG[909G 0,PWYL6.8LD56
MZKQNOLZK<;-NJEZXD5KGKN'C[58]"6B6KUY-)&>39G-5KRZ,,NM&O'"2BKI4
M@HG;H@*:J@'Y)<\Z\>JCL"G:IO%RH=8TMKG?NW9Q"2JT,_UKK_9D5*6"'33@
MY*5*YN-IB:Y!/I&18L3@F@T0)W:ZRRR2)@):TY@-G&R#U%?5-O:4I/=<WQ_#
M9HR]9=1[K8T92%[\P(PJS.07L[FNRL2U4; ]%$ATI 2)=R=,QEB =CC7RU1Y
M(6*:C(K7R]<@F.M]>;2B[&-WJ=I![ [1=64E4B)F-K2[Q2KW%-C57+B1C'"I
MU&('1*)E.] V :ZZZY>V"O5O=^YMP7VW3M:H-YVS3F.N&&CEJ=46RL/R'>Z=
MURV@MU2[1E6;-*R'1@@[ \H*:"KMPLL5,C4_8 M6$YR!;0K<'2=/3=SO]DOU
MUURV@X"\4U6G>=Z9KN(V>O-,]CNW+2(EJF\K<TBB+ENW.Z;RA5&BC4#IF-@'
M2D>?D.6OL;E7M-; L-.9:1UUR!O\V66IT6M1*%>[-=JL[9JQ;Z:!Y8[=67E"
MD%E63'MH.6Z!Q2<B<4DU@,LXY^ZL9[4LE =1KLL!5;?>]?S5M;S,.]DX^T:W
MJ,U<+:\?T!HJK9V5%8MZZ\8$FCE[!Y1,J?<E052<F V'TCM"T[:JR%OGM5SF
MLHB<C8*Q4T)VQ5B<>3]9LD=YTCG3YI7GSM6NS;5J=/QK%?MD0.J4J:Z_13L
M>3E;YF\CY[0=XV-'74;NHWT'<=@6.6AM0A5D-.[2A=CU2"I^O:[8Y4H5"^*7
M6N24QU;+ NX9'B2.%7)$G) P#?A[R\=1,!LD]AU@C3KQK"^5FEV&K7C;6M:I
M7R-[I4V]TJT\384E*A N"2,2Z*W,Q;)NI DB4Z1$E4"^*$# P'.B*N3&#G*7
MJ2Z3E6<<=HSDI;+(XFJG&,J;39,=CLD(59 \HZ<V"T*3>N'"":; JK15%3Q
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M_5L;MZ)"J&2U]<=-FB;BRO#^BM)22E5H>9>L6+$8EH .7AP<G20*#D ,V7G
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MJ7LF&N%>BY& CKCKW8LMK2V&K,PY:O)6JR%@H=XK\E*UI^\8I+F9.5%44UR
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MJH"4NHJ)"!Y1[)3&Z?0 X!(< 8 P!@%=_KS^8G].\ R]$_<^O?LY+\(V 2W
M*VM>F]2WNQP=PNVLZ);;56?#A 6*QU6$F9B)*T=C(,B,9"09.'*)&,B87*!0
M-T0<#WJ8%4^M@'.CJ35K>_K[60UU24=FN6HLG%_2K$,G<%VPM"1YB*V$K,)1
M0QXY(C8QA5$YFQ"I"/=E H *-J35NLG$Z[USKJDT5U:'97UB<U*L0U?7FW)%
M'"R:DDK%LVIW8(KO%CD*<1(0ZRAB@!E#B8"PL 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%=_KS
M^8G].\ R]$_<^O?LY+\(V 2W & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M &"4!R.R-GW?$6N5BY%:7EE7.*]]K0HSQ\BOX\)KUIEN (& #%$#%, "4P"
M@("'4! 0\@@(9&E$_< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@%=_KS^8G].\ R]$_<^O?LY+\(V 2W & , 8 P!@# & , 8 P!@#
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MC_JKN;AZ%:AWN%9])7*#\\'JOU9:_M'R/*/95!^IO[BWM.G,D@_U%YU$HTY
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M@)J)J"DH*2H$.4PIJ@4IQ34 HCV% (<!Z#T'H(#]W .3 & , 8 P!@# & ,
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M@P#E0<V@RR17,1"I-Q4*"RB4X\6532$0[9TTC0:15#E+]!1,4!'[H8!(< 8
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MYK[JOQLY [3T\BEY6U#M+XV[]1%('U@:(5+8KMW98!J8P=.S#SL<4A?O2AT
M,F_O'3F<-\P\?)?EL@NXN]?/6E&3_3KD77UR-G\37"?I7LR]]<'[J8#;O++5
MXBGMWCW&;;KZ'_5OW&&?!]+ B'D*N_TSL1U#6-)40#M'3BIB:. ^0A3>3J^S
M>G<_CMN;+&N?]7E1T7N75J4?=G"'I'<XEOT-CA+S37_*7#WTBQM<\M./VSY8
M*O!;"CX6]%$I'.M[^SD]<;':KCY#-U*1>6<#87!DS>03MT%DA'[TXAY<LLWI
MW>,"OO[J92Q/\96U96_Y];E'WVGZ"E;AY%2YI1UK^<O:C[ZU1L=D(6PP!@#
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M:H\1.M\=?-NZ2Q)M>C6GJ*2;]/!'*E<_FI2O1-#0O"JJ";R>)GN0.V["1/J
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MDY-M(M\7!PL&+AA4U4P;U:A",$WYVHI:DLRR+H8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P"N_P!>?S$_IW@&7HG[GU[]G)?A&P"6X P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"F=T;YU[HJ%CI&Y/)!
M].6-]YFHU JT>K8MA[$L)R@9&OTBILA&0FGYNH"JIT3:-$Q[URLBD G"3VO:
M,S=K90QDE5!<UEDWRUUQ^=.;X17F\K[(IO@5J,>S(DU#3E2U;?!)>=OR?R^0
MUXBM$;$Y)2+"\<O6K.,HS1XG*4GB7$2*<M3(HR1@4CYO><TV[#7:MS0'LG+%
ME#V;BU ^HF\5#Q 35F[86QP>)TVW++:TGEM:3?GC1%\:H?G?2R7:XK@7+R*\
M5.O#XV>6SL?JBODKT_&?H[#=V)B8N!C(^$@XUA#PT2R;1T5$Q;1!A&QL>S1(
MW:,6#%JFDV:,VJ"92)IIE*0A     #,5LLLNLE;;)RMDVVV]6V^UMOBV_*RQ
M;<GS2>LF<$% 058BVT'6X:+K\*S,Y,SB(5@UC(QH+QTN^=>%8LDD6K<'#QRH
MJ<"% #*',8?*(Y]NNMR+';?*4[7IJY-MO1:+5OCV)(2E*3YI-N7I,OE,^# &
M , JC>FX*KH#3VQ]T7510M:UO4Y:SOVZ E![*K,D!",@(LINH+3-CE5$&#)+
MZ57;E,@>4V16^;OB[!M&3O.;_#8U4IM+MEHO9A'\Z<M(Q7EDTC/O"WPZW[Q;
M\1=F\->F4GO6];A5C0E+XE2G+][?:UV4X]2G?=+Y%5<Y/@BF.$>GK3JC23>6
MV>1,V]-V66<WOOIT4#=2;.V0="2>UE$3'5$L7KJ 2CZTQ(4PIE9Q"?9  '(;
MHK:,K:ME5NY_^_,VR65E/_+7:-P7YM,>6F*[.6M:&ROQ.^(NQ=?>)T]OZ';7
MA9TQA4;'L47Y=LVY2KADRT2_>[A>[]RO;7,[LN?-KH;?9EQSN, 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , KO]
M>?S$_IW@&7HG[GU[]G)?A&P"6X P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!7?Z\_F)_3O
M,O1/W/KW[.2_"-@$MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , AFP-B4;553EKUL:U0M-J,&CWTG.SSU-DR0[0]E%!,3B*KM\[4Z
M)H-T2J.'"I@(F0YS 4;K#PLO<,B.)A5RMR9OA&*U?_F2\K?!+BWH>ZZ[+IJN
MI.4WY$:<]_O/F '9:>V7&GC(\(':?*$5KO(G=D8H;KT8)'#QFC:#*(_^L</:
MA\@/U"QQ3]H<ETVGIOXW=9V^KR?&QJ'Z?)?8O-]%%_/T+W]QA]O+;E>_"/\
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M]D$EO-F;G+8P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MV\=FVEY&2I::0R\G >J;1Z+         '0 #R  !]  'W #-AG'#;;U?:?N
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M*A$RZ2R2BMJDW*::A#J-U&$"1-<A1 3)'.C%)K%*</((E,4P?<$, D. , 8
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MT9=]3UKW#J/*<)[[G*22=E==\(;;B.7-RXN#!PEI8]=_\STY)& , 8 P!@#
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M+8<GJ)3;3F&CD=5)[4AJ\[LDG15)M2;">2D&;1@NW.]-&!#^<4#L@>"Z#NL
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M<?!M/2'7&)8_\GMFZ6?L8[)-6_FF[+MHC[/?+7YORZ8G J+MK0DF,<L AY%
MD;(6OM")&_PF$W9,'EZY7JZ;ZBUTSEMF*O\ *;CC2?ZM+M?P$;G6>'>.O_9V
M]YN<_P#);/GP7ZV1&F/OM(NZ.Y><K+!'+/(3Y:>^6ZA4P.BVN6W./%0,OVA
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M8LW[F930D_YQV6?/?B>=PFRGMJI:\D%![)F&V:G>-3.$5.O3NU3;%K5:;%,
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M ,EL_P"PU+_2V/\ W:/FG@QB=OWFSI+TX6)%^\LJ23]\_1X\<MIGLFL/-M[
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M 0^G )#@# & , KO]>?S$_IW@&7HG[GU[]G)?A&P"6X P!@# & , 8 P!@#
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M)9T*4FIR<I0BM576VVVE77R5QCV0C%022BD;B9A1DXP!@# & , 8 P!@# &
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M>5"T& , 8 P!@# & , 8 P!@# & , 8 P"N_UY_,3^G> 9>B?N?7OV<E^$;
M);@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , QZT1%.'S>4<1D>O)M"&3:2*S)LJ^:IFZB8C=V=,SA$AA$>H%, #URK&^
MZ-;IC.2IEVQ3>C]:[&4W55*:ME&+L78]%JO4^TR&4BH, 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8!7?Z\_F)_3O ,O1/W/KW[.2_"-@$MP!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%=
M_KS^8G].\ R]$_<^O?LY+\(V 2W & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 5W^O/YB
M?T[P#+T3]SZ]^SDOPC8!+< 8!IO6>69+%M_<] 5J]1AJAHN9L43=+2_VQ$&O
M -ZY0*W>W=B9:C;U]6:4K!T[.BU!V9\4 .FH;LCT I@,KI/DY*;2ME:J]JU7
M):U-LC49=Z:I=NK3&64UEUZ24@(U^C9&C%BP-3[K$DN$,X<1I3R+<$I#H1X<
MZ*Q" ;9X P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M@8AR& O4IBF#J X!(< 8 P!@%=_KS^8G].\ R]$_<^O?LY+\(V 2W & , 8
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MUKV'NEA$MZ7\U36FC:]QD"!HK$D76M:;W@VU9LSAZX8H;.<W&68)A,*KJ./
M*1J@$(T G1S@'L/\P7=^P=%Z9I<KKF;CZ9*;#WYI?3<WLN5BV,O'ZIJ6R[<A
M V#82S*9[->%:&;'!)N>2.1@FZ<I&5[8 "2@'G18^67*&%V:\X^5;D A;&59
M^8%QBT%&\A%Z'KJ6D+/1]SZBM5ZNU#L,9 Q+&A2%EI4TP02.YCDXYVFFHB59
M),P&[T#?WA3M/;5CV/S)TGM6_&VF/'#=E>J%/O\ )UVNUFUS%:NFM:SL%*/M
M+*H,8BL.7< ZG3M47+9BU,N@4#*%[73H!K92]92>O_G&G>6+9]XV=+;!X3;4
MMXN+@\8$94N$=\A*LVA:'1(B*:,FU?J5=8% A ZJN73@QW"ZIU#^0#7_ %I"
M\=XKDK<N17&^ J.NM!\$JAR-1MVQV$Y.2^S>6>XI^!?3>QH&5D9QZK8MD4'6
M,@R4.+Q\^=JNK )$V:A4$.H 0GE)IK2U=X4,8^>O>L(CF=K?C?6=TWXUSLSM
MSL:-I,[>W^X=H/M%F?OVL97-KW#8Z[B-C+:5B[E55.Z0=J'%4I\ V1VY4I%S
M\Q'Y96[Y6^;/E6^W9#<KNK:JO!V$?!:>@FO%Q-XO#Q5<9M2+IW&7D72B\X^=
MKN'"BX @3NT4BE$#$[>L7&QU2^1W*[DQ1&VW47G+8]#XX:E<.I9RRVC=M%0+
MC3VLJ;[,D5<1MA;S6Q6UD? A*IR$$U!=25(W3.JIV@->ZSQ_K&I[]P>TIR.D
M-:6G6$GJOGMM&P4R3F64YQWHFS[.ZI]BB-<T->R*>:!9ZFJ$L_:PZ:AS.&J*
M;IX@"?D.F!#1I%YG^'7R@=TWO:VSY))IR%X=4F$U7+O46]),9;:-O6C]B2Z"
M[()RT61U3T(YG%+N7)FS6-3 Z!#'7,J(&_/)_6DM!?,L^7SLV9VA>+6WNNU-
MR0U7US*NHYOK[6<3"\;9T'PU.&9,D7+F?LLHB=R_DGBZZYR&*@F":1.@@7S\
MQR5-%5CB2(,(-^$CS_XF1"A)V%C9M)NG(7APD=Y&IR:"Y8Z:;@'5L\1[#EN?
MZR9BC@&CNG.3_+$^NN$F_+5OP;E';YYKV3C)<]72.M]?Q=94I,IL3;]7B9II
M/P47'VI*XUI"AH&06(Y(S7(8"+-C"0ZBX'H?SXN^^Z/K*CN./\_7X6>F=I5R
M'M352T:SJFR;#356<HZDX32SS<:3K6CW82[AJBH#:207%6.2= @3O^P8H'EU
MKS<]CWYRY^6Y9OX^;:?)13GFK6;!&WVB:[UU9C6W5AZVTDJ7=*W IV"B35I?
MQ4X$$\F((R1%FA0-'E9.CNA,!,]+<UN1TX/#O;<QMR-O4IRBWUMO5>PN)[6J
M4AF&I*_3FVS3-'$ ZA(S^*;*?HHT9D>:6F5'2+CQX]M!D!DL B)>0NS]U\(-
MM7C9W*:@6R6WUPAY6W2R<7O8ZK1UGU8^J</,Q)%:?)584; R@*6F?S7/(V@K
MEP[D3E.BLW5 S7 -M/EC[NVELA:P:^V\NIKN3U3I'CFUUKHIJG7Y",=Z@L>M
M85[7]XKW-NU-+VFP7"79O(]TU;JHQD$#(K84E7)U%Q J7YBW-7:6D[)O-WI+
M:]G8V/C94-46ZT4:1K^FX#4"*>P9 %(>'LLK>F\OMO;%EN+9JN"3.H>:&S!K
M]11V1V4>] @>Q.5O+:$U9SDY&0N^TV4?Q7Y?0-&IVIG&M:"\JEBHT@KI]K*5
M"WV)2.3MYXY0FPEC-7#-TTD&RB(B==<%" B!6/-+<&R-SZHY.R=ZW?'U2)U9
MSTU-H>L<8Q@:&W+*U:J[8U'+0%RD)&29I;.<VFSF?J3359!PG'#%MA3(V6)V
MG10/3CYB4VM!ON"ZB#*#=J/N>6H&)5)J$C)D[$QJ;LYR1_##)-W Q,T@HV#N
M7:'8<)%$P%, &, @:':.Y;<N&^N/EN[SN.[3;10Y67O8^LK]JU_KJA0<&LVB
MH;:<]6IJNS%5A6-H0N31Q1$6IC=\HR=D7#_1E.4>] I-AO+:&UK7\K#DC?=O
ML=L[!N]GY(;++H*+@:1#IZUL=<T3L4B%+K:=6CQO?=(KL$X=^28&1>*21NV7
MN#CX80+IXI\PN4NZF_A+SO1C3X/:O#BZ[UD=C3*''!-30%VC)B.:Q=GHM5J$
MO:Y=QJ2.3=.&+IO>FB4F1]'G[1P4.=! #;'Y8W*K='+LFTK]N67CZ;(U=I0Z
M=$:#8U]U#JM8XU?2GR<@'*]IKD-<W$7ND\F92'1*<T6VCV0$+VW/?'P#4#E3
MO/:VIN:W)W^$%CK>OK5.7+Y8FM5+DG0ZG.S:E=VK<-A0%A932DJR%Q8&0-2E
M\.BLL0S<.V""B(G,; )KL7EGR@U)LOD/QT?;N:S#.N<F.%FMHCD1::'0XZP:
MCU]RJAK#*VZ3G(Z-CH?6[XM4=023*%>2+1ND19^47(N!*FD8"%<B]DW1K>N)
M5A8<@ZER&NVHKS\Q:+J&U:A5X5@[0F*)Q0L<A!0EIBX=)>GSFP*I)IE0DU8Q
MNE'.UR=/#(F[Q H$[F?F ;>CZ!P'LU.V#6]D6_8?"GD?NS;M(AT:I)R%ZV%K
M7CK#W.K%D(^ 8N9:M%#82+](S>/3:E4736;B0PI"F0#1'DW>[790U5M6Y[[K
M'(:SWCY5W,+:CV*?535XU^C2%NH-$EY*L(0-6:>'D*0H]$S5LTFROG0&CEP4
M=+B8Y$@-KK%R9Y50.G.=6T:9O8E4A.%I^/K[6^M6VL]</:O,P[[1>KK;8Z=:
MY)W"#8C5F<<V)8$P8N63UB8>TFX,3LHE LWE#RRW\VD>=DI6.0L9Q^#BAQ]U
M7?=6THE4UO+$VW/;,UG(6Z3GY=78<;(3<C%M;(D6!BDHA1%-*12$53NE!%J
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M0>:M$_,G?\>8/4<AK?7ZU5G-6/=FZ[HZE;M%B3BFMP%U%L;H91F\:.VCI)1
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M?VIK&)3CLSY)N0JPJ+F%4I  W4 P"SL 8 P!@# & , 8 P!@%=_KS^8G].\
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M=YF%K*6TG\Y5$Z=0HNH.9:5>W.OZPDY5"<<3=U9Q2# (,S<SHJBIGA6Q2K'
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M,0,))ONR=T%3N]'HFWX"(57*4G?DK!-BJQ;<3=3E9LD ,)C )A V3P!@# &
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M!4Z/)SD.9O.%:KF5BVBC>1;.$!*8$RJ' OW & , 8 P!@# & , 8 P!@# &
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M!@# & , 8 P!@# & , 8 P!@# *[_7G\Q/Z=X!EZ)^Y]>_9R7X1L EN , 8
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MTOW4?+_0>];.XIFKK19)NRMH9W.G9S.JMO4EF$<R7:-5UAF;Q0Z[#F4*X?)
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M?1#AR2,<SQE4@3D!'_3"U*9R &\F , 8 P!@# & , 8 P!@# & , 8 P!@#
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M._NI%S>7'9:/:W-U6RL5&ZZ#,SHCEP""C8HE4,4#'O>=K![3V][H6GKE=J[
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & 5W^O/YB?T[P#K4[]UX/\ >'_L$_\ MO\ H??&_P"E_P#4_L_NP"2_
M%& /BC 'Q1@#XHP!\48 ^*, ?%& /BC 'Q1@#XHP!\48 ^*, ?%& /BC 'Q1
M@#XHP!\48 ^*, ?%& /BC 'Q1@#XHP!\48 ^*, ?%& /BC 'Q1@#XHP!\48
M^*, ?%& /BC 'Q1@#XHP!\48 ^*, ?%& /BC 'Q1@#XHP!\48 ^*, ?%& /B
MC 'Q1@#XHP!\48 ^*, ?%& /BC 'Q1@#XHP!\48 ^*, ?%& /BC 'Q1@#XHP
M!\48 ^*, ?%& /BC 'Q1@#XHP!\48 ^*, ?%& /BC 'Q1@#XHP!\48 ^*, ?
M%& /BC 'Q1@#XHP!\48 ^*, ?%& /BC (-^N/U_^_/\ ^M_<3_\ B?\ ]C@'
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>proxy01_def14a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy01_def14a.jpg
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M+R*R0K?B*]5G0G)_3K_)PY3A=_S$YE#BY##79WG&5(<APR^GA'4I1/+1!5X
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M:LT!]J&D,0RLH2Y(*-$+62MI)4L*.B3Y(&N9.]?.MW13)NNO2C-<X:R^]6/
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MI2E*5SKU ]+U]8>DF08M'EBWW"2VV_ EJ&TL2V'4/QUJ_P"$.M(Y:\E/(5^
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MFV9^-:'F&%R'G;FIX1W3;'IB$(:*0E(5\,\C:2"I7;)&U:&]=_5/>[4N_LG
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MBR7'$I65-A)Y $$5,63I5C&/3DS85N4B8)SUR+[DAUQ:I+K*6''5%2CLJ;2
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MI2E*4I2E*4I2E*4I2E*4I2E*J?4?)AB=E:G.9+9\78#Z6UR[TP76EE23Q;2
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M-YKU#9NC^6YW;K)<\CL%O_"#!M+P^='RJ.B5-G:R1M*^)\;WR7J99$^G>_\
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M/);4 O02!OP= #?@51>N/HU8ZE];^BJ&,=A)Z6XI:+C;)D>/+^%<AA;(3%+
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M]R&1/M,F59Y"&%,O1UE"IS(X$(>= '(ZUH  "OTS_*CI=B^DTAD?$/-WVTA
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MOJ,@M=@%U M]KD!?-88:[9 2LZ!Y;5Q  (V2>]]9.CN-]=^GETPO+(KDJRW
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MTZ_5]-U\1>N73V;U >P9C-;"[F+)*5V-%P:,M*@.13V][Y '93[@?2JYU/\
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M9-CW&W2VDOQY<5U+K3S:AM*T+22%)((((\&MSD"=;\UCFG[BA6!]:SR'WH%
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M;4M:U$!( \DGP*VD/(<0E:%I4A0V% [!K3M=^MM\1(7;KA%GHCR'(KRHKR7
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MG5^]7F,=1<MNESC8Z_DWX3&Z>7J4W#LF_A)]XYL(C1W4<5!TJ0X\0U_2X_4
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M/U<P68NU(8S''GUW=Q;-N2W=(ZC-6A7%:&0%_F*2KP0G9!\'S4C(SC&X<]V
M_?+8Q-:<2TY%=EM)<0M3:G4I*2K8);0M8!'E*%*]@35.Q'K[A&>Y9DF+QKG
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MZIK'HMR2U]21DMJO=@MW?RB7=Y#Z(CJWA!7<4S$12THEAWV4GYD)+:R'$+)
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MW7([R'6D@D+&QL%) YWGWKL<QK#\T%LM#L[+[5-E(8B&V.F/!C-26&$JG'N
MI45O%&T$@J22 $I4:Z++]:W3J/=;[:V5W.?<;=*3"BQ8<9#CEU?,WX)2(J0Y
MM13)_+//A_6&T?-49:O4M?[GZ87NH2+7"3DLN_2+!;(#[3C+7?5>5VZ*'D%1
M4DC\M3@Y#R%@:\:D(OK5P*38KM=6X][<B0KDFT1G%0D-BY2B^ZQVF%*<"4JY
M,.DI>+:@A/,CB03)8AZQ.F^=9CCN.V6XR);U]CLNQ)?:2E@/.QE2FXR]JYI=
M+*%+UQXC7$J"B$GQRSU@8AA]^R:U3+3D+CMCN35F5(;AMICS)ZV$R/AF'5NI
M2IQ+"BZH**0$I/G92%:BO7#TO1;A<%SIZ8/-:B_\)L",FVHN/Q9 5R[*F'&P
M%:V7%!''=:_^O'@1CQG46W)'S\/<Y=Q1%MZ)!M+4#M_%+D]MQ0"4AYH@H*PH
M.)ULG5?<_P!;O3^T8U9+U=(]ZM+%T+KJ6Y<5H*:BM%D.RRI+I0ME)D- J:4X
MK:B DE"PF_="^I4WJ5BER>NS4:/?+1>[E8I[<,*#7=BREM!:.1)TML-KULZY
MD?2NCTI6*S2E*4I6-5FL:K-*4I2E*4I2E*4I2E*4I2E*4I6-5FE*4I2E*4I2
ML:K-*4I2E*4I2E*P?:N4Y3Z=,>RG/9V5KN-[MDJY1D1KE"MEP4Q%N 0R\RTM
M]L)/-2$2' /(2=(Y)5P3JK)]%N$1H\?X"XY#:I\1BVL0[I!N7;E14PH3D%LM
MKX>"N.\XAS8/+EL<2 1[W3T7].+S-M!EQ;@]:+3:OP>%8US5&&PQ\*N(>(([
MB=LK4DI"PA2CS4DK 57TYZ/L0F6%%KN%VR*ZA-HNMD^*FW$+>,:X,,1WQX;"
M04MQF@C20 >2B%*4HG5ZM^F%'5KJ%C3TVZS(.'0<6N&/3XUOG*CRIB)#T0]E
M9""%,K;8<2X-@_,G6O<25W](V%72U/1&I%YM4E=[GWUJXVV=V),=V8@MRFFE
MA&DLK;44<-$@:((4D*&K&]*^.8)<KOD6*QY4J[R+.Y9&[/<KFI%L?@B.TS'@
MN)#:RAAI+/R%*2L%UTDKYFH'!/1)C5HZ.8YAU]G3)<V%BUPQR=+@/EM+XGN-
M/3'$\DE7+N,IX*/D)'D'Z3<_T88#<&,BCN.WM,*[,R8[,1%Q/9M;<F4W+E)A
MI*2&@](:0XK?+VTGBGQ6M>O1'@-]N<^7)F9!VGES'8<)%R_V>UO29C,UUV(@
MH/;5\2PAT;*@"5#13I(OF%="K%A&6Q,DC3+K.N[%F-C+]PE]XNLF4N4I:OE'
MSEQ:O(TD)TE*0 *J%\]&V"9 UD#<ER[A-[9NT>5VY@!";C/:G2>'R?*>\PCC
M[Z3L>=[J<ZL>F?%>L.0?C%ZD76-*7;D6M]-OE!I#[");<ML+!0KREYI*@1H^
M2#L:U%?ZHN&-9.U?XLN]P;E^)3KB^[$G]LROBYB9CT=PA&^SWD!24I*5 %2>
M12I0,[G'IZQ[.NI%FS>X2+F[=;,4O08AF$1&Y"$.(0Z$<2I)TZK:4*2A?RE:
M5E(UQG!/Y/K&D=-<7MN8W>]3LIM]HBVQ^=#NBE-L,MQGV'(L;FW\L=0E2" 4
M\P5@I4DI3KHKWH^PN4BY17YM_79KI;4VZXV5-T6W"FE,)$%,AUM"1R>##;:0
M=\04)6$\@"-?JAZ<)-Y].>2].;!>ID^X78MK_$\AF*6XI0?96HJ6V@</D:TD
M(0 #HZV2:]K5Z.<!B/WY^<FZ7U^_VNX6F[O76:75SVICS;CRW%)2D]P=EI"5
M)UP2A( \;K-P]'6"WW%F;->WKQ?W/V@CY++NMSG=V;.ELMI93WW. "FRRA+1
M;2E(*!KW))CLI]$& Y7,O<IV;D,!Z]RY<JY*M]R[7Q8D2&Y*F7/D.VT/-)6A
M/N.2QLA1%2<GT@X<^B]MMS[]$:N%R%XBM1KAP1:9OQ?QA?B#A\BR_M?S\]!2
MD#2%%-9R;TVL0/3Z]T^Q&>ZF7%N2;[;IM\>,@F<FXBXA3RPG:DJ>!!.B=*^I
M%:$_T88/>+O>KW(EWXWVY28\MJYKN 7(@+8?6^UV5*;(5Q4XM.W@Z>"N&^&D
MBS8MZ:L9P[.H^4VR=>FYB(\=F1'<N"G&)KC+!CMR'P1S<=#1XDE7%12E125(
M21YY1Z8<4R@7MQR3=84ZY9&WE29\22E+\.>B*W%"V2I"DA)9;X%*DJ!"U?<:
MT;KZ0>GE\OERNMPA3)LBXXH,.E)D3%+#D(:_,*B.1D$)0.\5<M(%2%A]-5@L
MDV-/7>,@N-S9M-PLQGR[B0^MF8XRMU7-M"."P8[? M\ G1T-G=5:V^B/ [)\
M)(AS<@CW-J7)E2+G'N"69$P2 RE]IS@VE*4*$9@_EI0K:.7+DI2E6SHET>G]
M/XKL^ZW5U5XG7&\72X0[>\1;WGITSOA10I(4I;3:6VTJV/!<\'ENNMTI2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2L&JGD_5'
M'\/N[%MNDIYF0XA#JU-Q776X[:U]M#CRT)*6D*6"D*60"0KZ))%L!V*K5\ZB
MV''9CT2=.[<MI<9"H[;3CKI5(6M# 2A"25<BVY[ Z"%$Z W6XWE]I=O_ ."H
MFMKNFEJ,9&RI(0EM2MZ&AI+S1\_18J7[@UO?C[UGF*!0->,J8B*A*U)<4%+2
MV.VVI?E1 &] Z&R-GV \G0\UJ6>_PK_&;DP'3)C.-H=;D(2KMNH6D*2I"M:4
M""/(W^^I$*%.8_OIR%.8KP5-0F6B/Q<YJ07 0VKCH$#RK6@?(\;V?) \'7FQ
M=XDFX2H3+Z'944(+[23M37,$IY#Z; .JV^8_C_"HZ;D4&!=(%N??#<R?W/AF
MB#^;P3R7HZUX'GR:VHDU$Q@.H#B4DE.G6U(.P2/90!]Q_?[CP14=^U]I.0"R
M)FMKNA"S\*C94 E+:E;T-#276SY/LL5+A8/UK/,"G/\ OH%@^W^-1F1Y+;\3
ML[USN;RF(;2D(*D-+<4I2UA"$I0A)4M2E*2D)2"25  >:DDK"@#H^1OV-9Y@
M5@N >_C^-1,/+[1/OC]HCSFGKBPA2W6$;)0$J"5;.M @J (W]14OS!IS'_U*
MQS'^/L:R%"G<%"L#WK"G D57+=U%L-VO35IAS3*G."00VRRXL ,.%ITJ4$\4
M@.!2 21R4E03O1U8^X /)U_&LE8'OXIW!_Y^M"L#[_X5HV^^0KI(N#$9\.O6
M^1\+*0 =M.]M#G$^/ZCB%>/'S"MB7,1#0E:TK4%+2@=M"EG9.AO0.A]R? 'D
MD 5\/7!#,EE@H=*WM\2EM1 T-G9 TG^_6_I7R;Q$3=$VY4AM,U3)D!@JTLMA
M025:^VU ?WUM\QK?TIS%.8-1\Z_P;;<;=!DOAJ5<%K;BM$$EU2$%:@-#Z)23
MY^U;,::B5W>*7$AM9;)<;4C9'U&P-C]X\'[UYW"[Q+68PDR&V527DL,I6K1<
M<4"0E/W)"3X_<:VPK_R16HY=HK-R8@+?0B8^VMUIDGYUI04A9 ^P*T;_ /:'
MWK;[@^_M[_NH% TY ?\ TZQW!Y\^U9YC^^M6WW:+=&G'8KZ'VVWG&%+;.TAQ
MM90M)/W2I*DG[$&MHK ]_'\:%8'CW/V%:EON\2Z"1\*^A_X=Y4=[@=]MQ.N2
M3]B-BO.)?X,Z[3[:Q(2N=!#:I#.B%-AP$H/D>00%:(V/E(]P:UG\OM,>],VE
M<UO\1>=#*(X)*RLM*=XG0\?EH6KS]$FI<. @?7=.X/;?G[?6H,YQ94Y)^ *G
MMIN^]?"D*Y?H+GVU^@%7O]*];?E]INMVE6V)-;D38J2MYIO9[8#BVSLZUX6V
MM.M^Z34QS% L'VIW!7A)G(BALK2XH.+#8+;:E^3[;T#H?O/@?4U\.W6,S<(\
M%;R4S)#:W6V"=+4A!0%J ^P+B ?_ &A]ZVN8K0O=_@X[;ES[C(3%B(6A"G5
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M_P BEJ;[J='7D%OY^0^7B"K>@34,?4CA[69KL$F8B#VY4N"J7*5P1WV#$Y)
MUY!^,0>?Z1P.R-@U9)O6/"K<JXID9' :5;Y#<20"X24/.+[:$#0^917M&D[^
M8%/N-5ZY+U1QO"Y;S=^N\&V-I0T4=YX]QQ3@>( ;"=^4QW"-;WP7X''9@\LZ
M^8GC5\M-H1=K=+GW!1(2980AIKX=;_=4K1!3Q2CP-G\U!UI0-6!_J3CS;]M0
MF\VWMS&1+2MR4$#X<M.N)=3XT00RX?)'A"SOY2*@L4Z]X?E;V0_#W>(B/9WN
MVM];N@M(:86M?$@%(2J0A!"AO>ON*V;CUIQIN:F%;)\>\S4W./;'X\5X<FE.
M/A@K\^%)0L\5<=Z4.)T?%2T_J=BEK8>>F7^WQD,.2&G2Z\!P6P.3R3]B@:W_
M !'W%+7U.Q2\PVY4*_09##B65)6AW_UKYCM@CW!+R5-Z/GDD@C8K3RCK-A&%
MW=VUWS)K=;;BVV'517W=.!)!*?&O<A*R![D(40#Q.M^=U*Q6VQ')4F_VYF,V
MLMJ>4^GAR[ D:W[$]I25C[I4"/>HVS=8,:R+*HUCMDT3'G[8Y=DOM@]I+3;_
M &%A1.N*DKV"DZ(XG8%?+'67$9S EQ,@M;UO;[Q?DF5Q#:6VNZ5 $?,.&E;V
M 4G8*A6(/7' KF_;6(N56QYZXN*9C-I>^9:TNEE22-?*0ZDMD*UI?R_J\5$Y
MMZA,7P/-6,<NKQCND,+?E. AIE+K4MQ'L"5$_!J&AY^=)^BM3;O5W%85Q3$F
MWZUQW'GD-1PF6%ESFVTM*CH:0#WV]$G1[C?G:P*VKAU3Q&UY2K&I>00&+ZEK
MO+@+= =0@H4L%0^FTH61OW"%:WQ.HJ'UPZ=N(CKCY1:N,R&NYM%#FNZP$K47
M?;R"EM:A]2E"E#8!-3+W4W%8\BYL.7Z"AVVA!EI+H_*Y*"4[_BI24^-^2![U
M]7/J1B]FFN1)U\@Q)+:WD+:>="5)4TP)#H(/]5E27#]DD&J1?/4IBV/7<0);
MR#Q>CI>E,NE;+:'I$EA!Y<=J6%Q2E2 -A2PD;T:N-XZDXC9K/:[U<+W;V+?.
M <A2UN I=24<N:#_ %0@E15[ ;)(%:PZO8DQ<+?;IF06N/<+A*7%B1TR@OO+
M#ZV4I!T/F4M"DA/]9"P.7$FH\=:L%N4!%RCY#995JC+4MV:Y*"4,)3'<>[B2
M4Z(X(6>0('%*SOY2*W'NMN"1(%OFOY1;6(T]]4:.XZ[PYN)<2V4Z(VD\UH1Y
MU\RT#W4-RU]ZB8SC%YAVJ[7N#;KA+25LLR7@@J2 KR2?"=\%ZV1OBK6]&H#_
M %@>G(8A/*S"U-HFN*;8#CW%2RD(*CQ(V$A+K:BHC7%:5;T=U(N=7\,;>NS2
MLCM_<M>_B@'=\"%A"@/'SD+4E!"=D+4$GYB!4'*]06'1+O88BKO#>C7R0F-!
MF1G^XV5*9[B>X=:1RVE*02=E0]O(JT7'J+C5IM$BYRKQ%:A,2E05N\BK_:$J
M*5,@ $J6% @I )\'[&JNSU_P'X^YA^]PXHAR&H@EN*VB0%QFY(6VH \FTMN@
ME?Z4^22 03N6SKAA\V1,8=NC4!V/>'K($RB4]V0UPYE/_!MQ Y'QM21OR-[%
MKZNX_?NH[V&VR6S/N$:$],E*8=!^'[;S;7!0UYVI:AL; +:P?(J0F]3\4MM_
MD665?H+%SCLE]Z.MS1;2&RZ0H^P5VTJ<XD\N *M:\U7K_P"H7 [+@\W*$Y%;
MY5NCAT)4V]KNK0UW2D'7@%)2KD?ETM)WHC=C1U L3<-MV=/C6][X6++=CON
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M3;=H;4]#<*]I' A9CON%#?LIP#^DI0^[=T/R2+D>,KEXW;[B]#O<6YHOKDY
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M  -<[E>FR^VO'K!"MUHBHMT6VVQ%SM$%<0"=,;CR6GGB)#2VEJ2MQE7-8Y*
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ME*<)6D!+9WXC'>M>1VC(2U:HAF2;FPVTS'7W)3,8LOW4N*"%/(45.)CH'Z_
M23HAL)JP8_U:R#..H/3]U3ENL]GF7.9$>LZ92E3RXU;G'#S*5%MQKD0H #P
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M+D^D?]@V.IEX5,E9=:\FQ@8W(QN#;6_BUQ(\=N/ #+RW4[>0@.%Q:SIQ2TJ
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M'?Z=$$#?O]*LY<3]Q]1[U7[!U L>476?;[9.3*DPO]\$@A(/=>9*03[D+C/
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M 6DD'B1L>#K>OXZK"7VUJXI6E2M;T"-Z^]8^):(![B-%12#R'D@Z(_CNLEY
M_IIWY^H^GO57C]3K#(O[-D^*6W=EIY+B.-E*F3VTN<5_1)*5I(&_.]5+6')X
M&1LRW(+I6F+*>B.A:>)2XTXIM?@_3DA0!]CK8KY;RJW.WN3:DO\ ^UQXC,U>
MQI':=6XAM07[':FE^-_;[BHC_2E8EVW&)K3LAYO(WDLVY"(ZN;A*%+4I23^A
M*4(4I2E:  ^Y JU-R&W "EQ*MI"O"@?!]C_ Z-91(;<&TN)4.(5L*!\'V/\
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MBZCP?H=^PJ4#[9<" M)64\@G8V1]]?:M*Z7R+:;<Y-<4IUE".X0P.:BCQM0
M]P!Y)'T!K%FR&!?K)$NT20E<&4PB0VXOY?D6D*'('])TH>#Y&Z\[OD\"R3;7
M$E.E+]RDB)'0E/(EPMN.#>OTCBTOR?&QKW-?-BRJW9$F>J$^5_ RG8;X6GB4
MN-J*5^_TV#Y]CJI(RV0@*[J.)3S!Y#13]_X?OKQ3<VB^ZVKDVEM*%=U8 ;7R
M_JJWY^F_XC[UM%0 V? KX3*95V].(/=&T:4/G'OL?>LF0V'>T5I[FN7#8WK>
MMZ^VZ^1*9*$J#J"E1 20H:)_=]ZB;#E\#(VGGH9=^';><CE]ULMH4XV\XRM(
M)]R%M*']Z=>XKTOV56['&F7)K_ .RF(8"!R(<>6$-A0'L"2/)\ >:RQE%ODW
MN;:D/_[7#CQY+VQI 0\IQ+9"O8[+2_;[#[BMZ=-$**X^6W'N WVV4\EJ_<!]
M37JAY#BE)2M*E)_4 02/MNL&4R$%?=1P"N!5R&@=ZUO[[\4,EI/<VX@=L;7M
M0^4:WY^WBL.RFF>7-Q".(V>2@-#[U&XUE=NRNU1KC;WBN/(2I:.XG@OB%%))
M2?(&TD5)_%-<4GN(TI7 'D/*OL/W^#X_=7T'D'G\Z?D.E>1\IUOS]O!%>$J>
MB*V%<5.GN);XM#D02H#9'V&]D_0 FH3%>HEBS5QU-GG"8E#+,@.!)2E;;J.:
M%))UO8]]>WUK*.H5B=RM>.-STN7=L+[C"4G392EE12I7L"4R62!]>7[CJP!]
M!*TA:2I'Z@#Y'\:\85P;FL,KXK96XGF&7AQ< _>G^\?XUJ.9-;&KO%M:IK0G
M28SDQIKE^IEM2$K7OVT"Z@>_]+]QJ05(;2V5EQ(2 5%14- #W-13.76V5D,B
MRQWC(N$9+:Y+;2=AA*TJ4V5GV 4$*U_"I7XEKBV>ZC3FN!Y#YM^VOO66WFW>
M7!:5<3Q5H[T?L?WUZ4I2E*5@^U<-ZP]([GE>?QKW:[:Q)F/08T!F[KG*8=LB
MV9*GOB6T ?F%275#0T=H"3\JU$=JM[CKT5*WHYBN$G;16%%(V=>1X]M'^^JS
M>\=F2^HV/7II"#"@VZX1GB5?.%O+BEO0^H_)7L_3Q]Z_/4OTTWVVV#'H-NM,
M%NW0[;;&[C:(*XJ$S)C<:2T\\0^PXTI25N-*YK3R4-D$*0D&_P#4/I1>;M8\
M"CQ+<Q>+G9XB8:YEQFH>2RK3.W'$N-?F@EG9=:[3R2!PT%K I>/=!<HL<:6N
M=;$7[MRXZY\"9.BAG( VX^I3JDICH^8EU#NY"EJ*@4$Z 6?.X]!\ON5M?L*\
M?M3%I>^)D%#=R+C" ]&C,_"I2M/-24]IP%2M CCH?,0F9R/H3?9>9"=;;? B
M-?B;SD><VXA+D)@O6I:"A.M^!#D:0DC1XCV5XJD7TXY1%Q1$<V)B7=$%MI*9
M5QAJC=]+"VU2RRF(E"TK44\E*(D\0%!:5 A74.LG1Z[]0[BJ9;_A&IC&/2($
M:4ZH)6AYR1'6MM)4E?!+K33C:ED*T%^0H;!Y78NBUZ8Z@R8+6,,HE_ 09,2[
MS9T<NX\#/DN'LH98;:VH-E7!D#2E!))2LD3]L].5\L]VPM;,)F/&APH*71;Y
M,9D0)+,E3TESDN.MU7>"D@EE2%++?%9XD*$),].>5R+<([5DC1;4TXXRFT1Y
ML,N+6IDMHDJ?<BJ0X$:XI<6V)(2ZM16I20#9;EZ>+DNS7Y(M%MGS;E$O2)2Y
M#B%+GK=EQGHG>6I'S'BRYY4-(*O8;-:-IZ#91:9LV9-MB,@0W,[TVWR9L5+&
M0([SJTE:4QT_,CN(6/B%K^9!0/ETNMMSHA=XV =,[;+P:QY"C'EW$RL??GI$
M=@/AQ+7:<6@A? + V0"!LCY@ 9KH=A,^U=0;JQ.EINT'&XB&&)Z.1#EQE(:5
M<1M7DD+CH5]Q\2H'SNM"P] )MMRJXW@6&U1);=[BR8,QHM]U$=-XF2WRDA.V
MRMB2A)3[J(4D[ %;?1WH[?L&S.RS)EHA1FH]I9CSIXE(D+>=$9AK31[:74:4
MT0I"E+9*4I4@)4HZH_2_HI<,HL6-25XE:[3:FYS<BXH6^ETWH)GE],AY!1OD
MV$JTE>SMY21\J03(N^GO+WX+D"!%M^-7%+3<9[(8LKD[/D)4ZMRX+"0E86XA
M:V""2H"8[Y(;3RN/2?$EIZKWE2;?&A6&RQD*BPXRNXU#N$QMOXR,% <3VA&0
M=C_^+5]ZH</TR9C&N&1!Z8U+MTBWSXD&.N0/E4RTY$M7(^_B/)?*B=Z4E'UJ
M\)Z/9&<-ZJ6M4>(M_)+1*@PFU2"$+6Y(N3B0XH#:$E,MK9&R-J_J^:=?O3YD
MMY<$B%88U@LS_>88Q:VSHB6[:ZIII FI<<C.(2HEI>U,I2ZD*"DDJ4M-=4S_
M *:7V_9I8Y%NE(;M,AEIB]NK6.X?A7#(B+2G7SDO%05Y'RG^ZN4S?3ME-PL3
M,6#9;5C<R.&(H?C24*+DE$*<PY= H(V''%26=[!=*4%2MJ2D5]7'H#D+V#3X
M?[(PKPQ<(\^,UC=TGQ$,0'GX[#;<I/8C-LM\"RX--H*P'2L'DI:1T'(>CDS)
M\TQF3=+?!NEBAQ;:U-CRR'$K4PU/"]MD$+'*2R1OP?/]6M?+>D%[O/2WI]:_
MPZUW*_X_;G&G/Q%?-H/FUO1QIS7+1=6WLI(.AOZ54<6]/^5PI321&C6RUS[O
MV[A$7)C\A:^$-W7".RVR%EZ(ZV6VTA(3+6KDH[)W,?Z.Y9C5XMUVCX];TRK.
M^PN6(TY"',B?3\0%S5J*0$+_ -HY?F;4>;B=Z2DJM/2GHQ=\7Z?Y)#E)A6C*
M;K;HL)%TB+[KC1;M<>.#W-!12AY#BDCQ_6T"JHGIUT0F0,YL]XF8I9\>M%O[
MJF;3%?0^B/)$=EKXMO20 MSBH; Y!+:5$\ED#1R+H%E,_K6F]QYC:<4-S:4J
M(IX;,1Y2)<U.O?:I<2+H?5+CG[Z@#Z8KO-8*+A8++)E)Q_LB4XMM1,_\-3&0
MK].]H<22'#[!8(T0:F;QZ>;\Y;;JY;(T&!=;F;JY<9#+B$N7 .W"+(9:=6IM
M04%LLO-DK2I*.X04D*4#Y6KH9D-H7%F.X_'OEI:"%.XQ<IL929"2]/(;5P90
MPD-F4TZ$!' 'D$DE*2=W*/3Y=,AZ&8!BC]HM+]RLEJ>AO,NN!QIA2X+C 2TX
MI.R I21RT#H;^E:^4= ;U<963P[;8[9'1,8N*&[RA]+3DV-(:#;%O6V$[0VS
MI&O/$".WQ&UGC<NF?1?]A<W?N,>T6VW0) O"'A""4=Q#TUAV(E20 "$M(= '
MLCD0/U&J@GH9DD>WH=O%FMN9QK9+%NBV&;*0EN7;&676HBUJ6@I2XE3ZUE*@
M=>X)4E.]&/Z<\B$R8Q.AV^X,/MPD3)BW0#<"A5E[I<3QY'Q;Y7Z]\N2?ZYU#
M7O"1C/4>Q65RT6V=-=R.#,M+"5\';3"1=Y+Y,='#YD%E0*PV0E'$I7H);Y7?
MJQT9OV791?WX%G@/OW!M2X^0/20A^*S\ N.;>$\2K@XXI2B0>.GEDCD@;LF?
M](IUPM>)P,98B6V(TR;)=(S7%A";6]VS(#8"=%0+"0E(U_O%'8JDN="KZJX.
MK5CUI+D6<S)DSDOMJ7?5B[,2TON)4GY%LLMNI3S).W2A)"/)B\5Z Y1CC#3U
MSLK&3HC+::N-HG3HGP]]6E$A!E%*8R!RY/)=W(*W"2H$[;0I6[FO0O*;MT1P
M'$HMHMKMPM%A>MSH$EK4.28R&VBVZ\TX T"%@N(1WAI' IVNJB_ATW*,XEVJ
MVV&V7F\PXUQ3>+FIULR9*5W.$ZAIYMU!0EQ#;2PT)'-M79!2%-G=7+#_ $]7
MQ$G&V<EM5MG6N$]RDPY#Z)390'KPM">/:0A82)T4 !"4C2@$@( J+'IYR9RR
M7B$_8;;(D3,:$.2_+F-2?C)0C1D)2E2F@XV.;"@I*U+:&D+0$J*M7?JGTFO^
M7=2+5>8;:EP&XL5M@)E1V/PQYJ0IUQ?);#CH2XE2$GX=:%'M!*CQ(4GGM@Z!
M99;$O/W##K1=K:MN.'L9=G1FXTEX,2FUN (92@)0MYLI+G<=4@E2EEQ"4UTO
MIGT:G8;G;-]<MUOC.R'KL;A(BK)<D)><C&,%*(Y+"4M+_424^/J357B] ;Q(
MN;:)UBM"D1I\5Z=<%N(=5?E)N;4HRG4%&TK;:2\D<R22\M*3Q )L.9=$59;U
M3D72;C]JN%H?=B2779:&UEU34"XQ^*T*22HI7)8(*MC6SX*:B>DO17*L7ZAV
M^\7TKD.LQTERX(FQR%I,)MGX90['?<"'$D@*=[?RH6!R)2/"[>G.=)R%V\QK
M/:4W-4^7-$Y2P'BM=[:E-+*P.7(14+3O>T[*!H*.XO%^@.0L./JNN-VHQ5SK
M)), .QELER-)DF4XA"64@#@^DI4X7'EI20XOEH5"1O3/EJ[,Y =@M-.FP)A,
MJ9FQ4,,@6HPU0B1'+RFR[R<TEQ+1#Q40%I(5UG#^E4K%.LLZ\0+#;[78%LN)
M[S3C:U+"D,A"6DI;2XT!VU!32E+: ""WQ)4!S*Z>G?*YMP4ZBPV]A^+#3'GW
M5B:RJ1DG&<T^>XAUI:!R0E2OS@H<_D/R:56P_P"GK*6T,LP+5&:D*M_!Z9.N
M;3W)'!P?!A2(Z%L["D-?E?D=M2CV^:03-/\ 0JY7--TGQ<1LV,OO1X;4"%&D
M)7\&$W1<E\!0'%!6WQ6I+?R%1XC>MF M_IYR=C#+1%8QRW8_$MK5MCSL;M<J
M*ZW=7&&7FW)1+["V5*Y.M*'=1R5V 5%*@@BP8GT1R"PYIA3TVQP;DNSW!$Y>
M3R+@EZ9'C?AKD7X))[25.!+BA]$H*3RXA>Q7AEOIYOLZ5>[A:8<*)-N4ZYRI
MKK+C:';BPY+B.LQW5+;6DA;;#B"'$J0GD 4D*-:J_3K?%8_<UMPVT35QX*66
M7GHCKZH[=PE29$$*^'##:%H>:^0-EK8X':4\JRWZ<+S.;CLW"VPYL!$=SMQ;
MC(:?[+AC3D-ITAI#>D*DM@!* E WQ\(!/3\GLM]R+H]=<8;MB95YCPH\)8N"
MP69JNTRITI4KY5>ZTCF"@K3I8*2H'F6#]"<GL%^Q^4]8X04Q=7)(DO3(SJ8D
M7XOOAOMH80&U\%KT8I0GG\JTK; )A_4?TGR:Y7/+LA8LD-^"4.$NM26VE2XZ
MX"HX:60TJ05%U>E .!I* E24*7NOF]=*KM+SJ/%9P*U1TW"UW1=NMOQ;:6,;
M6M<!I,ELI1PYEQM;Q#0"TE7R[4I9J<E]#,FCS'Y,VPVS,H)<>[MHG3$MMS%+
M?N*D/+Y)*04B4VK7N.ZX4[4A(,%?O3WF%QR;X]W%K-<8:)G?F053641[BA,^
M)(;'EHNN?E1U;,EQ>EGBD);)(W;OZ>\LG);D&#'%L*VW?V=C/Q2EIHJGEN,G
MOLN,E,?XEK7R:\K[>BA 5V&Y8W=+QT;NV'LLO&ZQ;>W:T29KY6F4X([1+G=*
M4E0V2DK*1LI5X'M5?Z?](+MA]XN\Z/!MT1VX6ZXMOK0X1\3*=GO/L*>* %*
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MH?$\BYXWVT#B/FWX9WZ=F<VZ?XYB:[XMB!:;6NU*[T%N2EU*F$,A\-K/!+Z
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MGC8++:DK^A3Y"DDI,-D_I_OT6]PKEC60"*^+M%?2INW,-ICL-A9Y/(24)DJ
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M@4)4 L!2#K8SZ?KE9KOT^;>==?;M:T3KO*YH#+JFX45A$9(!Y+_VB)'D!12
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MYX [[8< !77/\ 8ZC62W8?%<;R=#\=#$6/;GF76HS24I92HN+0"V E)5R;?
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M;;='>;47"I)05+3RY!M100!*]('<F.:)3.<R-;:HLLW1%V;>$)'Y[?P'PI<
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M%BZEWZUVF6^[?)5]M\SXR,W):E1TQ[C^%W!+A4IY0"FR\IA'% [ *@$**7%
M328_4"6NZ+Q:7F2K?"MMQ?LGX^76GWIO9B )D)="5+2%JD%M*])*@YK:$IU,
M"SY%D7I\S:#<';W<0ZI7X>V6)K$WLI2RHH3WS\2L\P[HJ )V4I!2$DU>-9<^
MQ#&I4>SJR)$&:?B9B)'Q+BHS:KJ^7.PAL=UL]A:"4M#F4;4 5C9N&30\\N/2
M?$&6[AD NH_$')4BWMNQ9*THB2U1$NA6UC\P1A\VE+4$\@.2DU6,G9ZFVJ,W
M"AW#(UVU$AY34UQJ3*E?$J@PG&=]C2E-=]<[Y5Z9"TA"N*0D#4N=KZ@Y-#S&
M%DJ[U(0>2Y4.!&F);5V[A'7'5'7R[>OATK/"/R*@5=S2T^=QW_2?#M+UY9FY
M"W=6^$=IF<Z414M&VOK6XI"P$<N^&OG7[+XCP"H&SXM=KY.Z>]36+#-RJ6N'
M?&XT(WA+@NC,4Q(*Y 9#J0OF$N2%-A8Y<R/<:K?Z80\DGYM;WY4S*!C,2-<5
M6\793S2WDJ?92R925@*6L)[_  #GS=OBHCEYKN@\5FE*4I2E?)0"=Z'^%9UH
M5&RLBM4.Y)M\BXQ&9ZFE/IBNOH2ZIL;Y+""=E(T=JUH:->,7*K%/CN/Q[M;Y
M+#:5J6ZU);6E*4'2R2#H!)\$GV^M?-VE6$72T,7)^ )ZW5/VYF2M =4X$%)4
MTDG94$K4-I&P%'[U%Q^IM@F9;(QV)*:E2XK0=E.,O-%J/Y='%9Y["P65[3HD
M>"=#9&Y,FXOEUB+<B5:[K:)2 LA3K;K#R L#?N0I/( ?;?C]U>PS+'4O-Q1>
MK8'E2/A$,B6UR+P.NT$\M\]D#C[_ +J^HV76"7-1#CWBVORUN*:3':E-J<4M
M*>2DA(.R0GR1[@>:^'<VQMF([*<OMK1&:>5&<>5,:"$.I.E-E7+04#[I]Q7Q
M:LVL=Y7?Q&GQU(L4I4.X+4H)3'=2VAQ042=#27$DD^WG[&MN'DUFN3L1J+=(
M,IR4S\3'0S(0LNM>W<0 ?F3_ ,0V*\#F6/"'-EF]6WX6$H)E/_%-=M@G1 <5
MRT@G8]]>]:N2=0L:Q.VW";<;O!CMP8"[F\@O(+@C(&U.A&]E/V(\$D#ZUN,Y
M?8'TS%-WBW+$)H/2BB4V>P@@Z4O2OE3X/DZ'@U]-958WGX3#5V@./SD!R*TB
M0VI4A!!4%-@':QH$[3OP#]J\UYCCR8:Y:KU;!%0\J,J09300'1X4V5<M<A]4
M[W^ZM6WW'%+8\].B3K4RY=IG97(;?:!ERDCAPY;^=P!''C[CCK5>=_ZDXQC4
M>4_-O$%"8C[$:0E+Z%+96\\&6@M(.T[6K7G7L?L:T,AZOXMBV3"QW&XL1IP+
M'=#BD(0PEY,A3:W%*("4GX5T;/UX?UA5C=R>RL25,.W2"W(3&^-+:Y" H,?^
MMUO?#_C]OWUHW&XXMD\1RVS)=JN<=<=N<N*XZVXDL!04AXIW_N]I!"C\OCWK
M3>ZFV,Y+C=DAR&KI*OS,B3$7$>:6WV60GN.E7,;3M:4C@%$DGQI*B+>$@CV
M_=3MI_JC_"M6-:8D.5+DL1FF7Y:TN2'$( 4ZI*0A*E'ZD)2E.S] !6UVT_U1
M_A3@G^J/\*<$@:T-?;5."?L/\*=M/]4?X4X)^P_PIP3]A_A3MI^P_P *<$_8
M?X4X#6M#7\*< /H/\*=M/]4?X4[:?ZH_PIP3]A_A3@G[#_"G :UH:_A0(2/8
M"G ?8?X4[:?ZH_PIVT_U1_A3@G[#_"G;3_5'^%.VG[#_  IP3]AK^%.VG^J/
M\*<1KV'^%. ^P_PIVT_8?X4" /H/\*<$_8?X4X)^P_PH$)'L /[J=M/V&_X4
M*0?< T[:?ZH_PIP3]A_A4/D^'63-+>F!?;3#N\-+@=#$UA+J L CD ?8Z)'\
M"1[$U*,16HS#;+;:&VFTA"$)2 E*0-  #P!KZ5Z<1K6AJG!/V'^%."?L/\*<
M1K6AK^%.VG^J/\*<$_8?X4X)^P_PIP3H#0\>U.VG[#_"G!(&M#_"A;2?Z(_P
MK2A6.#;YTZ;'B,LRYJDKDOH0 MXI2$IY*]SH  ?:OJV6B'9XB8L*,U%CI4I2
M6F4!*05**E$ ?<DD_O)K,RU1)[D5R1&:><BN]]A:T EISBI/))^AXK4-_91^
M];(;2!^D?X5HR;# F72)<7XC+LZ&%ICOK0"MD+T%\3]-@ '5;_ >^AO^%.VD
M?T1_A3MI_JC_  IP2?H/\*=M(^@_PH$ >P _NIP3K6A_A3@G[#_"G!.M:&OX
M4[:?L/\ "G;3]A_A7A/MT:YPWXDN.U)BOH4TZR\@+0XA0TI*DGP002"#[UI8
MWBMHQ&UIMMEML6UP$J*Q'BM!M'(^YT/<GZD^:E @#V %?5*4I2E*4K!]J_/G
M5/H3D^<]0Y-UB+M+5M6I*T.+>+3A'P3\<I<;2R2XH*>V%J=*0CY0V%#D8:^=
M$YEKR.QVF%%AB/>)K,2<Q"8(:39VX443$K(0$HY/0V$I'U#NM>^K7U>Z.9+G
MN;0;C;G;=&@MBWJ4\7RQ(08\T/N;XLJ4[M.NVDN(2A7(J"N7CFU[Z!9$O)+'
M;GH%C@*D6M-E1+M@=>^)3&BS@9,S\I(0ATOMME'):OS7!R5NK7<NA&737ITZ
M+#QRW+O*E-R;6S+<^&MS1?BN;94&!W5*$9:E#BV.;N]D;)W)7ISGN.K>;;LR
M)':G=M[CI:77[NF=S"N&P>"0"H>>8'N/-?%K]-4JVR(LAENT1);?P'*9%;"7
MDEJ7/>>6E7 'D4RV]'?E25;T-$P^->E^]1(4%JYIM;ZX<=<7\Z8J6ATB!(C-
MO)06$);)+^]:4H)V"XO0%72'T=O;.$Y)9W4VIZ1-N$"XM!Q:E,RRPQ"2XS(^
M382XN*M).E[2YL@G::W>DW22;AN47C(+G%M,9ZXL)2U&MY[@@[ER7ULMK+:"
M6]/(.P$\EEP\0-5R[I=T.R1S#<1NR\<QNWN6F*V46%2G&FKOM;BRY,Y,?E.H
M[G-(XNZ<*SOYAJ3?]-62MVURVQOP%+3]E>B/R%N*4A;ZH3T=#8:4RHH2V7$)
M0\A:3V4<%-J.C6EC/1/(\CB*G*Q_'K+\#?;K/2R'%I7>BNZEX,S!V!Q;(:!"
M_P P*_*6$@ I,[$].%W6BY2'#:+;/GR(3S:X1*C;4(G2Y#K+"RVD\4IE )T$
MA2@O82#47:?2]>SCC,&XHM2WV@ILI=FKE-+XVR7#;=2DL(2V>4E)UQ4H('E:
MR !]7STO7EZ>I4!4!NW/,F&JWQIJH3;*%1(+2GAP87M7.(O:4\%%)00XD@BI
M^[>G^Z+ >@LV8R/C)\UU*]H^)4[>XUP:YJ#9)4&F%H*B#I2AK8V:L>8](I>4
M]5H.0.Q;5(M#:K<ZZB2.3JE1A< 1P*"D_P#NQHI)5X+9\#P:Y6GTHY-^$2[6
M_,A2T2+7V4ON7!P--.FV?!%GL!C:VO<\BYQXK(+7( F>R#TU7JYY5D,EB3$5
M;Y<ER=$5(F+2CYFFT?!NQTLZ+)#?;4>XI/;(TWR%6_!^E5YQW*(V1OP;-&?/
MXFLVN$Z2S#,IV%I#*RTG8"8SKBSQ3MQU6AI1-=B3[>:S2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J/O&06S'F6WKG<(MN
M:<7P0N6^AI*E:)T"HC9T"=?8&H@]3\1"D).4V4*6>* ;BQM1T#H?/Y/S#_$?
M>I*RY39\C+HM5UA7+M!)<^#DH>X!6^)/$G6]'6_?1J5I2E8W2L<O/L?\*?XU
M]5C59K%-[IO5-TV#0#59K'M0'=9K%-UFL;K-*QNFZS2E*4K!.J [I0'=9I2L
M;INLTI6-TW3=*;K-*4I6-UFE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I7-^
MN.9NX7C]J>8MD.YOS;FU"0F;%>DH:YH<45AIE"W%G2-:2G^EL^ :H\_K?BMN
MO=NMB\73(DAQUI]Q%M" \XV%MJ^$"P"O_:6PQI?#1()\#==,Z27QG*\*@7U%
MD;L#\T+[L-+24+;*'%H"5Z'ZAQ\CSHD@$^]72E*P?:OR_P"I2?(9ZI61UEZ"
M@VJ%#FMMS7BB4M2KDV%_AH'A4@H:4A0/N'&D^RU;_3<:0U+9#C+B'6SL!:%!
M0.B0?(_>*Y3EV%V.;UYQ&X2+<T[-7;+C(+I4H$N,KA=I9&]$H"U:)'CD?O7(
MK#U3RS$\&Q.%(NECG2V[% N$>YW..IEN,EZVS%\7%=U6^/PHVZHC?-7( >1=
M[GUGNXZ:XC<D9)9[(_=<B59)-YNT) 9:0D2=D)0^6BX2RE(6EU39)V/!XB*M
MG6_,+S DSGKM9K-;W)D"V">[ )CPPZP7535*4Z-H=TA+:5$!/?;)4KV.I$]1
M.83G6DMIMCD=F&+N[-:BK+<M#6N[#9'+0<<80N:@\BH-.-CBKRHWB]]4+ZKI
M!;LJB3[7 -WN'.*]+2VW_L#KCAC=ONN(;+RF@T?S%H22I0\'B*YOC_6+*+&W
MD&0QYD2YP;H_*>8@.P7$=EU%JB2.[LN%80#S): \))THD<C,R?4->+$;C$?O
MUAO#$=MQJ#>V60VQ<WP_"2$M@.J25)$IQM24*/S(!\>15;L^?W1Y6$61S)(4
M!F/DT*.FU2=JG7-I;[BR\ASN \ 04:XJ3IEP$[(UNS>L]^Z>W;J"[;KI;<A6
MS?;@T,>*-RK>VEA#GQCJRZ/R4'W!"$<5I^<$$GH-KZEY1=^D<BY-S;8S>/QV
M'9X]R2EF4TIIZ9'9+JVV'E-A82\L<4ND<D G6RD41_U'98)5X:?>MUK3\8Y"
M0AU,13\-;<Q+ 26S+3HN(Y+YR.RA*N(3SY)2=&+UROG42-@;DV_66SJ?O=G0
MJU-(/>NR5R/G>86'?" 6RD@!:3VW03Y&K7FO5C)\=RO+6+0]:XD.R_%W!]#L
M,NN3 PS:R&RKN#AR$MP%8!( 1H>#RMG4OJC=,7S9=OB7&V0D0X<:4S:Y;!<D
M7QQYUYLL,$+"DJ3VD:*4K^9U)4 D&N<.]=<SE141K;DF.W1:H;MR=NL.VE;+
M93"=D*A<.^=+0IM&U%6^#H!2%:49:W]>+A E2FG#:;=\7<(K<1E:>*GUO79,
M9U*=JVXH-+2? \$A1&CJO.U=:<M7;+2S=\AL5K-ZA6VX?CCL -Q[8F2Q.<*%
M)6]Q7M4)"$J4M/ET^/"14';NK>16Z\3W%7ZV3%W">^D75Z(H,VAA:;. X$*<
M!#.I*U@.$>5-DG7+=BQGK7EUVR2%SN%HE6=F?!MJS&A$"Y)D29;'Q;3G=(0A
M26&W$) 4#M0Y$$$8SKKWF6-=6SB$2VQ'H[DAJ*U,6R=)5.[0@*5\WLE35P"]
M#SVD>1LU2'<RRNY9G:IMLR2+;>,8S&+?\'W&&4)C7?F0UW1RYEA&R? (/U U
M;^N^77NZ8EC%RAWA-E_$\:N,I<1.RVZ^8T=QOSR2H]LJ40!Y("O(\FO&X]?<
MSLN3MV!:K7*?@3GF')4@,1$7/C*0UVTAQ\%"DH6G?:#JBIQKY0#HSO5SKQ><
M$ZGQ+/;5PIK*%1&W+4XTA#SQ?+OA*U/!Q2R$#B&VE)&E<U;\"-A=<[M(8A-J
MS_$NV['7<575,!98YA$98M_'O?,XH2%*!02YQ"1PY>3YVKK9F-_<A08=[L9F
MW5Z 7"U;RM5C6^X\AR$\CO?.\@-^"K@>3;A4G1 $"QZALT0[88UURS$[&;E:
M47LS)EN4AM17#;?3$;29'D\BKYB2HIY:3L UZWOU-Y8WD$^+"5;(CJXCQ1 F
MQDE<!]MN.HH6D/\ =<*5/+2HJ;:2=)X$_J-GC=8LK9O"<;G/V^9-F7"1 AS$
M0BA*TPI#IG*<0%D _#]DI .N1)\^P@+5UWRZ!9(]P[EG3;GFDPV8J(2DHA:M
M\.0J2M?<)4AOO.DHT!VT#Y@02;E9>K]YD]*KC=G+S:)[S.2O6+]H8S'&&Q'$
MKL?%+1W"DE \*^<(*_/A/BN<X7USR.PP+DIF]6?)3#O$U,>W1V#W\B2Y.E<G
MHBNZK@VT$:TD.)'9=V0"GC:)'J$N-BQ^?-=R_%[XVBRW"<S.BQRPR):&8CC,
M8DNE*U?[0X>*3R*>.P""3]1.L.=G*B7+A9W+4+DEOX)-M4ETLJOB[8$!WO'Y
MN&G"KC^L :XDBH_"^NN=Y[(M<!J59[0]=I306ZIEB4[;N4>:XN.66Y*CR28J
M$\G>"N2706_8)K5T]0^4V"Q7K(47VWIF3&(]W;MDEELM,(39HLA3:5NR&PEM
M3KOG7)Q7G@A6EJ3/)ZI9!8\CNK9OL JG7:6V+E<8_--ECJ<MH2".X!VTA\ZY
M%(*EMJ/C8,UB76W+KUD]J[TZTR+-\?#MBQ&A%/Q_?^*2);;G=/%"@PVXA("A
MI:AR(((T\VZ^Y/8KGGB;?>K!+D6J;+ML6QB(52H:&X DHFOD.[4@.$)("4I*
M7$ *"O?;O'6W+<=O<]A=QM-P=MTA]B79!"[<UN+%0AUV<H]TZ2Z@+XCCQ'>9
MT20>7P.MEYGW9APW"RXU!O<9B6Q?YT8*;BQ%NW%<4.[=2E1=;CM$;4G];FO)
M2!1NF/J+RZ'A]H8U;7H\6U1XZC*<:*TH$9E?XD4E\R%MGN%U0+:4AOB>YL$F
M:=RZX+P"\W']N;4\\CJ1$BIR1M&H26]1D': [QT-E) 7P*]DZ&Q5UP7K)D^0
M9?9L=?=M\HSWW)3%QBQ%!J5;8Q?9?D(^<@<WFXRDZ) 3+3KD!L\ZZGY+<H%T
MZOXNS<9;0R^1):BN-R5I,/X2VQUS.VK?Y7*,4$<2/GV?<DU+8YZB,GO=S>M-
MON=H<^(1#$:0N(D_"A=UC05;:3(+A'!Y9_.[:BM&PD)\5]3?4KE%GR&V0.];
M[K)9E_ALBWMQ4,.3%B3*9"T;?+G-8CH*4M-K0DE04O>DB-E>IK+H_P 7&C7W
M&[PE"VW$W:.TRQ&948*)/PKA>E(1R*ED["^8;;5\A5LBQ2.M&>HN29JI]ECV
MY4F2M5N-O4M;3;%RBQ"WW^\.14F4LE? :+:-#RH'PM77K.,HNZK=%<M5J<G7
M5N"D/-L/O6W<EQI3:F42"M2BEO\ 4Z&M+2H<5 Z3=NBN<77+<K?G7B\,*^.Q
MJT26[:VD(0A]3LY#JVP5$_/V0=?N V>.Z[92E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4K1N5D@WAR$Y,C(D+AOB5'4OW:="5)"Q^\!2A_>:J\SHMA%PGW*=
M(QFWNR[BI2I3RFSR<*DJ2H[WXWS43K6U$J_5YJQXWC=MQ&R1+1:(B(-NB(X,
ML-DD)&R?<DD^23LG9)J3I2E:S]OC27F77F&W765%32UI!+9(T2DD>#KQL5ZL
ML-QVPAI"6T#V2@: ^OM6'([;BPM2$J4D$!1'D ^_G^X?X5Y?AD70'P[7A/$?
M(/ T1K^&B1K[$_>HF\8/:+XFT-2HC9C6N3\5'C)2 T%!IQH HUHIXNK^76MZ
M/TJ6=MD61'=8=C-.LO#3C:T!25C6M*!'GQ]ZC,CQ"#DEDF6MX+C,2DE#CD0A
MMS13Q5I6CHE&T$CSQ) (K=9L-O8L[-J1#9%M::2PB(4 M!M( 2GB?&@  !^X
M5L" PE7(,H"M\N02-[UK>_OKQ7@FQV]#+#*8,9+4<\F6PTGBV?/E(UI/N?;[
MU]_A$+OMO_",=YL%*'.VGD@$[(!UX\^?'UK(M41,ER0F,RF0XG@MU* %J3O>
MB=;(WYU66+;%C141F8[34=&@AE" E"='8T -#1^U>3UC@2!)#L*.Z)/'OA;2
M5=WC^GGL?-K0UO>M5]FTPU/-O&*R76]A#A;!4G9V='6QL@'Q]?-?:K=&6I15
M';45>%$I!W[>_P!_8?X#[4>M\:1(9?=8;<>9V6W%)!4V2-'B?<;'@ZKS19X3
M*5);B,("E*6H); !4K]1/CW/U/U^M1=@P>U8_'=;:8[ZW)DB<IZ3IQ8=><*U
MD$CY1Y  &M!('TJ4>L\*2PMEV(PZRM(0IM;84E21[ @C1 ^@^E97:8;O>YQ6
M5EY)2Z5(!+@( (5X\@@ :/T KZ1;(K:4A,=I(3QX@( UQ_3KQ]/I]OI1=MBN
M.]U4=I3GRGF4@GQOCY_=LZ^VS]ZP+3##G<$5@+"> 4&T[X^?&]>WD^/WG[UE
MVV17DMI<CM+2W^@*0"$^->/'CQX\?2L*M<1;K;BHS*G&EEQ"R@$H41HJ!UX.
MO&_>LNVR*_)$AR,TN0$\ ZI *PG8.@=;UL Z^XW7G^!P VE'P4?@A[XA*>TG
M27-[Y@:\*V=\O>OMNU0VE.*1%90IQSNK4EL J7K7(G7E7CW]ZB;A@]HN5^ME
MV?B(7)M[3K+"2!P"5ELG:=:)!:1Q/]'SKWJ4_!X1><>,1A3KNBXX6TE2]#0V
M=;.AX&ZBWL)MLC*XU_=;4Y,BQG(T="B.VR'""ZM*=?K6$H!42?"0/'G?M?\
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M*4I2E*PKV-?SOS+HCFG7_KUZE,/LJ\0@XK<+U9&[O<[M'>=NT4)M\5?*%Q'
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MPL*^!C<@Q\*#V4[[/_J_;]/_  ^W[J^HMG@P74N1X<=AQ+*8Z5M-)20TG]*
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M[3>/89*BQ(=V#I4JXESO)<<"=:#?-D\"">23OQ5@PKKI.ROKEUDP)RU1X\;
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M;0-_8>=#9 WYK@O6/(\[ZNY#U/ZLXKT[RZR,2<'9Z<X]&O-I<8G3Y$V<%29
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M &IVS_JLK_)I_..^G'^U.V?]5E?Y-/YQWTX_VIVS_JLK_)I_..^G'^U.V?\
M597^33^<=]./]J=L_P"JRO\ )I_..^G'^U.V?]5E?Y-/YQWTX_VIVS_JLK_)
MI_..^G'^U.V?]5E?Y-/YQSTX_P!J=L_ZK*_R:[K@N<V3J3BMMR7&Y[=UL=R:
M[\2:TE24O(V1R 4 1Y!]P/:I^E?)6$ZV0-^!7*.I7JNZ1=(+B];\NZA6&RW)
MC7=@.RPY*1O6MLH"ECW^U0F/^N/H'DL=;\3JUBK3:3HB=<$PU_\ Y+W _3[5
M+?ZW_0[^U_!_^T$7_P =/];_ *'?VOX/_P!H(O\ XZ?ZW_0[^U_!_P#M!%_\
M=/\ 6_Z'?VOX/_V@B_\ CI_K?]#O[7\'_P"T$7_QT_UO^AW]K^#_ /:"+_XZ
M?ZW_ $._M?P?_M!%_P#'3_6_Z'?VOX/_ -H(O_CI_K?]#O[7\'_[01?_ !T_
MUO\ H=_:_@__ &@B_P#CI_K?]#O[7\'_ .T$7_QT_P!;_H=_:_@__:"+_P".
MG^M_T._M?P?_ +01?_'3_6_Z'?VOX/\ ]H(O_CI_K?\ 0[^U_!_^T$7_ ,=/
M];_H=_:_@_\ V@B_^.G^M_T._M?P?_M!%_\ '3_6_P"AW]K^#_\ :"+_ ..G
M^M_T._M?P?\ [01?_'3_ %O^AW]K^#_]H(O_ (Z?ZW_0[^U_!_\ M!%_\=/]
M;_H=_:_@_P#V@B_^.G^M_P!#O[7\'_[01?\ QT_UO^AW]K^#_P#:"+_XZ?ZW
MW0[^U_!_^T$7_P ==<;<2ZA*T*"DJ (4#L$5]4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E?G3UAXI:,V=Z367(XLV?CTO+N,F#"E?#F6X+9.4PPI?)/RN.)
M2@C8WST2 35-RGJ9T^ZW])8-KP*]67#>H&(2HUVM.(WUQNUR+;.B'?P3\913
MP;6CNQU%&T<7202-;_E'ZC\NL;&,NXI;Y+MP"KG'G6WOK07[3!9CNQOPV2D'
MD)#*R&BK7%:&&EI)!37YSV?N:#DI02G9)^@KV?B28R0IUEUI).MK00/^^O-"
M''$J4E*E)3Y40#H?QHM#C12%I4GD H<@1L?>ODJ(/O\ ]]>B&7G0@H;6H+/%
M.DD[/V%>?S;(\[IR/W- 2HZ&S_?7TXAQE?%Q*D*^R@0:^F&'Y)(:;<=(]^"2
MK7^%86TZV[VE(6ES^H00?\*^5A;:RA84E0\$*\$5E*7%(*PE10/!4!X%?/(_
M>G(_>G(_>FS]S39^YIL_<TV?N:;/W--G[FFS]S39^YK*2>0\GWK_ $0?R?\
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M0"VI&]=O940:K-HZ>8=T\]4'43%86)6MZ&]TU>?MMGN4]4@)N#]D9D*0R]W
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M\RL'^2E]-X/_ .QUP_YY,_S*?S4OIO\ ^AUP_P">3/\ ,H?Y*7TWC_[SY_\
MSR9_F5C^:E]-_P#T.N'_ #N;_F5D_P E+Z;Q_P#>=</[KY,_S*?S4GIO_P"A
M\_\ YY,_S*Q_-3>F_P#Z'7#_ )W,_P ROUU&91&8;:1L(0D)&_L!H5[4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E8/M7)KGZF,,M/J'M'1A]^6,SNEN7<XZ
M4QB8_;2%JX*<WX64-N* UK2?)!(!E,AZEWF-?KS"Q_%E9#'L:657-QN6&']N
M)Y]J,V4$/.);*5D%2 >:4@E1('.<]@=&KYDTV^/8U:\FRM5V@&1+<;<0_P!Q
MB0VPVXT^H?,AAP(!2T>(6-*^8U:\Q]1EJP?#\7O<^WOI_'K<;DVT"I2&$);:
M<<"W @@:2[X.AOB=5;(G6/$9GX7V[P@FXN*:8!8=24J2[V2'04CLGN_ECN<=
MJ^4;/BO:\]6<4Q_)#8)]X:CW9+(?7'4VX>""AQ:2I024IY)9=*02"K@H $C5
M:=]ZX8/C402;ED4:*P5)3S4A:OU,?$ G23H=G\PGV"022 #J"B^I3"Y681K(
MFZ-!F5&#S$PI< +G?+*FUI*!VP"6SS64I/=1H_,"9^X=:\,MBYR)-[0VJ'(;
MB. ,.JY.K=[24-Z0>Z>X>V>WRTKY3H^*\\CZN6K%,J?M=V>BVV$Q#8FKGRGR
M@*2X)9*4I"3M21#4KR1L*.O( 5'H]0&*+OKT#XI\,M6\7!4E4-X>3),;L<.'
M/O=P:[6N?D?+7UD'7K%[5.QN%#G,W*9?9D2+&:;Y@<7UD!15Q*4J 2M7;44J
M(0K0\&HB\=>W[/F=QM*[5;78<.Z)M/R78?B#CBHB) <3$[7EL<]$A>PE*EZT
MDBOO$^N,Z^VO'KA+M=D2S>I,*,TBT7SXUQ@R&UKV\.RCCQ"-:!.SO[>9C)NJ
M5RMUVO,:R8V;Y&L+#;]T=,P,+!4@N=IA!0KN.AL!9"BA/SI'+9.JTOU-6],Z
MV-BU.&)*3=''I8>'&.B*%*841K9^(0A2D_;6O-2V4]>86&.8D+U#3:VKQ;WK
MG->DJ<+=O8:;:4X"I#2N:^;R$ '@#Y.]\4JEWNN^"Q79[3^0,L.06TN2$N,N
MIX\E-HT-H^904\TE2$[4DN)"@":DL-ZK8KU 7,18+PU<%Q$)6\E*%ME *E)W
MI:1[+;<0?ZJD*2K2DD5JQ^L&,W/'+[>;9.-QCV>&J=(2RPXE:F0E:DN-A207
M$+#:^*T;2KB=$ZK1M?7S"K@PT7;PW"D&WM7%UA]IQ)90MMMSBI7'7,)=;)0#
MR 4"0 :D;GU>Q2VSVH#EY8$YV0N&AHI5KO)6$%"E:XHVM24 J(!4H)!)\5%X
M5USL&<=.7LL@N*4B+;47&9"0VX7&0ICO<1M(*P0%!*T@I44G7L0/BV^H7!Y-
ML;E2[TU;5?A;=W?:E-N(^'94RAXA:BGCS2VXA2D;Y!)"B #NI5CK-A\E%N4B
M\I_V]Y;#*5,.I4E:' TH.@I!9^=24[<X@E0 /D5=0=BLTI2L*.A7)NFWJ9PS
MJIU7SSI[8WYCF088ZEFY!^*6VE*)*5=I>SRXK!2=A/GR-CS6^GJE>)LQ$NW8
MPB?C7XFJUJG)GA,LE+Q9=?;C%&E,H<2K9[@44I4H)( !E('6'%[UC5\O=IN(
MND2SLK?DB.TOGQ2V7 I*2D%25)22E204J_HDUYXEUFQ?,)%N@Q+@$W:;!:GI
M@.MK2M"5M(>X%12$\PAQ"BC?( @D &J[:/4EC5PR]-BDAVW%QZ1&9?DM. +>
M9G*AJ3KAI*2L(TM1"=N)3O=7:R]1K!DB+HJV7 2_PT%4@)9<!X@J'-&TCN()
M0L!:.224J )(-<^L_J=Q^XX"F^.AIF\.V9V]LV1*W>2FTLK?0TIU;24I=4TC
MEPUO6U)YH 49V%U^Q1M 1>+@U9IA>FH^'<YN!*(\A]GFI:4\4<_AW"D*(*M$
M)Y$&I63U?Q;ON18M\@/S&YJ8"FE.* #NX_).TI5Y E,:^A+J!L;V-!OU!8 Y
M8WKNC)&%6]HH!>#+OS!2%+2M">'):"AMQ7-(*=-K)/RJU+W'JQB5HMT&?,OL
M6/#G16IL9Y>^+K#CC32'$^/(*WV4_P 7$[]ZB,KZ[8IC=JN<ANXM3YD2'+E(
MBM\@EQ4</<FR[Q*$*4J.ZE/(_-P5Q"M5(V/J]BE^Q"5DL>\Q_P (B(YRI+B5
MMAD<0H<DK2% %*DE)U\P4"G>Q4/+Z\XXQ=+1'9D?%MW.8S!06VW4NQG%B3LO
MMJ0"TD&(X/FT=@["0-FSXQU$L.8M)<M$XS$ESM>&'4$'AS!(4D$)4@A25'PH
M$%).ZLE9I2E*P?8U_)OUQ7K'<0ZS=:\PR/'I.7.6^^8U9H4 Y#-MK3*)%H>>
M<6!'6.1Y1D^#]R:HF*VAS,;%=Y'3>PW>W3\OZ/S;DC'X5XEW)0E-Y"W'VTIU
M97OMQ]D#V^:I_JYZDLS]3O1W!W;)E&363'KW*5BM_P /L%F8EO\ QD-@3/B(
MSJG$O.)4"P% K1H(6?(\'B4%^VY+TYQ[+L&B+DG%8D>-E*+GEDMJ;+N,D(CM
M2$L!92EAN2XA22@CEQ(6D)\5^M_7/><@QOI9C+O6'#[A>)T2TPK?%S/'+L^A
MF/.>8;%R=E-,K:;YI> 4P@CBYP6#P&Q5$].7K"L&==7.FV*3,JRJ3?K-<X5D
MQ[*%VQEM=XMSVTOP9\02"TP.7:0E]'<<XH*O!-<"N6>8=TNZ3],KC>L(EYE?
M,GMT^XRY\G+[E#*5-W27&0E+33@2 $,(\_4[K^FGH$QV)AEXZ[8Y;')9M%HS
M=<2$U,EN25M-"*R0GFX2H^Y\DU^NZ4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E0[V(61_)&,B<M$%=_8CJB-7149!E-LJ/)327=<@@D;*=ZW51R+II>)U^O
M$NR9.JPPKXEA-T:;B\WR6QP[D=[F.RXIL);*BE>@E*DA*ALTEOTU2)67S;U*
MRMN6XM]1'^Q$O<3,:EI2XXIU6RD-I; 2$)"2#QWO=ARGHD;UBV'V5%_3#38X
MJ()?7'"C)2&FT>!S'%6VDD>5>Y&O8B'N7IDBSLO<OBKG%?\ BYJI,QB; +W)
M'Q:I+:6OS0E*DEQ:2I:5@@I(2E2039LNZ,MY9?+G<'+LMAJ>]"<<90T"4B.A
MY! 5OW4'M[UX*1X-5AOTWSI5LG1[CE3;\B2P]&#L:W=E*&UVP0$_*75$D =P
MG?E1(\#6MJ[>GVXS\JO]Q9RM#%MR%KX6Z05VX.+6P>WL-.]P<%Z0I/(I4-+/
MR[ -:]@],D:PY W/9N49+46Y"=$X0E?$A'Q7Q"VG'5.J"@2 D%"4> "H+4-U
M9,]Z,JS;)E7E-W1"<^$;C)9=@MR6]H9GMA2DK/%8/QY)21H]K7]+::C,],<F
MX6V(S(R1J0]'0E;:'8CJF&W42E/MI2DR.YV4I<=;X%PJ 4DI6GB!6_:O3O,L
M+MK8MN1185G:N<2\SX+-J"3)E,'?Y:N[^4VO2-@A:MHWR)4K?OD'0![(,HO,
MYVY6IJ#<KFS=2XFT;N3*VV66PVW+[ORH)8!.D;XK6G?G=>-HZ$WRSXW9K;&N
M^,1)-GD0I,65!QQ3 >5'0M'^T)$G;G)*S[*3Q._<'53-TZ69),<N+L/*H=K>
MOD9#%Z4Q:U+#BTH[?>B\GOR7"UI'S]U/RH.M@[@[YZ8+9=K=F$%JZ.PH]^7;
MNREMK9@-16T-EM!Y#EW$I<"CX_WAWOZW#J)TL_;Q^,M-S5;@Q#?B ):Y[#CT
M5SE[C7'X4#7_ !_N\UZX=")=QOC;R\B2FTQ+FY=X$,0OS67WIC<I\+=Y_.DE
M#B4@)3Q[NR5<4U.83TF.'7>9/%W7*7(BNQN/9""CG-DRN0.SY'Q/'V_H _75
M5_I]T#E8;'RE,W(475^_6QFVO240U-.[;#X[ZU+=<+CB_B"5;(2"D!(2/%:#
M_IPG3[.+/+RE"K8E*I3;;-NXN)N"HP84]S+IVU^M89UO;A'<(2G4AC_13(;#
M=YUR;S&.)-X?4Y>.S:0D/-F0MY+;')U7:UW'&R5<R4JWX4 JIK%NCXQJV3(9
MNJI295@@V(K[(04IC,O-]T>3Y5WM\?IKW.ZJ,CTVW"=8DV23E31M:4B2&VK=
MQ<^/,5,93W,NG\KB%J#6MA2_UE*0*]+YZ8XUXR^5?%W.*\)TMQZ9'FP"^%-%
MY+J4-_FI2%)(6.2TK20L?*"@$]R2-"LTI2L$;%0]MQ"R66\72[6^T08-UNBD
M+GSHT9#;\M2$\4%U8 *RD>!R)T*Y=EOIV_:Q@6AZZ0!C N*[BB.]:D/3XQ<>
M[[S4>45_DH6YL[#96D$@*\)U8,4Z33;1!O3-VOR;H_.M3-C9>CPA&#$1E+H:
MVGFKFYM]:E*^4$Z 2D"H_$>BEPQNY6=;^1-3+;;GOQ!,-$'MK7/5$^%6YW"X
MK312IQ0;XDA2_P!9"0*\)'0)<R1>%NWX%N>\MQ"$Q==M"KG\>4D\_F/(J;WX
M\$'6P=[G23H9'Z5NW!34J+*"XK<"*XU#+3R(Z%+* ZXIQ?-0Y 'B$)^7? %1
MJNR/3-(>QM&.#*0FRF.VIU!@;>5-1;A!2\'.YH-\$H66N)/).N822*D&O3X\
MS,EM"_MN66Z3TS[M =@A2Y);F.2F4-N<_P M.W$H7M*^01XX%1J#PKTE1,,4
MZXWD#LN0ZW"YO.,':G6)R93CNBL^74,Q63]A'2?/@#PS7H]?<3M]BF8X],O%
MXMUFCV%ER/#9=X);C26BXIMQ]L$++Z?9?Y90"0M)4*G<C].S&?\ 3W K)>)W
MPLK'H2([ZF05)?U$#?'8*?"7T,/#[EA/@;V(.X^D2'.AMQ4WB.$.6EB!*?D6
M\O/*D,L*:3):)="4%2E!Q04E9Y)VE22HFKW:^DUS18LD:NU_C7*]WN*U#7.3
M:T)CH;:;*&MQEK6E?ZUJ6"K2BH@<0!JLM>FAUR'V)N2JEATM(?0(ZP@,I^/2
MMEHK=4M">W<%I1R4LH+:3\P/$6KI)TE?Z7QWT";;I;LDMID/1K<J.IUMILH;
MV2ZLE6R5$D\?)"4I%=)K-*4I6#[5_/GKO;(-F]6'4$/]0\UZ8-W:R,Y'/N3=
MD@3;0_&@1FV2X@K*WE*1S*2.V#RY ;&C5)Z*]*(?J@&1WBYY/U&>LV0X=)L4
M+*<DM=JAPVX@N++A[ 8?Y;+K2]<D >5[(.@=CIGA^0^D/(\N=O$23A/0>WYE
M-D-7>WLHGO)0MAF,PY*2LK4B*04E*FP72X=*3Q\BFYUZB_V@NEQL6%]3+=E7
M3&3C<>WWF],64L3HTUM*N"G&"PV-S9!:CDH*^(6I0[9 552R?..I'H\MF)X@
M_(@85A-P0J:Y%FLJEN&5/99^,#23WDK5:G5?+S4E1(3R#NR*ZYTAS;!^EWJ1
MB]);5U"[5EN%RLEUQQRUV]N25J5%#DJ)+6ZUS:,]U]#WY:E!O03MK7&J%U)N
M]@]'<!O"9/6'J*U#@/E%JMMOQVS2T28[RG'7)+#BUD!H/%:5!:DKYK\)(V1^
MV/0W@5RPZP9Q<+Q&S5NZY!?/Q.5(SB'$C2I+BF4)+B$QG7$E/R@;.CO?BOT[
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K!]C7YIZO7S(\4ZHWR3:;C-A0Y
M[%G:ER5*[;,*.!<-K;<$5_AR>##:E%"]=WSPY)4*K^V74>S7$J0M-K?NDM$I
M^48K[34RX? 6U*6>!ANN%*D]Q7;XLJ)"P%)+9 \;#DV3]4(6*,?M3>;JMV[1
MI%QF)M;3*K/(3)6E#3!+/$I4UW-J4'/"$N;'<&YVW=3,]?BP')5UNJ+^88"+
M,+6GLR(J8*U.3EJ[.TNB0G6@H#:$HX?F#>C?<_ZG6"(U;_QN8IG27DWF?%X+
M7*7!C/-Q2EF$Z%(+BY!" A*E% ;#@.@?U/8[@;C;VW'%-JD)'!\-@A*'0!S2
M-^?!V/-2-*4I2E*4I2E*4I2E*4I2OE9T-U^75=;NI-QZD7+"8,6"U,2\_;(E
MP>C?E&5&[DIQ1'+?%<1V  /HMQ9^U05O]4V=W6WW2_MVMABS0.%S^&<C@NO0
M9BA&@)2>7ZTOH?6LGW2@#[U>L;ZI9-D/12_7K(X\!F[QG/P],%Q@<5OQBTQ-
M5PY?,GXD2 G1\)2C?FHAGKWE.*]R\WV7$N-C0A4Z0PQ"#*V&#+DQ&T)5R/(]
MQ,8DGR25Z !TG6G=<\_MM]N]KFRK%:IUNB]F2W<5LMH:*8:'E3 @++W$N*4D
M$I[(2 2K:5;U!U:O\O([%<#F3-J@S[8Y"?GSHC'PT3MW!U"I9"75-*)[;3'<
M2OM$O(4-!034A Z_YA L<O,+DY&F62(Y&@N6^- [?<6]!YL2$N%94 ](5'2E
M&M!$@>21NM+J!U/S%5CRJT2<J@P;LQ FL2H,*&&Y5M3&CI<_$2HKWVW5#0V
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MDM.K<;2XE2V]<TA0)3L;&Q]/'FJ?:>J6!WO.)^(V_)[',RVW@N2[-'G-+F,
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M]G"+2C%L2NJKH[^T]XC(R*Y*3&M$R'';84CX"220T_(0A;;J6SMQ#S+9*@H
M]TMMCA9]"SJ/EEQC>GQ:[=&?LUJ7:T85%OO,.*F6M_13\6V@]MA,A?+@EPK+
M?YA34A9.E]KZ:=3'[=D0:ZX9#C>&N7*RXE)EF_QI:'6F7NT6^2U1 REU :X(
M7\0@!T=L$"MS'[-A'03HK:SD_3!W+<OG!</&,,ND0L3+X%OOK=GSK44K6PXP
M \PS('-1;"  $J\?L;^3>O>)W7I/?&<$P>7B6'0[J6;5/N+13,O;/ 'XMY?%
M(6L**F]I*@ @)WXK]=4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5R3KOTE
MNO4^]]*I=KD1([>*YC&R&;\4I22XPW'D-E+>DG:R7DZ!T- ^:Y'U?]&UX>E6
M&\]/KI&OERMTRX27;)U+G2[K;'S+CAA2@#S+:F@"4) X_,H>-US]'\GGD]FF
M6*V6V^8]/LTB-CJ;]?KG%>-[C/6I85RMR_*4)>"4HTI0X)']*IWI]Z"[O9\Z
MCL7BYVFV819&;RQ:YF)JDP+]<47"2'N,Z0G6NR$A*2A1W^[R*[59>@D^R]><
M4R43_CL1QC#7K!;F;A+=DS_C'I+:G7G%K!Y[990GF5<B2=@C1KEUR].?6N7U
M+NF;MY!AC.1VNUW.!8;Q"ANPY5W7) 1'7=@ELMJ3%0!P0A*]J0#\H)%;O0+T
MFY+8\.CV/J.]$@R+;<Q>6;GA627),F\37/,F1<EK".ZI:DMZ3Y2!L:  K9QK
MT<2H7J4SW,;M.AS,"N\:>NUV5!4'XTRXM1F[BX?D  6(W@A1/YBM@;.XG$O2
M[U6<:Z=8)F&3XU,Z5]/[E$GVV1;6)"+Q=$PO_<+,E*ORFDH/$K*"2KMI'CR:
MLV>^F?)\IG^I5^-/MB4]2L>M]HM7>6X"PZQ$?96I_2#Q25.I(X\CH'Q]*W_3
M1TFS[IK=7&LGPKI1CMM3;4QDS\$9?1/DNI* GOE;* 4$!2CY)Y:\>YKDV0>G
MS++YU%ZA6S'DVG\4M>?,=0K;%RR,ZY:+RQ,MPC+:=[8)Y-/,O<2 HI(22/F!
MJL73^3@R]K%+=9;?>\2G.72PHL-_GW:WO..VQ(N#LP.VK6^' /%I*%%( :;5
MOQH7>Q^B[J!9.KSEYB958(%HA7>\Y#;<B1!<>R!V5.86TVQ+4O\ +=89*@K6
MSS#2$\4ZV*KEOIMSMF#=X^5C'OQ[J1D>.VQZWX-"?:@--0I?QLNZ/A8_W[B&
M5\E: 'R)Y*)!K]1^J/I/=NMO16ZXA9)$2+<9<ZW2D.SE*2TE,><Q(6"4I4=E
M+2@/'N1[#S7)?4/Z5L\ZD9SFLO$KWC\#'NH5DA6')$WJ.\Y+AM1W'"'H? %*
ME*;=4G@OB H!6_'C:QWTJ9/9>NEKS%4^V*L\/.;EDG9[KA?,1^RM6]M&N&NX
M'&RI0WKB=@D^*N\/TY0[AZCLSZA9+9[!?K?<K;:8MI3-B(D283\4OEQP=Q!#
M>^XV04*V>'G6A7,\L]&^3Y#A&<PV[M:V[S+ZH.=0K*A3\EN.XC@VA,>2XUQ=
M:*DAP%;1)2>)!/FJA>_0=E3B+5=K9$PT7>7;[E:[Y9)%QO"+:42I/?#R7D.]
M^4L?I=2\4H?V3I!\U^V<4L#6*XU:K/'2VABWQ&8C:&4%"$I;0E "05*(&D^
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MIKR6#B]NM[%MC*A,B&N7:H<B,$R7Q;$1W7R9#+C96EY))4I/-065@\D@&_\
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MY]];5^]0F$XEA][OE^O<.V2+#:47>\68RVG9]O;4A*DI<90HD*)4E('LI2@
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MZXOR15_RKI'=', Q''K!,BQEV<I#ZGEO,%\=A;:U)>9TZA16OFK@I)<')!4
MHFN'JZ"YM'Z9WJP&WVAYFUW9IZ&4V]Y3UP=0Q&B[=1[+C%(6LZ45%*$H_H%1
MZC)Z%Y+<)]UN+TRS(DY*M*;PTVTZI$)M+J%I5!40#W"$;45A(+G%?]#B?>U=
M +C"F*D*N,(J5<8\Q2FV5A7!M4PE&S[_ /NL:^GA7WKPSSH5E.6=-\<QN-=+
M=&>BXZ]9)KA7(;0I:V6FPZE312XXV.VK;"U)0ODDJWP /OG_ $[R+,.J$IN+
M&MT:SS<:BVV=<9<=:GV@);KBA%<2-<P #I6@"6E_T>)TL,].EPQB]VB5*G19
M3-IEH[#KLB7(=D1T)E <D.K+;:]R$'BV-;#AY +"1\6_H5E=HB(>BR<>5+C)
M<AP[=(;D.P&HRX_944\RIU&@ 4,\E(;27&TJ 7R%EZ>]$96"WJT2A/:EL0'+
M@HDH(>=3(1'0@J5]5 1_F/[QKVJEH].65B]3+J_/L\Z2A"VXB5O36-$S ^'&
MU-* AJ""I(#"2 K95W L@368],LJD2\!M-O%FN+L/&+G:+A=+G 4&4=X0FRI
MM+8TA:@AQ00=!24J3M/O7I,Z#7J##?-HFVJ5*><N,<B[QUN-F-+:8:4XKCY4
M\D1T_N4%K3M.]BMY'T0R'#;#E%PLLD7#(;FJ(Y:^W&6ZN+/C.!$-?+CH-K;V
MJ0I>AS4XKV6:L,STU*79Y%FA3X\*W+DO%"PP5.):5:&[>D*'CD>3?-6SHI)&
M]FO.1T-RNXY(K+9$VRLW\R!.%O82\8/=;5$#2-D!7$HBJ*E\=A:FR 0CS7;?
MZ5[^VY<%2[E:W/Q1Q^8^B,[-98B2%*DE"68Z7 VM [Z/+@)!#OA06 GJN4].
M[N[9\179%VQRZX\V6D1KHVLPGDKCEA9(0.0(!VG0\CDDZY;%(C^F^Z1(=QA(
MND*1'5:)=MBO2&EET*>MD&%S6/8 &&I1"3Y2YKZ>?FU>F^YP+\B0[<&),2%=
M4SX;LB5+><4A5Q9FNH+*EEEL[:*04)/(A"ODT0;KGO2V?E>>8U>F),1$*WEE
M4AE]"BX2U*;?24:\>>"AYUH\2*YN]Z9LF7(L[/XS;E0(*6%^\A&UH#Z5)[22
M$+)[P(<<Y% 24)2 0H7BU=%YULP[,;(F;%2J]V:/;&'&FE!#*F[>(O(I^VQR
M 'T\57;UZ=[S=[+;DBXQ(EQA29]P_P!E6^RAU]Z?&EH074<7 D?#E!6/FV4*
M /'B;#(Z'*NG3NQ8S.<C]IBY/SYZ$N/O!P/"3S2EQU2G%+Y2-\U$;*2=)V *
M)*],V6NV9M)R"W2;M-AI;N\I0D1_B92T2^_("VB' DKD@]H*2%I1Q4H "I)W
MTXWYBQQV(5UMS4QAYY\K[2T!SFU$;XA8!*%:C* < *D<D*3Y0*J.0=(\IQ5F
M/9(L5-YFWF8VX^[\)+DL-(-Y^./"0LK*'4I6ODM]20HH;6DE2>W5OQ+TU7*P
MS;>Y(G0Y0MBPS'D./RY#C["6)C:%*2ZM2&E<I2%<6QK:7"%?.$IU9GIAO*+=
M"1$N4)3L=EJ*8P>E1&%M_AD>$LDQU)7L&.%!/L4*4@\20H2LST[W)JSO1($Z
M AP"Y=HN-N *+\B(ZT%G95X$3BHDD_,GR=5<\RZ6RLERB;=&Y+#29)LNMH/<
M2F%->D.#E_Q!T!/V()-42+Z=[Z\;9\=.M*1:+>+/$$5AP!V.B%-CMO.@^SI5
M,!(3L)"5@$\_'N_Z<[@ZIE*9UO2PVZPLM&.KB4MLVILIU[?_ +M7H?9Q'V-:
MUQ]-5SGY1<)B[LE=NNTMQ^6TF7+8,=(N#\MHMMM+2VZO4C7YGA*T!0Y E-1T
M7TSY'"L+;#$VU?BS++5N:N+TNX/.HCMLN-)<05N*"=\P51N"FE)!0HGY5)Z-
MU&Z33<UE]]B9&85^!/6D%UH\@I<B.[S''](TP1H?4I^U4K%O3OD%OS:-?+K<
MK=*1&D1UA".^OFEEZ2X%)0O\MC?Q TTTD)04$[5L$:BO3'>8=JLR8=RAF5;(
ML&*EAMZ3":=#5O,-PE;!"T^2%) V"GDA6N7)-APSH=>\2RW&2B59G<=L4J5.
M;<+#QGN+?BEDM<E*4 A)/@E2E%"6TGRC:O$=![T[>[67YMM-KLER,R"I+2S)
MDH<N+4UT2-CCR26N*"G>U'F>)\5*7CHO=972VW8U&GPQ.B7!^6774+#2D.N2
M"1X\@A,C^!*=> =U7,B]-]WFK0_"N$0K;X-)BJ?E1&5-&W,Q%[5'4E6P6 H)
M_24*4@\20H6;,>A+F50'8+5R3 C_ +*JQYIQ*5E:5=UI:5[Y<N'Y0!3SY$']
M6_-5MGTWW2=*@29EQ8@_%2G7;XS&DRY:Y+8[2XX2_(45*6AYAM7)02.*E )W
MY/M@WIWN6/&T*N,F!*<M[C32E+=ES ^PU EQ$$ID.$(V995VTZ2E(4GDK8(@
M5^F'))3*%2+G TN,_:W+<S-N#45J(XVRDE*T.)>< +'AAQ92E"PA*P$ GH_4
M+I7=<GR!$FWR(#<&=$B0+@9C:U2&&H\DOI7&4/'<45J!Y: *6U;/'B?.X])+
MJ_TMMF.,S8?XC#GIEEYQ*PRL?$+<*?'S#Y7#K]X^QJL.>G.Y(; ;EVF0ANUM
MPD1I4=WLJ6W#9822$*2I*>;(4"DA2?E(\I%;5]Z?9=:L8Z>1(:+9>;W;\H>N
M;J[BAUV,RA4><1S=">X5)[J$!]22I2RE2AM1KXL/0>^X=;V'[7,M,Z[P[DU<
M8[<UEQN*Z?@3%<0OCR4E*>:U-Z"N*0E)]R:KL[H#<\)LUXN:9+=VDBQ-6J/'
MA0UJ>#L8-*AO-!*20Z9#:>>_E[;<<$Z8V>U],L>N&*X;:K;.0RJ4B(EV8ZVL
ME3LUQ2G)*M:UQ+BU*!WOR?W;YC:_3E/@XK$M+\FTS%MN\W?B8BW&'T_@B+;Q
M6@*2I2>:>9'(?(= @UISO3WE-TBLNR+O%^.;W("$RY6TN(F,R&FC*&GEITVM
M)=5^8"6S\X1HQDSTMY!<'X49R\0HUK2XB2[\._,4ZVM0D!X)"UD/+W(*DOO%
M2AKBE" 04VZV=%LAN%HSJ/?95EB2<A@PH+/X+%<#38C-J0E3H605A6QM(UI'
MR;.@HSF"=,[W:\W<RN]/VU$V6F:J5"MJ7.PVMX04([96 3\L'DHD E3G@ "N
MIUFE*4I6#[5Q;JUFV76G.85JQ^ZP;9$+,!3OQ-O^)4M4JY-PR0>XG00EPK ^
MJDIV=;!YQ#]0V32<BL%LD7"W2A)W;YL545IKFOLRE%X)+Q=)5V6S\J RD*4G
MDI6PG7Q'/LB5<HT*U2X5NF7F<PE4QR'WS&#W9YI:2I8 2 /E2?"3Y\^QLF!]
M;\AR/*<%:G7BT0G;K,;A2+%\*/B);1M;LI4UI17R0DO-\=<2D!"D[Y'Q#9KD
M63V;J?F4^VY,GG9#>)Z(DF,'D)9:MEJ>3'X\QQ2I15\^M^5D>5$U/XYU?O1Z
MDVNSKGVN-;IERF1TVR'%2J0K4R8CN. N!8!#*2'6TK2"'.X$\@1#Y%UYRJ'<
M,R9MV2V25-B7.=;&;2W!"G[4TUP[<M_\S;@)4$D$)2KO-Z((/*1N?6?*;-=;
MQ&5?K9+F1/CVU6<P@F1$^$<0EAUS2RHB9M*4CB/,IKM\N!Y2.#=9,GO^3V*T
MSW8T9Z[\KPXV8I3^'PF0ZB9#6HD O,2$L-*60#^:3K0JU]5L^OV*WO'XUI>C
MKBY*1;(#RV.ZEJ<IUM25D@^4?#_$N:]OR/?YJH5@Z]7LWZVJN%YM*[;,E,KN
MC?8#)Q\+6\CX20X5^%DH2 I82>32_&EI"9#*.KV6KZ/8'D-GGP(MRO%LD7*2
M^Y"[S;@:M[LH)0CFGB%*;2"=D\2=>=$5?/?4#EN"6B6F1>K<_<K<Y+D<E0FH
MZ)B&XL-\-GN/> %2U-\6@MU8""-:43T7$>IF47*5F;,EAJ>]B45Z/)8CL%LS
M)W)UUD(.SI*HR8ZM#?F2/ZNJYO/ZC9)<Y,*_VO/+/>7K38KO<W785K/9/%B
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MM7D_3D20/85**AL*<6X66RM?'DHH&U<3M.S^X^WVJ$.#6M>1S+VZVX_-DPS
M_,62AIA2N3B&TC7'FH)*C[J*4^? H]@]L?N5BEK0X19 KX",%GLLK+9:#G#Z
MK#:EH!/L'%??=3*H$=:'4J8:4EX\G 4 A9\>5??V'O\ :O14=I20DMH('@ I
M'BOA<)A925,MJ*3R22@'1UK8_N\?PJ,QS%(.,"X&+W7'KA+7-E/OK*W'G5!*
M02?LE"&T)'L$MI'TJ33"CH24I8;2DE1("!HE1VK_ !/O]ZPJ!'5WML-GO#3N
MT#YQK6E??QX\_2OI,1E+J7 T@.)1VTK"1L)V#H'[>!X_=1F&Q':#33+;;8WI
M"$@ ;\GQ^_9_QK"(4=MM*$L-I0E(2E(0  ![ #["OIJ,TQW.VVAON**U\4@<
ME'W)^Y_?6&HC#( ;9;0 2H!* -$G9/\ >2:&&P5+466RI?ZB4#:O;W^_L/\
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MMYV?\:^A%9!!#2 1[$)'CSNHJ_8C;<BLYM<ICC"+K3W;8/;^9MY+R?;_ (T
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M<J\,QV50OB7(!G,LA1="RI;25)!X<0OB%$!22=6Q>M#'+U.L<1>*Y/;G+E\
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M6U$@%:QY2M23\+](73M>(Q,;,2X"V1<>F8RV!/<[@A29#4AT<_?F7&&R%>X
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M^TADSIT:&'UAMHR'DM]Q1]@G9&S^X5[&X1A-3#,AH2U-EU+!6.X4 @%7'>]
MD#?[Z2[A&@=GXF0U'[S@9:[JPGFL^R4[/DG1\#SXKP5?;:F48QGQ1)#H8[)?
M3S[A3R"-;WR*?.O?7FO.1DUHB*4E^Z0F2E\1B')"$D.D;#?D_JT=\?>OF=E5
MFMCS[,N[08KL=*5O(>DMH4VE1 !4"1H$D:)^XK"<LLB[6NY)N\ VY"N"I8E-
M]I*O'@KWH'R/&_J*\$YYC:XKDE-_M:H[:DH6Z)K10E2M\03RT">)T/KH_:I.
MW76'=XJ),&4Q,C+)"7H[J7$'1T=$$CWK:I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E8/M7Y2]2]HQS,/
M4OTBQKJ*B'(Z?OVR\3&8%U<"8$RZMAA+27@HA*U)96\I"5?7D1LBN+8-C_1;
M+^L>!8D_<6<HZ*0\0N,C#HV4R%+@/W$71QN8EOO<0Z6&N*6@=Z;)*2=<AS%^
MW9-E,'HU Z=7)Y;5DSC,WNGTEQTO)E0(+/?AQPXHDJ9<+3C )/Z2!Y K<GVK
M#>LOH]ZJ]1)&,PY<N3U87)MDBYPD_%PV)=TMW>:\C:2I*U(6/KYJT>J_IK$Q
M#U!3XV&=),(RZR8MTM^/..WB(H,1&!=)2G'8K3:?+H*UJ*=I)'+1Y$ [?1KI
M]TJR+*[SCO6"^6G-;!CW3^PC%+AD+X98=M3L9QR;.BI6L<5=X<"L?.A+;8V-
M5,^DG+9KO5#HA=\PN:FY3W2>Z(;FW=X(=?CB\,B*I2ED<E*82TK9\GR?O74_
MY13')/47I[TELMEN_P"%3[MU"MC5ON[&E_#/F-+4R\DCW 6$'8^F]5^;,$ZH
M(S'K%&S/(XZ<:D_Z7+'&O#4XAI$.>WCC\:0V5'P!\2AQ*23Y\:]ZQUKL#75*
M?F46RR&Y2IW6J0+=+BK"D*EL8VI2.*QX)2^VD'7L17-.K%\1U9RO+^HC46),
M3G=FM\Z-'NQ*8ZX[62V^$RVZ=;2V1'7R_<HFK5GM@.*XQUOQ1_'L&M-QFJP^
MX-V/#Y9=QH,_BJ6=O$I"D/K6K3FT#\KB0#[F]=7>E$BV=,<7M;73KHY;+G=^
MI./QD6S$9#CUNN(XRPANX'LA01M:AX2KY5+\?2N]?R?6."U6_JC,?@6O$KJ[
MDZX5PP6QM+:@V%Z,RAG304?F[Z0EXN) 2H*3KV-?KH5FE*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*56L[
MZ:XIU0LIM&78Y:\EMG,.B)=8B)#86/90"@=$?<>:C,HZ'=/<UQ>W8W?L)L%V
ML%M(,*V2K<TN/%T-#M(XZ1X)'RZ\5*(Z;XLU)QM]O'K8T[C:5HLRFXJ$_AR5
MM]I88 &FP6_E(3KQXJ/1T8P5O&[ACZ<2LZ;'<+A^*R[<F&@,/R^XESO*1K17
MS0A7+[I!^E37[&6,96O)OPF'^T*X0MJKGV1\0J,'"X&2OWX<R5<?;9W5,N7I
MFZ3WBR6:SS^G.,3K59E.*MT.3:VG&HG-96L-I(TD*42HI'@GZ5N9]Z?NFW5.
M5!D9?@UAR1^"S\/%7<X#;Q8;WO@CD/E3OZ"IQWIKBS]HQRU.8_;EVW''V)-G
MBF.GMV]UA!0RME/L@H22E)'L#H5&W+HC@%XA9'#GX98YL7(Y"9=W8D0&UHGO
M)'RN.@C2UCZ*/D5ZVCHY@U@M5@MELQ*S6^WV"49UKBQ82&VX4@I4DNM)  2L
MA:P5#R>1^]0TKTT]*YUG:M4CI]CKUM:@IMB(J[>V6TQ4O_$!D#7Z ]^9Q]N7
MGWKX@>F/I-:\2NF,0^G.,Q<?NKC;T^W,VQI+,I;9"FRXD#YN)&QOV/M6<:],
MW2G#0D6+IYC=HXSHUR'P=N;;U*C\^P]X'ZV^ZYQ5[CFK7O5RMV%6*T9+=\AA
M6B'$OEW0RBX7!ED)>EAI)2T'%#RK@DD#?L#JINE*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2O_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>proxy02_def14a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy02_def14a.jpg
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M2A*F21Z *DJ!V!]&J'8NW8J^-X+(;Q&,8N26U,E]MJ[K<D6Z2J),DH;=2(_
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MHO\ UM;M^Z47^)3^:GVB_P#6UNW[I1?XE/YJ?:+_ -;6[?NE%_B4_FI]HO\
MUM;M^Z47^)5?Q2!K+HMVM]*,.R_6NX:D6'*H-X?>B/VAB"EM46.%(WX%15Z2
MP?6-N/R[U[?'JJ:4I2E*52]:;E8+-I%FEPRF U=,;B6:7(N4%[;A(CH94IQL
M[_K)!3_MKRC;.T5@EKR?#!>],/ YN-7ZX0)<L6Z3(7:Y+UF-QF.Q EHJ=*UK
M4VL>:N&SIV2M-;2QZ/V=,IN&':?VJT6&<W;4FX8_$:MB^YM*>93,4VRZ4],N
M*:<1(4R5%104K*=@"*=F-UNF$X+FN-95HY"NV*3<@XV*'.NR'$7RYS;XONP<
M'$AE!4MJ021Z()&Q(\^U:I&F>DT#&G]6-.<>P')+"_+CV=5G:<ND<0VU(>=N
M#;C;74:C)<D<ENR$)Z;BBHD%04>R_GW9PQF9)ML2UJC3++=8UF:7;L:G/EN?
M;F7U1VXY2RI+JX[:7BGAR"0?/](;UK0>;HKH[D.2.MYI!OC^2V2,IQ=JQU4&
MV&&W&D34-_$I+1DN,///EODE9;">+:$@"L]+S#LV7C$+:PK%%S+3?;=%3;H[
M^+3VD3FX+#ZH+#2W&0 L,MO])((4I!.VZ5>>!L6J>A.I6.JNN58!;H$&9:\;
MEQK8;7(EW!Y;L:68L=$5M@%0991("%,\DJ:4XHA*-N6=R/(^SJR_'A67';)?
M<CGXW#L]F:1:WNZRXLR(\W;HAE!!:;0^VAQA!4H*"5*1N 2*QN/XV<QUJM=L
MU2T]@8ZSD^-NPHUD,E,IAQ=J>9=CNI4G8MNI1/D)2I)WXMJ]0VW[>B>K>FV!
M9_K$Q>9$?$Y,:ZRH+$;NCB(+-IL\1AL-LK".GNA+RG5-))5\?N$[$5F<;S[L
MV86Y86+/;H5B<5,G7QE#5AE,&WR(:%1Y3TK=L=U+*'5(/6XA*7  -E#? :G:
MYZ'Y#J=I]D&0XS O,:)&NKRK_<;))-QL;\%4-T(<CEDNMH"90?*G$A*$I2X/
MTMZO^'1] ]1K]<(5ALMHN-TR\2KC< FUK0J6(,Y#;RWE%(X\9?%0!(YKW6 K
MS56#FZ@]G>+*N+TNU]&X1+E&@N,.X[.3*<D2YSD^,6VBUS<2[,CN/)6@%*G$
M;[^K?J,9AV8KUW&QMP+;(C9)!A-H(LLKNY8E3Y#D9+SO3XL%4[KD!PH4EY1'
MD2*B9J!H3=+0RK'+'8[FU'EV#'2R_!D06A 7<]H3D?XDAYA,E+BVE('34X@C
MJ)_2K&9KKWH'G&28/FK.)'.\D1=K3!MUR5C\A$J&U-6XJ-*07&07&PIEXHXA
M7QB"$['<U=\IP/3.Y87;C:-/K?<G;M-=L,"'<X3T()6N>Y*>4OFD.(;#[#LG
MDD;K*$E!]-)K#08.%X!<583EVG%FL]NNMG=MTE=KBNS(#\%N4CIA2>!Z,?J3
MW20YQX+*]BI.RJ[S</0ZT7JQOQ\3@(>L+S\&UANP2#*5):EE"@R.'Q_&075!
M1Y'J<UI.^ZJ[VKEPP^!G>"YJW;<.C7R=&?[IE.6!44QVFVPI*0HA)"]GG-N6
MQ0"X!MN17'9,KT]A:=X/;)N(M6AVTML7&S6I,%]4&!+"'A&#;_ )2I8ZA;"M
ME<5C=(Y 5CVLFTYSC(F,HR_$K:YDQC&VP^[0'ILY]I;6_!'!'I#B](3MMR *
M]M@H[VK+L-P'3[3:;G-AQ2SE=HM[%Q@K>;4PA(C0UQXRE']) ;CO.-CRW"%*
M%4'#)>D-NDOSKKC&*S9M@81CT2YXI"=NC*H*8G)302E*U)2RPZM"R00E#P3R
M^,**M2Y&AF$85D.#(L4:)B<AIZ1,@Q[/(7$N(V:ZO36E![RH!;(/ J.W%(_1
MV&1R7(\%U.U*Q;&9N.)OCST>Z1^]W& \VAA!CAN6RVM20A2BE?2=1RY)\P1N
M#MJA]O3!W')5Z?TOQQ%ZN&0KQ"='6LI0JW%U$=Q]:MAZ)AMLK4D@ J2E)5Z(
M56Q,BNFB%\9N%WN]C3.>N,A\/ARRRER)7>;>MIUX-A')3;L**XGJ <2AHC?<
M55W;KH9+U$>F'"HDAN[6F4;C=%V.45AGIQF7.\-EO9$=<9YA2G5@)4C@3OQW
M387+1H'C3UK81BD(+Q>8LVDL61YXJE+EM(=[LH(/>%B4MCGQ*^+G%1V*=QGL
MDT1T8PVQ76X3L(MK,>\N-LR&8MO<<?F.JD]X;;0TWNLKZYZ@" .*MU>6Q-=;
M&L.T4S>^6T6G$X%PF8^T;I$>79W0B(J2\M\@*6D)ZI=4XX6E;J0OD>*55KW3
M!6CD#"X$YW ;;BLB:A=RCQG+)+,1M0B2@RVZM2.*G>YKD#@/6VHA(XE JSXE
M<=+\?PJ_X:YBD"#8[K*D6]VPVBV2)2[B"Y*9!4E"25!;4)8"3^@EOCY)XUFK
M?%T1R.^Q,>BV6!<'+RW< R?"WEQ)/?6FY<YLNE/3YNMI9<6@G?\ 1\MP0-B8
M9H[AFGLB,_C>.P;.['B+A-KBM\2&5O%Y:3Y^?)TE9)W)422:N=0KU5Y3RGLS
MZB7^VW+#TW;&TX1%G7B]6B00^+BY)F-S.E&?'$MI::>G.*+J2I2TH0G@D\B=
MA=G70!&@4O)X=O8AMV.Z&%*8*7G7I+3R(X:?:4XZ2I3(4@.-[J/'K.C9( WW
M92L3EC=L>QF[(O30D6=41X365-*="V.!ZB2A(*E;IW&P!)WV%: N?:%T#B8U
MBZ)ZG68./3GTVRWN8].Z]KDVZ,@N$L='J,EF-(2K=20 VLGU UT+5J'V9K=+
MN%KC>%6]JT-*4X^NVR6HB4VU[Q'BV^4=-Q3+DCO 2A15\;R .]8^_:KZ$6K$
MX5K79K8U@4Z==;M=H\R%+BR+;.A%F0XKN99YH="W6UD$MD!25)"@JJYJ-K)H
M;%CR+=!P!F_QS9LE=DNSK7+BL0UQ)#,R9&D;LJ<9YR5M/*6$$H/34 2M .R5
M:R:"V]$;$YRH-K9PAZ3/9CN6J0W#MTBWLI=?++O3"%.--R O9)*B'-]B358D
MN:"QM-,EU#Q7"[0\Y@3 MKC=SM\JUJAJ0R%!A86T7$;-3% GIJ(#BD^K<"KV
M[5' ,7T^U*SQ[2:,U9\*R+X/6^%$@2.\R"RT+0'' XT$)3W=8:XIY\6]T*](
M@'MXEKUI;BNE&J.*L879[%'LSU\1\&I462S"ND2(XVRZIUTL+'/@XP'&@%K;
M2I X[ ;;BTG=T=G90Q8\)LT=BX8B9\2*]'M$AF.RI3R&YZ69*D!MY1=0A+I2
MI1Y)\_GJB1=2NS-FLV]Y.W%AS+E*3UGW'+',1(N)E<K:>@V6P9*G-EQE=(*)
MVV5ZMZ[6/:O=F_!LJ5?<>9BM7E^S0'1<[389;RG(CX;8AM!Q#1'4=+3326O)
MQ192D@]/RP> VSL^XU>KA:;@8M\OVH4J8[*?NN/OM+Z%QGO+:@RBMO9CFZA3
M2$O<%.*83L"4IJX:1SNS]JD]/Q_#K+;9FUA,1Z)*LKS#<FV*EO!:1UD /-]Z
M2_S(Y'J<B3N=ZK.D=_T"U%CZ>6UO$K*F_L,,W>#&A6J3,BVYZ4%/HYRU,)2'
M'>@71UN*E%I*MMPFKNK/M$L'S>^@=VM-VQHW.5<+J+;)3&ANR$MS)Z3*X%KJ
MK'1=6@**CZ.PW\JU?:\PT(L&%Y9+SJ\G)DYO?9ESNZ9N+R8[C+T)ICDV[%0V
M7(W=V0PYR7LH\E.[^E5GN^6=F6X?!NYSK=:>5H?598!59)#2K6F')9.SC8;!
MCL-/.QR'' E"2^@@^GY]C*M0NS?=LMR7+;XBW2[[CS03-N[MJDE:VD/J@J6R
ML(VDI0Z\N.I;7/B5E!(!VKEM^=]G2Z7W Y#4&WMW>SD6&S*D660V[9^C($1I
MAX+;'=0) #3?6XCJ'T#OO7I9&P2-O57U2OE7J_VC_KKR[_@]O_);G'_/Z_\
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MN86W=R-U<>HGTT)KT'HUV>)6//ZKS\H@LS[WD[Z8+5QF2^\KEV\6V*R4.$
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M6TXMEUU/-"6E(0G9O;XQQ*R5 I0I.Q-=B=H:_P"0V5R-;\/9:R=^VBZ1X1O
MZ0C*BH?"B\6=@Z"XE'#B4[D'GQW(F;K#DMAA:6/)C,7@9!9 N0VZ\&''YSG<
MD,CD&U!""N2HJ(]0WV!( -FN&L\B#@OC"K*PF[-W5=F?M[DY1:1(0ZIM?!Q#
M2G'4^CR2&VBL@C="=E%.KIW:;R1MZ-D)MS$/$5(MTUZ,M:E3&X[D*>](1QZ7
MFOG&0$^8]7GQW(%K<[2=U1:U.IPM1EQVYLB4A^:]&:#,:.R^M32GHR%NDA[A
MMTTCFA0Y<?2K+V+52]Y9J=C;,6"F%B$^/=NE(,E*W93D9UEKXQHM@M>D7"DI
M6K<?I!)V%<NHG: 9TZS-NU2[.J5;$H:5)FQGU+=9YI<4"6DMJ2E(#>WQCC:E
M%7H)5MYK;J1E]QSS$+;.L4*R0;@U->E-IN(E+4A###C*DD-@@\G5I4E7'S3N
MDK3L3B/YRLER\W.V1\63)D-/-M0E(N"@T_RN+,'9;I9Z8(4^E9#2G@ ""0KR
MKKW/73(;[$BMV:Q(AKAWNVVZ]R?$$J[H7;D(SB64J:^/00A0*CTU .I(!4"$
M]Z\ZQ938]2,JL,6Q1+XU$8:F063/[LH,(C]22I:BTH<^:VDH3N0>6Y4@ U8<
M@UOB6<V4L6UV6W?8$>9:E%SIF0MV0PR&B-B4$=Z963Y^B5^7H^=$R;M)7B#;
M;/<Q8V+9;)+D6[!U4SKN2+,L/%:P@-#@_LVV>GN1LX/3W"ML\=:;WD.D6=WR
M#8UV2^V6VOR(PE![NZUB,76U)6ZPV5<2"%#@1R3L"H'>L:WKQ>\9LL)E_'#=
MRZZJUP)S]X3U)TQF0U&?ZVT=(:1S4ZI*PD\@T=T(*DBK1J9K6]IO=[/"=LB)
M_>DMKE="6HN,I4^VSNA"6E;@%9)6Z6D;)V"BK<##6/M!W6_3HML;Q-EJ[W3B
MNTL+NOQ3S?.4%J><#/Q)"8BU;)2X3S2/([[1BNK^1G3/"I!LR;]EMZBR93L2
M1-1%0VAC<N[NI;4DJ!4VA("0%$[DI )K*8#KJK/<GC0FK'W2SS^\^'W S.;K
MW02PM16SP'3!2^-O34=TG< $$TJP=HZ^8YB-H7DUB,FXWAU]JSR&I2G>^].4
M6E%Y#+"E, (4A8"$NDI\OT@17<QCM WJ3E<QV?8W&L?DJB,H1*DB._!D+BON
M*1TW&D%395')ZCBD;!Q*N.P5M6,H[1V4Y%C]QD6"(BQ7&' F**"\I;#JC&9=
M9=0X[&2H\.HO_BRA2AY%:?5MF]ZG3\.NK%G-J-UCVYB ;O<GYX0XSWIXQVE(
M0&OCCR0I2S\7L/, D\106]1\]MNBN'WJ1(8=O5Y<GO3WE/)6&$"!.D-I9V92
M-DJ8;(21ZD\2I6Y57.GM/7*R0(UON6*.R<F:8[Q)B0I+TI*V4QH[Q4A3,91+
MJC)0@(*4HY;_ !@&Q.P\JU4EX[DN/P$V)2[9=2RDW23(4PAM;K@0EH?%J3U1
MR"N#BV^0/%!6K=(UKCW:/R*U8#8EWS'6)E_>M<";NBXJ5WIM]A]?/@U&4OJD
MQE[MMMK2D+22M(!([\GM3OB.'8V(NO&2[Q@-"4ZXX\VB&Q)>4M+,=PMD=Y:;
M2/2"E;DJ0D;GXQ_M!WB$J]*NEE<F1GYD[P52I(:?<*'HS;4=UKICH^E+0CF5
M*(*%E0]6_:B:VY%)U&<L8M#/BZFA;T60SAW5,U*WW%N=ZZ/+IF.VE0^+WW(3
MQ!W-5?#>U?<V\-<D7+')EVG0(DDS74*<'&8VPY(+*EIC]!+0 ;:ZO4WYJ'Q>
MWF=G:B:HW' D65V19C*N<J,ZHV^-< ECJAR.WQ+BFMR.3XV5LG]$[@[C;[G:
MQRH.GBK\Y9HZ;FW=7;.Y 5/460^W)6PHI<2T7'$G@5 (:*SN!P'F17K9VDY%
MUQ=W)6,2>%CAQT^(K=G);DQY*FE.):0TM YI_P 6DJ)2H%T>AZ*MLE=-:[[8
M9C\6Y8C'9<M;:)=Z6Q> ZB-%<>Z;3K'Q04\HA+JBA0;(#9'GR3O5\BU^RFY8
M0N?:L<8MCS:($R6]XJA:HL23-++:DA3(2XLI:>4M)*0D;;+4?5V8/::N=S<,
M.%B#,BXJ<3TPNZ.-QE-*C2Y 7UE1AS($-2"6TN-DK24N* )&1D=HYY&/NY$S
MBZW<>=<;A0I*IOQ[LQ:F4):6PEM2THYO$<V^H=FE'AL4[Y&ZZ_(L6FL7,+A8
M)4>,J6]"DM.=1KHK2'0VM/4:0M3;KC;:$**$D]=!X^L537.TC=,MM%LGXY:#
M"=EJCMH[[)!9)[W:VI:".D5<VU3G&0?+TFG-QZMK;I#J;D>3X047BVLMWZ/8
M(EV;D=\#B):7T/!"G.+:0THKCJ*DI"@ I.Q)W HN*=I#(\?QN5?,PM3<ZVEJ
M)M(@R07$2%62/-6TAD-#="EESTRK<*< "2D;BVY'JWD5\T3RR]6BVFPY% 5W
M-HOEY+/-1:^.:6_&2I20ET[%3.W-!!! W.$NNM]_<QZU-LQ'+0N4F-+@3S+1
M*<G0^J6EJ=3TDAIPDM*X@'R<]8(4D=JV=I&79\;L]TO=DZEC>"(SE[$Q(67&
MDM]\><8Z8Z;:-WU@A1W#*O)/)-8^'VL1?,99R")C$U CM.]>$9J4?UI,>0Z8
MRRIOUA#;2N7EMUT;[@'>P3>T/<X@F-)Q)I^9:);<>\MHNNS<=+DQ,9"V5*9'
M6\BIP@A&P01YDC?L:QZLWS'S/AX];0ZU:IEK3=;B9:6G&&Y$E *6FU-J#F[8
M(424\>H"GD0=L .T_-A0&$HQ-^:\ZI2(B>]NO.R$-16'GUK#,9?!7*2TVD;;
M*4226QM6;NNLN2WBQM7+'\>9BVV5=(D*)-N$W@ZO_A)B)(0[&+?)L_&.!.Q7
MMQ)5P/$*QC7:4DP,55?!C3TVQQ4*CO2WKDD23-[JJ2AKIAH H*>FDN;C93@]
M$A)-62\:L7=O3;-+@NULV?(+,KN2&FY/>F0^ZRPXPOF4(Y =Z;Y#CZTJ Y#8
MG$W?7NZ8TA;3>->*QE3';1;)K]S2TY/EL26XSW60&B&4E:G5!0Y[AH^BGDD'
MM:SYMD5MDV^R6):X%UG)@]5]$M"6V4.W*-&=X%3"_3V>(2LIV )/'?:N3,NT
M O!\BNL:98%/6.V*;8>N*)@ZRWEPW)24I8X>:=FN)45C8J! (!VRS6KLR!CV
M22+[8!;[W9'X\=RVPYHDMNKD!ONX2\4(_24ZE*MTCB0H^8V)H=AUORR-FUYL
MMTL*'[NJ]MVZ/!3=4]TCLK0D\PZ& I?DAQP;I!/,)V&V]9;%^TE*S1F,FTXD
M^J5=%L>#][=?CQY#;J'G077EQ@$+2TPI:DMAT>F@!1W.V.@:\W^)D4^)<[*E
M<U^XN0+5;VK@@-A1;MG%M]Q+:AN')JR7$%0 "ALH\1658[1-Q<NCL0X?R$)]
MB#<.E<TJ<;ENR),=+3*2V ZGJ1QZ:E-CBZ#MNE2:^[IK%>;UHCFN0P[>BR9!
M:([H1$3(+BVG@TA:4+#K2%-K],)(6WM_I#DD@GI7?M+3+!,:A2\6;5-9G+@S
MV8UQ6]TCUVFDK;*8_I(V>2I2W0R@;*2%*(-?=Q[4+#3$),#'W9<V2EELLK<>
MXM22T\Z^PLM,.KW:2TD;A!!4ZD'B-U#GR36*_P!LR.T72!97I...8HY?[C!F
MOB)(AH2XT5'@6U*6\&U+'3)0-T$%0)%="9VKHS+TWN^-S)$0REP;=*#<O@^^
MF2F/L\1&(;2I16I/2+RBEM6Z0KT:R=A[0\N]7VWQ%XH["A.O0XDJ1(E+;>9?
MD+D-HX,K92I;?*.#S5TR4.)4$[@IK=*3R -32E*4I2E8#.HMAFXE=6LF#'@7
M=U+EJD**$(;3Z15R!!24D A0(((!'F!6I<-AZ/W7(K0FQ(MKL@R7UL;R)*7W
M9B'>;R7FU[=1:5M=0]8DAQ)4!RW56>N.8:529\B\R[C +J8J;N[<%AT-AI$9
MQ(67-N&XCO.GCORX+Y;;$&N/373_  ^\2[IDEN<C7)A]^%%CLM1W(Z82+?R3
M&:4A9Y%Q"EJ42H#?T"$[ $XAU[193M_4EV,I^3)1UQ&$HN..I?6H&($>EY/)
M=43&\N063Y[UU\_R7!=(-.EPK' 0S;[[89KL1ZW\E,%B+ *@HK/(!(:V"2=@
M=JYL"B:08=8<>8@O1%$K5$9=D-R%+YI;3%<ZB7>1:;XK2@)<V;2'$A/Z0W[S
MV.Z/8QD8PMYJ"S>)+.Y@ON/NK2A\!*"5J)Z?(10ALE0(Z7%O;U5B\,R/3")(
M7=I&0P;I<\AN"LI9DM0WFD<@PIEE;:2"1\0POCR.[IZBD@[[#(+M.C'7FI!M
MBA M/0>0EUTLIB%I#6X /!2ND^VWS&[@2XE.X! JN62Z:+95 O.3W"!'MUT#
MBHTUHKE*>8<5,/E'"-B%*D1>9,< ]1LDGD":S*-7-/-,\?R>]0H\6-"ML9EJ
M*_'=6Z+DPW#3,;4" HI0.]D%Q7D"O=2O2 KEB/Z.66#<I3K$&VF(RRW,04/J
MX\YO72V@@;.D3']CT^6SB@D[>21850=-<<O\6SK$6+<ISD><VROJGBL/O/QU
M*4=TM;O+D*0E13N>82#QV&$R:X:.YE99LZ[O19L*9,VD+XR4+>7W;IE1"-EE
MI4=/FH#IJ;&Y)'G69M<# LD5E-AQF3%8NLR#(A27X[:U I4MQ+BD%7H.A#KJ
M^7 GBI7$D'RK2^'W73B?A$/'XN&BX%ZX2(,"&W+EB2^N-$D!)?6M*5,(=;BN
M(2T%K;XKV/D% ;>E3-+['&L>;SF8=O=NJDW2'(Z3BW%$P0TISIHWV2F* E1X
M\$I&YV/G75QNX:/XM=IC=IEP6)MDZCZE!;[@8"4I:4VVI1((2EY" TV2$AU
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MSQYH+2TN)4D*("B%(!X$CEMQW&^]:0T^TZE:Q6')+FO*%VO(9,Y]P;6M4:5
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MP@+4EQ2"/2&X,KA2,VT[1:!'=NLN-=K:Q/1(0E(>#,N,Y)4?,)*> 63MZ_,
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MM*0XM*MD>8W(WOO9\[0&;9OD&/V3.[+8H<C)L4:R^SR\=DO+;$92V4.,/H>
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M4I2E*4KA>BM2!LZVEP?,L CV&N+PN']58^[3^%?;,&/'7R:8:;5MMNA !_\
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M<)()"!Y)]7J%;5K0G:$R;.1J?I;A6&96UA_PD5=5S+@NU-7!7&-'0ZA*4.$
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MW^*FE*4I2E:%[=?^:CJ%_P"QL_\ :6:WRGU?[33YJT5V&?\ -)TM_P"1&O\
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MI\!('TDCWA^%/@+!^D?]X?A3X"0/I'_>'X4^ L'Z1_WA^%/@) ^D?]X?A4?
M2!]+(]X?A4_ 2!])(]X?A3X"P/I'_>'X4^ L#Z1_WA^%/@) ^DD>\/PI\!8'
MTC_O#\*? 2!](_[P_"H^ D#Z21[P_"I^ D#Z1_WA^%1\!('TLCWA^%3\!('T
MC_O#\*? 6!](_P"\/PI\!('TC_O#\*? 2!])(]X?A3X"P/I)'O#\*? 2!])(
M]X?A4? 2!](_[P_"I^ D#Z1_WA^%/@) ^D?]X?A3X"0/I'_>'X4^ D#Z1_WA
M^%/@+ ^DD>\/PI\!8'TC_O#\*CX"0/I)'O#\*GX"0/I)'O#\*? 2!](_[P_"
MGP$@?2/^\/PI\!('TC_O#\*? 2!])(]X?A3X"P/I'_>'X5'P%@?22/>'X5X^
M[3'^#5G]H?-KQ=6M59>-6*Y.PY+MB\)$ELR(T=3"'BKK(W5P6L#R\@HCSJJ0
M_P#!;:@0(N+Q6.TM?6XV,+YV=D6<\8*N)2"V.\^1"5*2#Y\4D@;#RKU7V?\
MLX0]$='L9P=R\/7E=F86R9X9#'6Y.K<WZ>ZN.W/;;D?56PO@+ ^D?]X?A4?
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M4I2E*4I2E*5YFN>FN(ZB]M++F<KQ6R9.U%P2RKCHO-N9F!DJGW(**.HE7'<
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MS'9;6VI12L-IY GSJP(T3Q!E]+S-J[LZF<_<T+CR'6BW)>B&(XXCBH<26"4
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M/:*!0\O,>T5(4G8>8]HJ.0^<>T5/(?./:*CD/G'M%"H>?I#VBA4/UA[17&5
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M<8WT#7N"G<8WT#7N"G<8_P! U[@IW&/] U[@IW&-] U[@IW&-] U[@IW&-]
MU[@IW&/] U[@IW&-] U[@IW&-] U[@IW&-] U[@IW&-] U[@IW&/] U[@IW&
M-] U[@IW&-] U[@IW&-] U[@IW&/] U[@IW&-] U[@IW&-] U[@IW&-] U[@
MIW&-] U[@IW&-] U[@IW&-] U[@IW&-] U[@IW&-] U[@IW&-] U[@IW&-]
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MN"H,"-]7:]P?A6G=1NQGHQJYE4C),NP*WWN^2$(;=F/./(4I*$A*!LA:1Y)
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MO6E*4I2E*4I2E*5YZSC']3\3[1-VSG#<-LV7VJZXQ;[.MN?D7ACC#L>5+=)
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M[JLQF0Q'==8ZG3==;;2$AQ:2KT4[DE*2,W.T<Q>XW]^\OP7%3WKO%OBW!(6
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MH,V[<V$W')UVG'(<&XV^7A%UR%-\NMGEN,,2(17QCR6DM<T(;+3Q<!]))"4
M!2T[[&@]IW2:T7/$,1O-SMK&0W-BW30Q!M3Y@QI$M 5&YN%OA'4Z=^F'2E9&
MV_KKM6SM:Z,Y)J)*Q=-[:&1PI,Z,Z9MK>:0V_;PM3Z.NMOAR;0EQ8 5OQW4/
M(C>P:5Z_Z==HAF:WC,MRZFWI8FJ8N5J?BJ+3@5T9+:7VT\VU\5<5IW!V]=:
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M@4.]U;])S8HW.P.YWL%E[(64P\PLEUDW>R+C1,YRK)WVN+CH5'ND=YIEO@I
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M)7?&DMY$\U-+,]YJ2;<AV6&0X\E?4*"V(X)Y<B"-SON:UHNWZA89B5O4N=D
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MRJ0.+8 '- 6"KC7IS3JT3['A5FBW64],NJ8R53'Y#A6M3ZO2<\R3Y!2E #Y
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M8/'F5KV24[IX#<$DUKJ/VD[O9Q,N-TM]JF(:;>AO/6Q]Y3;LI$BYM14MA2B
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M;,V:J?"L#!D2IL1I/?4,$DAZ7&2^H+2K?S#J4ESBH5B'.T3I8K22)C-KCY)
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M!DS=I@6['I41J.VSX=#?/D[&<45%;ZSOR^;RJW_S8KO_ &\:K_\ 2-N_^!K
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MAYCCU2R&TF-P3P1N04;DA'I9.Z]CYR1>HTZ)=X<=H0#;'XB(SS+2D*ENR%O
M,NHY.;.)2 O=)VW/J%6O'.SN]C.1V.[19L!2X$IN0Z@PBDO;.W)2U;@^2R+B
M-E'?S:)._+RB-H#=(5@U"M3%V@,QLA96W :;A*"(JE.O.J6LE9405/>;:%!
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MYX)_2*$$[J W&Y \MZR6]?#KR&&U.+4$(2-U*/J ^<UUW+M"9A-S%RV$1'>
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M0[DY<I4:1>(TR$U/MMID,7KC)<CI;FN0U+>Y\E O/1$\7"=^[I4O<;[]3.\
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MA/2(UKCJ"7)CJ4$H:23Y K4 G<^K>M ]DMR^&XWJ=F6!YC;,_O[:;A?<CO\
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M4!('J %*C@GYA[*^J^5(2KU@'^\4"0GU5]4I2E*4J.()]0]E34<1\PIMO0)
M]0 IM0 #Y*%(/K -  /4-J; _)4TI2E*4I2E*4I2E*4I2E*4I2E138;;;5-1
ML-MMO*IJ-A\U32E*4I2E*4I2E*4I2E*4I4;5-*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
52E*4I2E*4I2E*4I2E*4I2E*4K__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
